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Abstract 
Foot-and-mouth disease virus (FMDV) typically exists within a replication site as a 
heterogeneous population. This diversity allows FMDV populations to rapidly adapt to new 
selection pressures, for example an immune response. High-throughput sequencing (HTS) 
technologies allow for this sequence diversity to be characterised, however challenges still 
exist to distinguish real biological variation from process-introduced error. To improve 
variant calling accuracy, artificial DNA and RNA based populations containing sequence 
variants at known positions and frequencies were created. These were used to systematically 
investigate the impact of different laboratory and bioinformatics protocols on variant calling 
and error generation in HTS datasets. Analysis revealed that variants as low as 0.2% could be 
predicted in all DNA populations and RNA samples with a high amount of template. While 
decreasing the amount of RNA input required higher frequency percentage thresholds and 
more technical replicates to maintain accuracy. The optimised pipeline was applied to FMDV 
infected epithelium samples derived from vaccinated cattle and identified capsid surface 
bound substitutions associated with immune escape, all of which were unique to individual 
viral populations. In order to establish more control over the viral and antibody input, an in 
vitro experiment was performed with FMDV passaged in the presence of sub-neutralising 
antibody serum derived from vaccinated cattle. HTS analysis identified capsid surface bound 
immune escape associated substitutions, unique to individual viral populations. This thesis 
includes a novel systematic approach to accurately characterise low-frequency variants and 
demonstrates the evolutionary nature of FMDV, with results suggesting at an individual 
replication site, immune escape evolution is a stochastic process. Characterising immune 
escape associated substitutions within FMDV populations has the capacity to improve the 
fundamental understanding of FMDV evolution which in turn can be used to inform vaccine 
design and FMD control strategies.  
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1.1. Foot-and-mouth disease (FMD) and foot-and-
mouth disease virus (FMDV) 
1.1.1. The disease 
1.1.1.1. History  
The first written description of a clinical disease that was probably FMD occurred in 1514 
and was made by Hieronymus Fracastorius, an Italian monk in Venice, who reported that 
cattle affected with a disease refused to feed, had redness displayed in the oral mucosa and 
vesicles in the oral cavity and on their feet (1). FMD was first shown to be caused by a virus 
in 1897, by Loeffler and Frosch who demonstrated that it was a filterable agent (2).  
A total of seven immunologically distinct serotypes of FMDV are recognised; O, A, C, 
Southern African Territories (SAT) 1, SAT2, SAT3 and Asia 1 (3). Serotypes A and O were first 
recognised by Vallée and Carré in 1922 (4), who showed that French cattle which had 
recovered from clinical disease had become re-infected with FMDV when mixed with other 
infected cattle from Germany. These two serotypes were named after their region of origin, 
with Type O being named after Oise (a Northern French region) and type A being named 
after Allemagne (the French word for Germany) (5). This work was extended by Waldmann 
and Trautwein in 1926 (6) who identified three serotypes; Waldman A, B and C, with 
Waldman A and B later found to be the same serotypes as O and A respectively. Waldman C 
is now known as serotype C. In 1954, the Asia 1 serotype was identified initially in Pakistan 
from Asian water buffalo (Bubalus bubalis) samples (7), while in 1958, details of three 
serotypes were published, named SAT1, SAT2, SAT3 and originating from Southern Africa (8). 
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1.1.1.2. Hosts, infection and clinical signs 
FMD affects cloven-hooved animals belonging to the order Artiodactyla, including 
domesticated cattle, pigs, sheep and goats as well as over 70 wild animal species including  
Cape buffalo (Syncerus caffer) and deer (family: Cervidae) (5). The severity of the disease can 
vary depending on host species and breed, with some animals such as sheep, goats and 
buffalo, as well as vaccinated animals presenting with a milder form of the disease. Ruminant 
hosts can also exist as carrier animals and can carry the virus for up to three years (9–11). 
These are defined as animals where FMD virus can be recovered from the oropharyngeal 
fluid later than 28 days post infection (OIE Terrestrial Manual).     
Following exposure, primary replication occurs in the epithelial cells of the pharyngeal 
mucosa-associated lymphoid tissue crypts (this is contested in cattle infection between the 
pharynx (12) and bronchiolar epithelium (13)), after which replication in pneumocytes in the 
lungs occurs (12). Following replication at the primary sites, the virus passes into the systemic 
circulation, where it can be transported to distant, non-contiguous epithelia, where further 
replication can occur (14). Depending on the host and dose of virus, clinical signs of FMD 
infection typically show within 2-6 days’ post exposure, with vesicular lesions forming on the 
epithelium of coronary bands of the feet, in the mouth, tongue and teats (Figure 1.1) leading 
to lameness, refusal to feed which results in the drop of body weight and milk production 
(15,16). While mortality from infection tends to be low, it can be higher in neonatal 
domesticated pigs and cattle due to myocarditis (17).  
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Figure 1.1. FMD clinical signs. Clinical signs associated with an FMDV infected cow; on the 
tongue and mouth (left), lower dental pad (middle) and a foot (right). Photos were taken by 
animal services (The Pirbright Institute) during an in vivo animal experiment.  
1.1.1.3. Transmission  
The most common mode of transmission is through direct contact between infected and 
susceptible hosts, also through indirect transmission events through contact with feed 
products or fomites (18). Animals can be infected through viral particles being present in 
faeces, milk, urine and saliva from an infected animal (19). Unlike cattle, pigs are less 
susceptible to aerosol infections (20) and are thought to become infected via direct contact 
or by eating contaminated food, yet infected pigs excrete far more aerosolised virus than 
cattle or sheep (11).  
1.1.1.4. Worldwide distribution of FMD  
FMDV serotypes are not uniformly distributed around the world, with the global viral 
population being divided into seven regional pools (21). Pool one covers eastern and south-
eastern Asia, Pool two covers the Indian sub-continent and Pool three covers Eurasia and the 
Middle-East. Each of these three pools have serotypes O, A and Asia 1 co-circulating. Pool 
four covers eastern and central African and contains serotypes O, A and SAT 1, 2 and 3, while 
Pool five covers western Africa and contains serotypes O, A and SAT 1 and 2, and Pool six 
covers southern African and contains all of the SAT serotypes. Pool seven is present in the 
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South American continent and includes serotypes O and A (OIE/FAO Reference Laboratory 
Network for FMD). A map showing the distribution of FMD across the world (as of January 
2019) can be found in Figure 1.2, although as of May 2019, both Columbia and South Africa 
have had their OIE FMD free status suspended due to recent outbreaks.  
Serotypes O, A and historically C are the most wide-spread viruses and have been responsible 
for outbreaks in Europe, America, Asia and Africa (5), However serotype C is now though to 
be extinct in the wild, with the last reported outbreaks occurring in 2004 in Brazil and Kenya 
(22). Each of the SAT serotypes are normally restricted to sub-Saharan Africa, however 
limited outbreaks occur outside these regions (e.g. SAT1 in the Middle-East between 1962 
and 1965 (3), SAT2 in Yemen in 1990 (17)).  Serotype Asia 1 is almost exclusively confined to 
the Asian continent, however incursions of this serotype have occurred into Greece in 1984 
and 2000 (5). 
Outbreaks have occurred in every livestock containing region in the world, with the 
exception of New Zealand, with most outbreaks today occurring in lower income countries 
(17). However, outbreaks do occur in FMD-free countries, due to illegal trade, contamination 
within tradable goods or accidental release. An example is the FMD epidemic in the UK in 
2001 (3,23), caused by pigs being fed untreated swill, where 2,030 farms were declared 
infected premises (23) and was estimated to have cost the UK economy an estimated £6.5 
billion, through the loss of trade and tourism (24) 
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Figure 1.2. FMD worldwide distribution. The global distribution of FMD (accurate in January 
2019) generated by Dr. Antonello Di Nardo (The Pirbright Institute).  
 
1.1.2. Classification, genome structure and cellular entry 
1.1.2.1. The virus  
FMDV is a non-enveloped virus with an icosahedral capsid between 25-30 nm in diameter 
(5), which encapsulates a positive-sense single stranded RNA genome approximately 8.5kb 
in length (25). The virus belongs to the Picornaviridae family (17) and is the type species of 
the Aphthovirus genus with the only other members being equine rhinitis A virus (ERAV) (26), 
bovine rhinitis A virus (BRAV) and bovine rhinitis B virus (BRBV) (27). The Picornaviridae 
family contains (as of July 2019) 110 viral species within 47 genera, with another 16 genera 
and 40 species being proposed for classification (28) (Figure 1.3).  
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Figure 1.3. Phylogenetic tree of the Picornaviridae family as of 2017. This tree was 
generated using the 3D sequences of 31 genera by Nick Knowles (The Pirbright Institute). 
FMDV is highlighted in red.    
1.1.2.2. The virion 
Surrounding the RNA genome is a protein shell or capsid, which comprises 60 copies of a 
capsomer and exhibits a 2-, 3- and 5- fold axis of symmetry (29). Each of the capsomers are 
composed of four structural proteins; VP1, VP2, VP3 and VP4, with all but VP4, which is 
located internally, exposed on the virus surface and contribute to the cell entry (30) and the 
antigenic properties of the virus (31). 
The structural proteins are coded within the P1 region of the single polyprotein encoded by 
the open reading frame (ORF) of FMDV. This P1 region is proteolytically cleaved to produce 
VP1, VP3 and a precursor protein called VP0. An RNA dependent auto-cleavage maturation 
event occurs with VP0 to form VP2 and VP4 (32).  One copy of each of the four capsid proteins 
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forms a capsomer, of which five capsomers assemble into a pentamer and 12 pentamers 
form a complete viral capsid (33) (Figure 1.4). 
  
Figure 1.4. FMDV capsid structure. The crystallised outside (left) and inside (right) pentamer 
structure of FMDV, displaying the four structural proteins; VP1 (Dark blue), VP2 (Light blue), 
VP3 (Gold) and VP4 (Red). Image created from the RCSB PDB website using NGL view (34) 
using the crystallised structure of recombinant FMDV A22 empty capsid (35). 
 
On the VP1 protein is the surface protruding G-H loop (encoded by VP1140-160) generated by 
βG and βH chains containing the highly conserved RGD domain (Arg-Gly-Asp), which is a 
critical determinant that mediates virus infection via interaction with cell membrane integrin 
receptors (36). This domain is also an important antigenic site of FMDV (37–39). While VP1-
3 are known to be associated with antigenicity, the immunogenicity of VP4 is poorly 
understood, however VP4 cross-serotypic neutralisation of another Picornaviridae family 
member, rhinovirus, has been reported (40).  
1.1.2.3. Receptor binding and cellular entry 
The RGD domain of the G-H loop (discussed above) has been shown to form a stable complex 
with cellular integrin proteins, allowing the virus to infect the cells through internalisation 
(41). Integrin consists of α and β subunits, with the major receptors for FMDV within 
susceptible hosts being αvβ1, αvβ3, αvβ6 and αvβ8 (42–47). In addition to the RGD domain, 
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FMDV can utilise similar tripeptide sequences, with a previous study demonstrating that 
when the RGD domain mutated to an REG (Arg-Glu-Gly) sequence that FMDV could still 
replicate in susceptible cells, suggesting that FMDV could use another unknown mechanism 
for cellular entry (48). Passage series of serotype O in susceptible cell lines such as Bovine 
Thyroid Cells (BTY) can result in the use of heparin sulphate being used as an alternative 
receptor for cellular entry (49). 
1.1.2.3. Genome and protein structure and function 
1.1.2.3.1. FMDV genome overview 
The viral RNA genome contains an ORF approximately 7kb long which is flanked by the 5 
prime untranslated region (5’UTR) and 3 prime untranslated regions (3’UTR) (17). Bound 
covalently to the 5’UTR is the viral encoded protein 3B (or VPg), 24 or 25 residues long (50). 
The ORF encodes a single polyprotein precursor approximately 2300 amino acids in length 
comprising four structural proteins (VP1, VP2, VP3 and VP4) and eight non-structural (NS) 
proteins (Leader, 2A, 2B, 2Cpro, 3A, 3B, 3C, 3D) (Figure 1.5).  
1.1.2.3.2. 5’UTR 
The 5’UTR is approximately 1300 nucleotides in length and contains multiple components. 
At the 5’ end is the S fragment which is 360 nucleotides in length and is thought to fold into 
a large hairpin structure (51) and play a role in maintaining viral genome stability and 
replication by inhibiting host exonuclease function (52) and the intra-cellular host immune 
response (53). Next is the polyC tract, which is variable in length between 150-250 
nucleotides, comprising of over 90% C base residues and is of unknown function but is 
thought to play a role in viral replication (54) and virulence (55).  
Following this is a series of RNA pseudoknot structures, a stem-loop cis-acting replication 
element (cre) (also known as the 3B-uridylylation site (bus)) and an internal ribosome entry 
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site (IRES). The function of the pseudoknots is unknown, however deletions of one or two 
pseudoknot structures have been identified in FMDV serotypes (56). The cre is approximately 
55 nucleotides in length and forms a stable stem-loop structure containing a conserved motif 
(AAACA), which is involved in the initiation of RNA replication by acting as a template for the 
uridylylation of VPg by the RNA polymerase (57). The IRES section of approximately 450 
nucleotides in length is responsible for the cap-independent initiation of viral protein 
synthesis (58).  
1.1.2.3.3. Open reading frame 
Following the 5’UTR is the open reading frame of approximately 7000 nucleotides in length 
and encodes for single polyprotein. This is enzymatically cleaved into four structural proteins 
and eight NS proteins.  
After RNA translation, four primary proteins are formed, namely Leader protease (Lpro), P1-
2A, P2 and P3. The Lpro is a papain-like proteinase encoding at the N-terminus of the 
polyprotein and has two separate AUG start codons, usually 84 nucleotides apart. This leaves 
the virus able to create two different forms of this protein, named Labpro (synthesised from 
the first start codon) and LBpro (synthesised from the second start codon), both of which have 
been identified in vitro and in vivo (59,60). Both proteins are involved in the autocatalytic 
cleavage from the polyprotein (Lpro/P1 cleavage site) and are involved in cleaving host factor 
(61). The LBpro  is the major protein type identified in vivo, with previous studies showing that 
variable viruses can be recovered from synthetic genomes with mutations within the first 
start codon, but not the second (62,63). LBpro is also a novel viral deubiquitylation enzyme, 
involved in negatively regulating virus-induced type I IFN signalling (64).   
Downstream of Lpro is the polyprotein selection which encodes for the P1-2A precursor 
protein, which is enzymatically cleaved (described in more detail below) into the four 
structural proteins and 2A NS protein. The 2A encoding region is 18 amino acids in length 
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and much smaller than other picornavirus members (up to 150 amino acids in length) as it 
lacks any protease motifs but is highly conserved with Cardioviruses at the 2A/2B junction 
(65,66). This region contains a conserved cleavage site located between 2A and 2B (Gly 
(2A/Pro (2B))(67), with studies demonstrating that the Gly amino acid (2A) is critical for 
cleavage activity, whereas recombinant viruses with mutations being unable to produce 
cleaved proteins (68,69). 
Following this is the P2 region which is separated from P1 via ribosomal skipping (65) and 
encodes for the NS proteins; 2B (154 amino acids in length) and 2C (318 amino acids in 
length). It was believed that the 2A protein was encoded by this region, however biochemical 
and genetic evidence showed that the 2A peptide is cleaved in the P1-2A precursor protein 
(70).  
The 2B and 2C proteins are partially homologous to those of other picornaviruses as well as 
other animal virus groups (71–73). The 2B protein is an example of a viroporin, a class of low-
molecular weight hydrophobic transmembrane proteins. The protein interacts with the 
cellular phospholipid bilayer for viral dispersion, as well as increasing the permeability of the 
membrane and promoting viral release from the cell (71,72). Limited knowledge of the role 
of FMDV 2C is known, but in other picornaviruses such as hepatitis A virus and poliovirus it 
is known to play a role in the formation of viral replication complex, membrane 
rearrangement and associated in the virus induced cytopathic effects (74–77). Studies with 
FMDV have revealed it to have AAA+ ATPase activity (78) and to be involved in triggering 
cellular autophagy and enhancing viral replication (79).   
After the P2 region is the P3 region, which is enzymatically cleaved by 3Cpro (80) to form the 
proteins 3A, VPg (which includes three distinct copies names 3B1-3), 3Cpro and 3Dpol. The 3A 
region of approximately 153 amino acids in length and is larger than other members of the 
picornavirus family (for example poliovirus 3A protein is 87 amino acids in length (81)). The 
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N-terminus (positions 1-85) is highly conserved between all FMDV serotypes (82) and 
encodes for both a hydrophilic and a hydrophobic domains which exerts membrane binding 
activity (83).  
The VPg or 3B region encodes for similar but non-identical copies named 3B1, 3B2 and 3B3, 
approximately 23 amino acids in length, and is unique to FMDV as other picornaviruses 
encode for a single copy of 3B (83). The protein binds at the 5’ end of the FMDV genome, 
and acts as a primer for viral RNA synthesis by its uridylylation through the action of 3Dpol 
(17). Interestingly, not all 3B copies are required to maintain infectivity (83), however no 
currently wild-type FMDV strains with less than three 3D proteins have been reported (84). 
The 3C region encodes a chymotrypsin-like cysteine protease (85), which cleaves the 
polyprotein at all cleavage sites except for the autocatalytic cleavage of Lpro and the cleavage 
site of VP0 to VP2 and VP4 (86). The mechanism for the cleavage of VP0 is currently unknown 
(80).   
FMDV 3Dpol is approximately 470 amino acids in length and is a high-conserved region 
between serotypes encoding the RNA-dependent RNA polymerase (RdRP) (87). The encoded 
protein is involved in RNA genome synthesis and shows no evidence of a RNA proofreading 
domain in FMDV or other picornaviruses (88,89).  
1.1.2.3.4. 3’UTR 
Occurring after the open reading frame of FMDV is the 3’UTR of approximately 90 
nucleotides in length. This genome section is predicted to fold to form two stem-loop 
structures (Stem-loop one (SL1) and Stem-loop two (SL2)) and is through to be involved in 
viral replication (90). At the 3’ end is a poly-adenylated tract of A nucleotides called the polyA 
tract with a variable length.   
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Figure 1.5. FMDV genome and polyprotein structure. The open reading frame encodes for a 
single polyprotein which is enzymatically cleaved into the structural and non-structural 
proteins.  
The lightning bolt symbols indicate cleavage sites, with red indicating cleavage by Lpro, green 
by 3Cpro and black by unknown means.  
P2(2BC) is separated from the P1/2A via ribosomal skipping 
 
1.3. Host immune response and vaccine strategies 
1.3.1. The host response 
Following infection and/or vaccination, a rapid humoral response is elicited, resulting in the 
generation of virus-specific antibodies. These antibodies protect animals in a reinfection, or 
infection in the case of a vaccinated animal in a serotype-specific manor with protection 
generally correlated with high levels of neutralising antibodies (38).  
The primary response to infection in cattle is characterised by serum anti-FMDV IgM which 
is detectable between 3 and 7 days post infection, which peaks between 4 and 14 days post 
infection before declining to base levels following 56 days following infection (91). IgM is the 
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major component of virus neutralising activity during the first 6 days of infection, however 
high titres of IgG1 and IgG2 are rapidly produced from 4 days post-infection, reaching peak 
levels following 14 days (92,93). IgA is detected in serum and oesophageal–pharyngeal fluid 
from 7 days post-infection, peaking within 14 days, before slowly declining to base levels 
except in carrier animals where a second response occurs around 28 days post-infection (94). 
While infected cattle develop a rapid IgG and IgA responses, vaccination only induces an IgG 
response (91).  
To ensure infection persists and is able to spread both within and between hosts, FMDV has 
evolved to counteract the host’s innate and adaptive immune responses.  
The Lpro protein has been found to supress the early innate immunity by cleaving the host 
translation initiation factor eIF4G, which results in the down-regulation of cap-dependent 
mRNA translation within FMDV infected hosts (61). A consequence of this is that levels of 
Type I interferon α/β (IFN-α/β) (which has previously been demonstrated to inhibit FMDV 
replication (95,96)) are reduced in infected cells.  
Further evasion of the host immune response during FMDV infection has been shown with 
the reduced T-Cell response. This occurs when FMDV infects antigen-presenting cells (APCs) 
such as macrophages (97) or dendritic cells (DCs) (98). Although this infection does not result 
in the further viral replication (16), it results in the production of interleukin (IL)-10 which 
directs the adaptive immune response towards a stronger humoral antibody response rather 
than a T-Cell response (99). The T-Cell response is also supressed further through induction 
of lymphopenia during peak viremia, as it has been demonstrated that T-Cells have a poor 
mitogen stimulus even after lymphopenia has been resolved (100). However the mechanism 
in which this occurs is poorly understood (100).  
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1.3.2. Vaccination 
Vaccination is a major tool for the control of FMD and has been successful in many parts of 
the world, leading to the eradication of the virus from Western Europe and parts of South 
America (101). However, the impact can be limited due to the evolutionary nature of FMDV 
leading to the development of immune escape variants (102).  
In the worldwide livestock market, FMDV vaccines represent 26.4% of the veterinary vaccine 
market (35), with most produced by replicating FMDV in baby hamster kidney-21 cells, which 
is then inactivated with binary ethyleneimine (BEI) and partly purified (103). Routine 
vaccination against FMDV is normally carried out in endemic countries or regions which are 
recognised as “FMD-free with vaccination”. Depending on the epidemiological situation of 
an endemic country, vaccines can contain more than one serotype of FMDV (104). For 
example, the O1Manisa vaccine which has shown to be a robust immune strain for many FMD 
type O outbreaks, however this vaccine doesn’t provide protection against all type O strains 
(105). Table 1.1 displays a summary of currently available and tested FMDV vaccines.  
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Table 1.1. FMDV vaccines summary. A list of current and tested vaccines for FMDV. Table 
adapted from (104)  
Vaccine type Description Reference 
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BEI Inactivated 
vaccines 
Consists of BEI inactivated purified 
antigen 
131,132 
New marked BEI 
inactivated 
vaccines 
BEI inactivated purified virus with 
deletions in different NS proteins 
133,134 
DNA vaccines cDNA of entire viral genome 135,136 
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ve
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n
es
 
Leaderless virus Deletion of entire Lpro sequence 137,138 
SAP mutant 
virus 
Mutation within Lpro blocks Lpro 
nuclear retention 
139,140 
Inter AUG 
mutant virus 
Transposon mutagenesis in the 
Lprointer-AUG region 
141,142 
Chimeric virus 
A chimeric FMDV A24 constructed 
with Lproregion of bovine rhinitis B 
virus 
143 
Deoptimized 
virus 
Deoptimised P1 region 144 
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VP1 peptide 
epitopes 
Purified VP1 produced in E. coli 145,146 
T and B cell 
peptide 
epitopes 
Combination of P1 G-H loop peptide 
with T cells epitopes 
147–149 
VP1 and NS 
proteins 
peptides 
Synthetic peptide based on 
immunogenic epitopes present in 
VP1, 3A, and 3Dpol proteins 
150 
DNA vaccines 
DNA vaccine containing P1 and NS 
2A, 3C and 3D 
151 
Baculovirus 
/empty capsid 
Purified VLPs expressed from 
recombinant baculovirus 
152–154 
Bacterial 
produced empty 
capsid 
Purified VLPs expressed in E. coli 155,156 
Li
ve
 v
ec
to
re
d
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n
es
 
Vaccinia 
Vaccinia virus used as a vector to 
deliver FMDV empty capsids. Not 
tested in hosts 
157,158 
Avian poxvirus Fowlpox virus expressing VLPs 159 
Pseudorabies 
Attenuated PRV vector expressing 
VLPs 
160 
Alphavirus 
“Single cycle” packaged alphavirus 
self-replicating RNA vector [Semliki 
Forest virus (SFV)] expressing VLPs 
161 
Adenovirus 
Recombinant-replication-E1/E3-
defective human adenovirus type 5 
(Ad5) expressing FMDV P1 and NS 
3Cprocoding regions produce VLPs 
162,163 
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Following manufacturing, vaccine products go through quality control testing, which includes 
identity, sterility, safety, potency, efficacy and detection of NS protein contaminates.  
The current method for testing FMDV vaccine potency is to challenge the target species, in 
which there are two in vivo based tests determined by the OIE (139) and European 
Pharmacopoeia (Ph.Eur) Monograph 01/2017:0063 (140). The first is the 50% protective 
dose (PD50) test, in which animals are normally divided up into three or more groups and 
given different doses of the vaccine and then challenged with FMDV. The PD50 value denotes 
the dose of vaccine which would protect 50% of the vaccinated animals, with a PD50 score 
equal to or greater than 3 is classified as fit for routine vaccination, while a PD50 score equal 
to or greater than 6 suitable for emergency vaccination. The second test is the protection 
against podal generalisation (PPG) test, where all animals are given the same dose of vaccine 
and virus. Vaccine potency is measured by the percentage of protected animals where a 
value of 75% is considered a pass level by Ph.Eur.  
The OIE Terrestrial Animal Health Code stipulates that if a country wishes to be recognised 
as FMD-free with vaccination that it must show that vaccinated animals are free from NS 
protein antibodies. This allows FMDV infection to be detected in vaccinated animals. As part 
of the licensing procedure, vaccine manufactures need to demonstrate that their products 
don’t induce immune responses against NS proteins so that vaccinated and infected cattle 
can be distinguished. One test recommended by the OIE is to vaccinate cattle with at least 
double the dose of vaccine at least three times over a 3-6 month period. Following this the 
presence of NS protein antibodies should be tested for using ELISA testing (against each of 
the NP proteins) or by immunoblotting (141).  
The efficacy of inactivated FMDV vaccine is mainly dependent on the integrity of the FMDV 
particles. The standard method to monitor the composition of FMDV capsid components is 
to use a sucrose density gradient; where intact virions (146S or 140S), empty capsids (75S), 
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virus infection-related peptides (45S) and protein subunits (12S) can be detected separately. 
Vaccine performance is mainly dependent on the integrity of 146S (142–144) which 
measures the virus concentration. However this method suffers from being labour-intensive, 
time-consuming and expensive as well as a lack of an international standard (145). To 
overcome this, more recent studies have used double-antibody sandwich (DAS) ELISA using 
polyclonal antibodies to quantify 146S, which have shown to be highly sensitive, rapid and 
repeatable (146). 
An important factor for a successful vaccination program, is the antigenic match between 
the outbreak virus and the strain used for vaccination (147). Using serological tests, the levels 
of protection is correlated with the antigenic match of a vaccine, by testing the antibody titre 
of serum from a vaccinated animal against both the virus strains in the vaccine and the target 
virus (148). A simple approach to measure this is to calculate the relationship value (r-value), 
between the FMDV using antisera prepared against the vaccinal serum from a vaccinated 
animal. The r-value is calculated determining the ratio of heterologous serum titre to the 
serum titre against the homologous virus strain and can be measured by one of three tests; 
liquid phase blocking ELISA (LPBE), complement fixation test (CFT) and virus neutralisation 
test (VNT) (149). 
The LPBE is performed using the vaccinal serum, which is titrated against the field isolate 
(with the vaccine strain acting as a control). Using these two ELISAs, the r-value is calculated 
with scores; <0.2 indicating that the field isolate is only distantly related to the vaccine strain, 
0.2 to 0.39 indicating that the field virus is antigenically related to the vaccine strain and 
scores of 0.4 to 1 indicating a close relationship between the field isolate and vaccine strain. 
Scores above 0.4 indicate that the vaccine strain is suitable for use, while lower scores 
between 0.2 and 0.39 demonstrate the vaccine could be suitable if no closer match can be 
found (150). For VNT tests, the neutralisation titres of vaccinal serum against 100TCID50 of 
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the field isolate and the same dose of homologous vaccine strain are compared to determine 
the antigenic similarity. One-way comparative values (r1 values) greater than 0.3 indicate 
that the vaccine and field strains are sufficiently similar to one another and it is likely that 
the vaccine will confer protection (151). CFT tests can also be used to generate an r1 value, 
however instead of neutralisation, the test measures the virus strain fixing to guinea-pig 
hyperimmune sera. Scores equal or above 0.25 indicate that the field strain is related to the 
vaccine strain. This test however isn’t widely favoured and is restricted largely to South 
America (150).  
Despite these tests being widely used, multiple problems exist with vaccine matching testing, 
with one being the provenance of vaccine strains. Multiple manufacturers may produce 
different versions of the same vaccine strain, where variations between the cross-reactivity 
and in some cases mutational differences in the genome of the same vaccine strain can be 
observed (150). Due to commercial sensitivities, the origin (and sequence) of the vaccine 
strain often remains unknown, which can further limit vaccine matching tests. Another major 
issue is the inherent variability and lack of standardisation in relation to antisera and protocol 
used in the vaccine matching tests. Although there may be agreements between individual 
vaccine manufacturers, the lack of a global universal standard can led to differences in tests 
results between laboratories (150).  
Multiple formulation types of inactivated FMDV vaccines are commercially available, with 
the main ones used being; oil-emulsion which is used for routine control, high-potency 
vaccines for emergency use (148) and aluminium hydroxide vaccines for use in cattle (149). 
These vaccines have shown to limit the spread FMD due to decreased clinical disease and 
virus amplification (106). However they are not without disadvantages, with oil-emulsion 
based vaccines requiring bi-yearly vaccinations (152) and aluminium hydroxide-adjuvant 
vaccines producing an even shorter duration of immunity (153). Both vaccine types can lead 
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to the formation of granulomas at the site of inoculation (165,166). Each vaccine types are 
also associated with short shelf lives due to 146S not being very stable (106) and vaccine 
production is reliant on large amounts of inactivated virus being produced in high 
containment facilities, which is both costly and increases the risk of virus escape. Vaccination 
can also be performed through the use of empty capsid vaccines, which do not contain NS 
proteins and have recently been demonstrated to be safe to produce in a non-bio-
containment facility (35).  
Though vaccination can limit the transmission of FMDV, the generated immune response can 
also act as a selective pressure, shaping the evolution of the virus leading to the development 
of immune escape variants (155). This will be discussed in further detail later in this chapter.  
1.3.3 Antigenic sites 
FMDV evolution can be influenced from external environmental pressures acting on key 
antigenic sites of the virus. The identification of these sites in FMDV has mainly relied on the 
use of neutralising monoclonal antibody (mABs) tests, which, combined with the detection 
of amino acid substitutions in viruses resistant to mAB tests, allow for the identification of 
antigenic sites. These tests have revealed important antigenic sites in type O (156–161), type 
A (39,162–164), type C (165,166) and Asia 1 (167) on the capsid surface of VP1, VP2 and VP3.  
Of all the serotypes of FMDV, serotype O has been the most extensively studied and to date 
five neutralising antigenic sites have been reported for FMDV serotype O1Kaufbeuren. 
Antigenic site one is linear and trypsin sensitive, while antigenic sites two to five are reported 
to be conformation dependent and trypsin resistant in nature. Antigenic site one is the most 
predominate surface projection and is formed by the G-H loop and the C terminus of VP1, 
with critical amino acids positions being located at VP1144, VP1148, VP1154 and VP1208.  
Antigenic site two is found in the VP2 encoding region at amino acid residues VP270-73, VP275, 
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VP277 and VP2131, while amino acids residues VP143-44 of the B-C loop in VP1 encoding 
constitute antigenic site three. Antigenic site four is found within the VP3 encoding region at 
VP356 and VP358, while antigenic site five is characterised by an amino acid position at VP1149, 
with the interaction of the G-H loop with other surface bound amino acids (168). 
Investigations of other serotypes have identified antigenic sites one, two and four to be 
analogous to other serotypes.   
 
Figure 1.6. FMDV antigenic sites. Antigenic sites identified for serotypes O, A, Asia 1 and C 
using mABs test. Figure adapted from (167).  
 
1.4. RNA virus variability 
RNA viruses are of global importance to both human and animal health, with the lack of 
proof-reading within the RdRP leading to mutations which can limit effective treatment and 
responses to outbreaks, requiring updates to vaccines and antiviral treatments. One such 
example includes the 2009 H1N1 (swine flu) global pandemic, where overuse of the antiviral 
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oseltamivir, led to viral resistance, decreasing the drugs effectivity (169). Other such 
examples include resistance to antiviral treatments in HIV (170,171), herpes simplex virus 
(172) and hepatitis B virus (173) (further detail of viral mechanisms to resistance will be 
explained below). Understanding how viral evolution occurs during transmission in an 
epidemic scenario (for example the 2014 Ebola outbreak) is important to limit the impact of 
an outbreaks (174).   
FMDV, like most RNA viruses, exists within a replication site as a heterogeneous swarm, 
consisting of similar but non-identical genomes. This sequence diversity arises due to the 
large viral population size, the high replication rate of each genome and the poor proof 
reading ability of the viral RdRP (175,176). Due to these factors, it is hypothesised that during 
each transcriptional event, a single nucleotide variant arises in each genome (177), giving the 
virus an estimated 10-4 mutation rate per nucleotide copied compared to the estimated DNA 
virus mutation rate of 10-6 (178) (Figure 1.8). The evolutionary importance of this, in relation 
to viral transmission and adaptation, remains unclear, however these factors allows a viral 
population to adapt to new environments and small evolutionarily bottlenecks. For example, 
phylogenetic analysis of HIV evolution suggests that most infections derive from a founder 
population consisting of one genotype and the resulting diversity is generated in an 
individual host (179,180). In the case of FMDV, the genetic distances between viral 
populations have been found to be larger within hosts than between hosts, providing 
evidence that the transmission bottleneck is small (175,181,182) (Figure 1.7). However, a 
tight bottleneck and a small founding population is not the case with all RNA viruses, with 
work on tobacco etch virus (183) and influenza virus (184) in vivo suggesting that bottleneck 
size and variant diversity transmission is consistent with dose dependence. 
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Figure 1.7. FMDV Viral diversity following infection. Following infection of a host with a 
small founder population, diversity is generated at replication sites following viral replication. 
This diversity can be influenced by environmental factors caused by the host’s immune 
response (which maybe vaccine induced), antiviral medication and by differences in hosts, 
replication sites and individual cells.  
 
Genome recombination is also another means in which viral diversity is generated within a 
swarm, with rates differing greatly between different RNA viruses (185). Recombination has 
been reported to lead to antiviral resistance in HIV-1 populations by maintaining diversity 
within protease and reverse transcriptase encoding regions (186) and immune escape in 
human cytomegalovirus (a member of the Herpesviridae family) through the homologous 
recombination of critical glycoprotein encoding regions (187). Another such example is 
selective pressure leading to diversity generated at critical antigenic sites, which will be 
further discussed later in this chapter.  
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Figure 1.8. Per-site mutation rate against genome size. The per base mutation rate for 
different biological entities, using previously reported data (188). The RNA virus group (red), 
contains FMDV (in black), Human rhinovirus, influenza virus A, measles virus, poliovirus, 
vesicular stomatitis virus, tobacco mosaic virus and bacteriophage φ6 and includes 
retroviruses (orange dots); rous sarcoma virus, murine leukaemia virus, spleen necrosis virus, 
bovine leukaemia virus and HIV. Single-stranded DNA viruses are bacteriophage φX174 and 
bacteriophage m13. Double-stranded DNA viruses are bacteriophage λ, bacteriophage T2, 
bacteriophage T4 and herpes simplex virus. Bacteria is Escherichia coli. Lower eukaryotes are 
Saccharomyces cerevisiae and Neurospora crassa. Higher eukaryotes are Drosophila 
melanogaster, Caenorhabditis elegans, Mus musculus and Homo sapiens.  
1.4.1. Immune and antiviral escape in RNA viruses  
Due to the evolutionary nature of RNA viruses, mutations caused by the poor-proof reading 
ability of the viral RdRP can led to immune escape and drug resistance variants can arising in 
viral populations, limiting the effectiveness of vaccine and antiviral treatments.  
As stated previously, vaccination is an important measure for the control of FMD worldwide, 
however improper vaccination of host can lead to the generation of a weaker immune 
response, which in turn can act as a selective pressure, leading to the generation of immune 
escape variants. This is a particular concern in countries such as India, where preventive 
vaccination is practised and therefore a large portion of animals have varying degrees of 
immunity to FMDV (189). Studies have been undertaken to ascertain evolutionary 
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mechanisms that occur critical sites which occur when a virus population is subjected an 
environmental response. These studies have often focus on viral evolution in the presence 
of an sub-neutralising level of antibodies or antiviral medication, as viral adaptation is often 
associated with genetic variation at a few critical sites. One study evaluated the fitness of 
two matched pairs of escape mutants of FMDV serotype C, against a neutralizing monoclonal 
antibody, specific for antigenic site A within the G-H loop of VP1 (190). Sequence analysis of 
two escape mutants revealed consensus changes associated with alternative receptors 
binding sites when the RGD triplet within the G-H loop were lost (48). Further analysis of this 
epitope region revealed it to be an independent antigenic element, as a chimeric FMDV A 
with the G-H loop from serotype C was neutralised by FMDV type C antibodies with the same 
efficiency as the wildtype FMDV type C (191).  
Similar to FMDV, other RNA viruses can generate immune escape variants with important 
implications to both human and animal health. One such example is hepatitis virus C, where 
previous studies have identified immune escape substitutions in known epitope regions 
within the E2 glycoprotein from infected humans (199,200). In vitro studies have been used 
to identify substitutions associated with immune escape. A passage series with highly 
pathogenic avian influenza virus (HPAI) with sub-neutralising antibody serum from a 
vaccinated chicken identified a total number of 5 consensus level amino acid substitutions 
within the hemagglutinin (HA) protein. The control passage series, with contained no 
antibody serum, was found to have no consensus changes following sequencing (193). 
Another influence which can act as an evolutionary selective pressure is antiviral treatment. 
Similar to ineffective vaccination, improper use of antivirals (e.g. not taking the full dose, not 
completing the course of treatment) can create a selective environment. For example 
current antiviral treatments for influenza virus are limited as the viral population can evolve 
resistance (194) with an example being widespread resistance to M2 ion channel inhibitors 
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being observed in circulation Influenza viral strains (195). One target for treatment of 
influenza virus is the RdRP to prevent viral replication, however the encoding region’s high 
intrinsic mutation rate facilitates antigenic drift within viral populations, leading to escape 
from both an immune response and antiviral treatment (196). Using in vitro studies, antiviral 
associated amino acid substitutions can be characterised under different conditions of 
antiviral pressure. A previous study used High-throughput sequencing (HTS) to identify 
favipiravir resistance in vitro in influenza A/England/195/2009 (H1N1) (197), a nucleoside 
analog antiviral which targets the viral RdRP (198). Populations of influenza virus were 
passaged in Madin-Darby canine kidney (MDCK) cells at a MOI concentration of 0.002 with 3 
or 3.5µM of favipiravir for 10 passages in triplicates. Initial passages showed a reduction in 
virus titre (measured by plaque assay), with viral yield higher by the tenth passage. HTS 
identified in two out of three passages the presence of a lysine to arginine mutation with the 
PB1229 protein of the RdRP at consensus level, as well as a sub-consensus proline to leucine 
substitution (~5%) located within the PA653 subunit of the RdRP. Further investigation 
concluded that the PB1229 mutation leads to favipiravir resistance with the PA653 substitution 
restoring lost viral fitness. This study demonstrates a fitness cost to antiviral escape 
associated substitutions, which in turn acts as another selective pressure leading to viral 
populations to mutate to increase fitness.  
Although antiviral treatment is not often performed for FMDV control, an in vitro study has 
previously been performed on FMDV serotype C to measure the effects of antiviral 
treatments. Infected Baby hamster kidney (BHK-21) cells were treated with ribavirin at three 
different concentrations (0, 100 and 500µM), viruses were then sequenced to determine 
mutagenic profiles. Results identified an increase of up to 10-fold in mutation frequencies 
associated with ribavirin treatment within the VP1 and 3D encoding regions. Introducing 
lethal mutagenesis at critical sites in the encoding region of the virus population led to the 
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curing infected cells by ribavirin (199). Similar investigations of lethal mutagenic has been 
demonstrated with poliovirus (200) and hepatitis C virus (201).    
Due to the evolutionary importance of immune and antiviral escape mutants in RNA viral 
swarms multiple methodologies are available to characterise them. An important technology 
is HTS, which allows for sequencing of a viral swarm beyond a consensus level in order to 
identify low-frequency variants associated with immune or antiviral escape.  
1.5. High-throughput sequencing  
Before the establishment of HTS technologies, Sanger sequencing (which today remains the 
gold standard for many applications) was used to analyse viral diversity, however, this 
technology was limited to consensus-level diversity. While low-frequency substitutions could 
be characterised through the use of isolation of individual viral strains (202) or by dilutions 
of viral strains (203), these processes were both labour intensive and time consuming. HTS 
allowed for an in-depth characterisation of the genetic diversity within viral populations 
below the approximate 20% threshold of Sanger sequencing. This had important implications 
to both animal and human health as it allowed for the identification of low-frequency 
substitutions associated with drug resistance and immune escape which may lead to 
treatment and vaccination failure (193,204). Data generated from HTS can also be used to 
investigate the entropy of a viral population, whereby a higher entropy score at a nucleotide 
equating to a higher level of diversity.  
Since the completion of the Human Genome Project (HGP), improvements in technology and 
automation have both lowered costs and speed for sequencing whole genomes. The 
reduction of sequencing costs has surpassed the notion of Moore’s Law, which describes the 
trend of ‘computer power’ doubling every two years (although this trend has stalled as of 
2015) (Figure 1.9). The estimated cost of the HGP was $2.7 billion and took approximately 
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15 years to complete. In 2006, the sequencer marketed by Solexa, the Genome Analyzer was 
able to produce 1gb of data in a single run and sequence a human genome for approximately 
$300,000. Today, instruments such as the NovaSeq 6000 System by Illumina can produce up 
to 6000gb and can generate a full human genome sequence for under $1000. Sequencing 
technologies can be split into three generations, with generation one including Sanger and 
Maxam-Gilbert sequencing, generation two including Pyrosequencing/454, SOLiD, Ion 
Torrent and Illumina sequencing and generation three including Oxford Nanopore and 
PacBio sequencing.  Each of these platforms have their own strengths and weakness.  
FMDV samples sequenced for this thesis were processed on the Illumina MiSeq platform 
present within the Specified Animal Pathogens Order (SAPO) four containment at The 
Pirbright Institute.  
 
Figure 1.9. DNA sequencing cost over time. The cost of raw megabase data produced from 
DNA sequencers in comparison to Moore’s law. Data obtained from the National Human 
Genome Research Institute (https://www.genome.gov/about-genomics/fact-sheets/DNA-
Sequencing-Costs-Data).   
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1.5.1. Illumina sequencing 
Originally Solexa sequencing, Illumina sequencing is an example of the sequence-by-
synthesis approach and as of September 2019, accounts for the largest sequencing platform 
market share. Illumina sequencing uses ‘bridge amplification, here adapter bound DNA 
molecules are passed over a flowcell containing a lawn of complementary oligonucleotides, 
after which clusters of neighbouring clonal populations are produced by solid phase PCR 
(205). Following this, complementary strands are removed from the clusters, leaving single-
stranded DNA. Sequencing occurs in cycles, in which fluorescent ‘reversible-terminator’ 
dNTPs bind to first complementary position on the DNA strand (further dNTP bind to 
nucleotides cannot occur due to the fluorophore occupying the 3’ hydroxyl position). The 
fluorophores are excited with a laser allowing the identity of the incorporated nucleotide to 
be monitored, after which the blocking fluorescent is enzymatically removed allowing for 
further dNTP binding in the next cycle (206). As the fluorophores are required to be cleaved 
away before polymerisation can continue, it allows sequencing to occur in a synchronous 
manner (207) (Figure 1.10). In all Illumina platforms, each of the four dNTPs are individually 
labelled, except for the NextSeq and Mini-Seq systems, which use a two-fluophore system.  
The first machine such as the Genome Analyser, produced paired-end reads up to 35bp long, 
this was followed with improved technology such as the HiSeq which produced 150bp long 
paired-end reads and allowed for a greater coverage depth. Illumina released the MiSeq, 
which was lower-throughput, but allowed for sequencing at a lower cost and increased 
paired-end read lengths up to 300bp (208).  
Illumina sequencing technology is much less susceptible to homopolymer errors and allows 
for an overall accuracy of >99.50% (209). However, the sequencing platform has shown to 
display bias towards some AT-rich (210) and G-C rich (211) DNA regions, moreover a recent 
study investigating systematically how low-frequency processed introduced biases in viral 
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populations have identified the Illumina sequencer as the main source (212). Although the 
two-colour labelling system used in the NextSeq and Mini-Seq platforms increase speed and 
reduce cost (as scanning is reduced to the scanning of two colours, which reduces 
fluorophore usage), it results in slightly raised error profiles and a lack of sequence diversity 
compared to other Illumina platforms such as the MiSeq which can result in ambiguous base 
discrimination (213).  
 
Figure 1.10. Sequence-by-synthesis. After solid-phase template enrichment, primers, DNA 
polymerase and dNTPs labelled with a base-specific, cleavable fluorophore and blocked by a 
3’O-azidomethyl group is added to the flow cell. During each sequencing cycle, one dNTP will 
be incorporated into the genome fragment, and the slide is imaged by total internal reflection 
fluorescence microscopy using either two or four laser channels. The dye is then cleaved and 
the 3′-OH is regenerated and the cycle begins again. Figure first published in (213).  
 
1.6. Processed introduced error and methods to overcome them     
Although most second-generation sequencing platforms have a high enough accuracy rate 
to characterise low-frequency variants, challenges still exist to distinguish between true low 
frequency variants from process-introduced error.   
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1.6.1. Process-introduced error 
One such challenge to variant analysis is the high coverage depth needed and as a result PCR 
is often required to generate sufficient template for sequencing. The enzymes used for both 
the reverse transcription (RT) and PCR steps are error prone, the degree of which is 
dependent on the fidelity of the particular enzymes used (214). The RT step is a non-
expansive process, whilst the PCR process is cumulative, thus any bias introduced will be 
passed on to all progeny of that genome after each PCR cycle (215). Other errors arising from 
the use of PCR include artefactual recombination (214) and skewed allelic frequencies 
through preferential amplification of a small number of variants (216). The fidelity of the PCR 
enzyme is an important influence to this bias, with most high fidelity enzymes having an error 
rate of approximately 10-6 mutations per nucleotide amplified (217). A comparative study 
using clonal populations with high fidelity enzymes estimated the error rates (mutations per 
nucleotide) of several polymerase enzymes such as Phusion polymerase (New England 
Biolabs) at 2.6x10-6, Pwo polymerase (Roche) at 2.4x10-6 and AccuPrime-Taq (Life 
technologies) at 1.0x10-5 (214). Newer polymerase enzymes such as Platinum SuperFi DNA 
polymerase (Thermo Fisher Scientific) and Q5 High-Fidelity DNA polymerase are claimed by 
their manufacturers to have >100x (218) and ~280x (219) the fidelity of Taq polymerase 
respectively. Such limitations can be accounted for through the use of statistical models to 
rule out bias (215) and through an endpoint dilution series of the template before PCR 
amplification, such that single or small numbers of template are present within each PCR 
reaction (220), this latter process however is both expensive and resource-intensive 
(199,221). No study investigating the impact of starting template input (either DNA or RNA) 
on the introduction of low-frequency error in high coverage sequence datasets has 
previously been reported.  
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A recent study assessing the ‘AccuNGS’ protocol identified that errors introduced during 
sample amplification are not predominate and that the biochemical processes inside the 
MiSeq are likely the main source of most types of background error (212). It was observed 
that A:T>G:C transition error rates decreased when qScore parameters were raised from q30 
to q38. It was suggested that the use of a higher-fidelity taq DNA polymerase, used during 
the cluster generation, could decrease this error rate.  
1.6.2. Error identification and correction  
1.6.2.1. CirSeq 
To circumvent introduced error, several methodologies have been developed, one of which 
is CirSeq (222) that corrects RT, PCR and sequencing errors by generating an accurate 
consensus sequence from multiple amplicons on the same read. This method relies on 
rolling-circle RT of fragmented and circularised RNA to generate repeated copies of cDNA, as 
each copy is a directly copied from the RNA, consensus sequences of each read are highly 
likely to be accurate. The limitations of this method however are the large amount of viral 
RNA required (between 1-5ug) and the long preparation time, both of which make CirSeq 
unsuitable for clinical samples and many research applications (222).  
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Figure 1.11. CirSeq. A schematic of the CirSeq methodology. Green dots represent true 
biological variation while bother dots represent errors. Figure first published in (222).  
 
1.6.2.2. PrimerID 
Another method for PCR and sequencing correction is Primer ID, which involves a degenerate 
block of nucleotides being embedded into a RT primer, creating a random library sequence 
within the primer population. Due to the different combinations of random nucleotides, each 
target template contains a unique primer ID, which allows tracing of independent templating 
events through the PCR and sequencing protocols. Amplification of each template with the 
primer ID allows for the creation of a unique consensus sequence of each genome, and 
allows for the elimination of PCR and sequencing errors (223) (Figure 1.12). However, Primer 
ID has its own challenges, namely it doesn’t take into account RT associated errors, the 
problem of differential amplification (223,224). Also the chances of a primer ID collision 
(where more than one template is tagged with the same Primer ID) are high potentially 
influencing estimates of false diversity (225). It is also possible that PCR amplification 
efficiency is impacted by the introduction of Primer IDs due to the formation of primer 
hairpins and/or dimers. The usage of primer ID to infer haplotype linkage still remains 
restricted due to the current length of HTS reads (224), however this may change in future 
studies with the continued development of long read sequencers.  
51 
 
 
Figure 1.12. PrimerID. During the reverse transcription, a unique barcode (PrimerID) is 
incorporated into the genome along with the primer sequence used for PCR amplification. 
Converted cDNA containing the PrimerID is amplified and then sequenced. Bioinformatic 
analysis is then used on the reads to merge reads containing identical PrimerIDs into a single 
consensus read, which removes PCR and sequencing introduced error. 
  
1.6.2.3. Digital PCR variant identification  
Low frequency substitutions located within samples can also be identified by the use of 
digital PCR (226,227). Molecules of cDNA are subdivided into many partitions, so that a 
portion contains one or a small number of genomes, each partition is amplified with the 
presence of a probe. Individual molecules can be screened based on fluorescence, with lower 
fluorescence indicating the presence of Single-nucleotide polymorphisms (SNPs) (228). 
Digital PCR has been reported to detect SNPs down to a frequency 0.001% in genomic DNA 
(229) and could potentially be used in combination with HTS, to confirm the presence of a 
SNP within an RNA population. 
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1.6.3. Computational pipelines for variant detection 
Bioinformatics analysis of NGS data is critical for the investigation of low frequency variants, 
with analysis programs such as Prinseq and Sickle available to rule out low quality data 
(230,231), while multiple short-read aligners are available, with each claiming to offer the 
highest level of alignment accuracy. Previous studies have also used duplicate technical 
replicates whereby a variant is rejected if it only found in one replicate and not the other 
(182) and have used a homologous plasmid population in the sequencing pipeline in order 
to identify a suitable frequency cut-off for variant analysis (181).   
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1.7. PhD objectives  
This project aims to understand the interaction between sub-neutralising levels of specific 
antibodies and the evolution of FMDV, which is hypothesised provide a pressure to generate 
immune escape variants. This process is thought to drive nucleotide substitutions in FMD 
viruses that can be identified from field samples, as well as from both in vitro and in vivo 
based studies. However, there is limited knowledge with regards to the early stages of 
immune escape within FMDV swarms. For example, is immune escape evolution in FMDV 
swarms deterministic or stochastic? Understanding the initial process of immune escape at 
both an in vitro and in vivo level may be critical to vaccine design and strategies for FMDV 
control. This is because immune escape variants caused by vaccination can be factored in 
when designing a vaccination programme. These low-frequency variants can be 
characterised by HTS technologies, however sequencing pipelines introduce error which can 
mask true biological variance. This will impact our understanding of immune escape 
evolution. Therefore, the key aims in this thesis are:  
1. To systematically optimise both the laboratory and bioinformatics approaches in 
order to develop a sequencing pipeline which can be used to identify low frequency 
variants with high confidence. These aspects will be covered in chapters 2 and 3.  
2. To apply this pipeline to FMDV populations derived from in vivo and in vitro datasets 
which have been subjected to sub-neutralising levels of antibodies in order to 
characterise substitutions associated with immune escape. Chapter 4 will focus on 
samples from recently vaccinated (and partially protected) and challenged cattle, 
while chapter 5 provides detail of a passage series of FMDV under different 
conditions of sub-neutralising antibodies.  
Chapter 6 will conclude the work and will combine the results identified in the in vivo and in 
vitro studies in order to identify a correlation. This chapter will also suggest future 
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experiments which could be performed to improve the sequencing methodology provided 
in this thesis. 
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Chapter 2  
Development of an optimised laboratory protocol to 
accurately identify low-frequency variants with DNA 
and RNA templates 
This work, combined with chapter 3 has been submitted to BMC Genomics: 
A systematic evaluation of high-throughput sequencing based approaches for identifying 
low-frequency variants 
David J. King1,2, Graham Freimanis1, Lidia Lasecka-Dykes1, Amin Asfor1, Paolo Ribeca1, Ryan 
Waters1, Donald P. King1 and Emma Laing2 
1The Pirbright Institute, Woking, Surrey, UK 
2Department of Microbial and Cellular Sciences, School of Biosciences and Medicine, Faculty 
of Health and Medical Sciences, University of Surrey, Guildford, UK 
Corresponding author: Emma Laing: e.laing@surrey.ac.uk 
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2.1. Abstract  
High-Throughput Sequencing technologies such those offered by Illumina™ can be used to 
identify sub-consensus variability, the characterisation of which is essential for 
understanding population dynamics. However, challenges exist to distinguish process 
introduced errors from the true biological variance. Although several laboratory-based 
methods have been developed to circumvent this issue, each suffers from multiple inherent 
problems. This chapter describes the systematic evaluation of the laboratory based 
approaches for a HTS setup pipeline that aimed to identify low-frequency variants in high 
coverage data with confidence. To achieve this, DNA and RNA based ‘artificial swarms’ were 
created by introducing nucleic acid substitutions at know positions and frequencies. These 
swarms were used to optimise a HTS laboratory pipeline based on different input nucleic 
acid types and abundance inputs.  
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2.2. Background and introduction 
Advances in High-Throughput Sequencing technologies (HTS) such as those offered by 
Illumina™ allow for the rapid generation of large amounts of deep sequence data. This data 
can be used to identify sub-consensus diversity essential for understanding sequence 
variation in viral, bacterial and eukaryotic cell populations. Indeed, HTS technologies have 
been used to identify both common and rare variants (1), associated with: drug resistance 
(2–5), immune escape (6,7) and evolution and transmission pathways (8–10), with important 
implications for both human and animal health. Nevertheless, challenges still exist to 
distinguish errors introduced from the RT (in the case of a RNA genome), PCR and sequencing 
steps from the true biological variance (section 1.6).  
In order to obtain the high coverage depth requisite, amplification of the sequencing target 
is normally required with PCR typically utilised to generate sufficient material (11). In the 
case of RNA, RT is required for cDNA conversion before any subsequent PCR procedure. 
While the RT step is a non-expansive process, PCR amplification is cumulative, thus any 
introduced bias at either step will be passed on to all progeny PCR cycles (12). This issue 
could be limited by the fidelity of the polymerase used, with most high fidelity enzymes 
having an error rate of approximately 10-6 mutations per nucleotide amplified (217). Other 
errors arising from the use of PCR include artefactual recombination (214) and skewed allelic 
frequencies through preferential amplification of a small number of variants (216). Both 
factors could be limited through the reduction of PCR cycles. As well as this, the sequencing 
process also has to be considered, with a recent study declaring that the Illumina sequencer 
itself generates the highest proportion of error (212). To circumvent these problems, 
different laboratory methodologies have been developed. For example, the use of high-
fidelity enzymes (11) and tailored protocols including; CirSeq (222) and PrimerID (223), 
although this protocols both have limitations (section 1.6).   
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In order to establish a laboratory protocol suitable for HTS on both DNA and RNA genomes, 
a DNA and RNA based ‘artificial swarm’ was created to benchmark the bias of each stage. 
These populations contained variants at known positions and frequencies and were used to 
systematically evaluate the impact that three different starting inputs had on the RT and PCR 
steps.  
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2.3. Materials and Methodology 
2.3.1. Preparation of DNA and RNA templates 
2.3.1.1. Plasmids used 
The starting template for the artificial swarms was an 11,278bp plasmid (named: pT7S3) 
containing a full length genome of the O1Kaufbeuren strain of foot-and-mouth disease virus 
insert (8218bp) (Genbank: EU448369) (240). Five of these plasmids, each with nucleotide 
substitutions at known positions along the viral capsid-encoding region (Table 2.1a) (kindly 
provided by Dr. Amin Asfor and assigned the names pT7S3 1 to 5, in the PT7S3-X format 
(where X = 1-5)).  
2.3.1.2. Heat shock protocol and growing plasmids  
Each plasmid was transformed into JM109 E. coli competent cells (Promega, Southampton, 
UK) by a standard heat-shock protocol to increase their yield. Between 1-50ng of plasmid 
DNA in a volume no greater than 10µl is added to 100µl of JM109 cells and left to incubate 
on ice for 30 minutes. Following this, the plasmid/cell mixture is incubated in a 42°C water 
bath for 30 seconds and then immediately incubated on ice for a further 30 minutes. A total 
of 900µl of S.O.C Medium (Invitrogen) was then added to each vial and left to incubate at 
37°C for 1 hour at 225rpm. The transformed bacteria were then plated onto liquid broth 
(LB)/agar plates containing Ampicillin (100µl/ml), inverted and left to incubate at 37°C 
overnight.  
Following this, a single colony was picked from each respective agar plate and used to 
inoculate 5ml of LB containing ampicillin (final concentration 100µl/ml). These cultures were 
incubated overnight at 37°C at 225rpm.  
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2.3.1.3. Plasmid harvesting and linearisation  
After prepping of plasmids was completed, each were harvested using the QIAprep Spin 
Miniprep kit (Qiagen) as per manufacturer’s instructions. To confirm the presence of the 
FMDV insert, a double linearisation was performed, whereby each plasmid was cleaved using 
the restriction enzymes Bsu36I and NsiI at two sites (Figure 2.1) within the FMDV insert (start 
of VP1 and VP3 respectively), producing fragments of 10,355bp and 767bp in length. Each 
plasmid were linearised using HpaI (New England Biolabs) restriction enzyme as per the 
manufacturer’s instructions, which cleaved each plasmid after the FMDV insert (Figure 2.1). 
Each of the plasmids were then visualised on a 1% agarose gel (Figure 2.1).  
 
Figure 2.1. pT7S3 structure. The pT7S3 construct showing the locations of each the structural 
and non-structural proteins, T7 promoter sequence region, restriction enzyme sites and RT 
and PCR primer binding sites. Prior to in vitro transcription of RNA, the plasmids would had 
been linearised via the HpaI restriction site.  
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2.3.1.4. In vitro transcription of RNA 
In vitro transcription of RNA was performed using the MEGAScript T7 kit (Thermo Fisher 
Scientific) from 1µg of linearised plasmid DNA. The nascent T7 synthesised RNA was then 
treated with TURBO DNase and purified using the MEGAclear transcription clean-up kit 
(Thermo Fisher Scientific) as per manufacturer’s instructions to remove plasmid DNA. A RT-
qPCR assay, using FMDV 3D primers (241), with and without the RT enzyme, confirmed that 
each synthesised product was >99.99% RNA (data not shown).  
2.3.2. Preparation of DNA and RNA artificial swarms 
Each of the pT7S3 1:5 linearised DNA and synthesised RNA was diluted 1 in 10 and quantified 
using the Qubit® (dsDNA HS Assay kit for linearised DNA and RNA HS Assay kit for synthesised 
RNA). Quantification values were inputted into the below equation to estimate the total 
number of template DNA/RNA copies:  
𝐶𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 =
(𝑇𝐺 𝑥 𝑁𝐴)
(𝐿 𝑥 1𝑥109 𝑥 𝑀)
 
Whereby:  
 TG: Total amount of genomic template in ng 
 NA: Avogadro constant (6.023x1023) 
 L: Base pair length of template (Estimated length of DNA plasmid is 11278nt and the 
RNA plasmid is 8297nt)  
 M: Mass of template (650 for DNA, 325 for RNA) 
Each of nucleic acid templates were diluted in nuclease-free water to 108 copies/µl, after 
which DNA and RNA swarms were created by combining the respective individual templates, 
whereby variants at the 20 sites (Table 2.1.a&b) were designed to be present at 10% (n=2), 
1% (n=2), 0.1% (n=8) and 0.01% frequencies (n=8). 
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Both swarm types were diluted in a nucleic acid template extracted from FMDV negative 
bovine tongue epithelium tissue (collected from UK abattoirs), to create three different 
representative starting populations for the both DNA and RNA swarms (High (106 RNA 
copies/µl), Medium (104 RNA copies/µl) and Low (102 RNA copies/µl)). These three 
populations were created in order to test the following two hypotheses (Figure 2.2);  
 The diversity sequenced from a low starting input population will be reduced but 
over-represented, which in turn will increase the confidence in the data  
 The diversity sequenced from a high starting input population will be increased but 
under-represented, which in turn will decrease the confidence in the data 
 
Figure 2.2. Modelling genomic inputs. Hypothesising the impact of starting template input 
(High, Medium and Low) on the HTS pipeline. Coloured dots represent individual viral variants 
within a population whilst coloured lines represent sequence diversity deriving from those 
viruses within HTS reads. The grey sections represent the amount of diversity taken from the 
High, Medium and Low population.  
In the Low population scenario, a small amount of viral diversity is sequenced however the 
HTS pipeline provides an over-representation of variability, whilst as the starting input 
increases more diversity is selected, however sequence representation of this diversity 
decreases.  
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Table 2.1. Artificial swarm variants. (A) The variant location and frequency (10% in red, 1% 
in orange, 0.1% in blue and 0.01% in green) of known variants within the DNA and RNA 
artificial swarm populations. (B) The total and cumulative number of true variants in relation 
to their frequency.  
* Amplicon position is defined as the position in the PCR amplicon 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Amplicon 
Position* 
A T C G 
1754 - 99.99% 0.10% - 
1932 0.10% - - 99.90% 
2149 10.00% - - 90.00% 
2297 - 0.01% - 99.99% 
2323 0.01% - - 99.99% 
2505 1.00% - - 99.00% 
2507 - 1.00% - 99.00% 
2755 99.99% - - 0.01% 
2761 0.10% 99.90% - - 
2767 99.99% - - 0.01% 
2791 - 99.99% 0.01% - 
2843 0.01% - 99.99% - 
2955 99.99% - - 0.01% 
3106 99.99% - - 0.01% 
3376 90.00% - 10.00% - 
3645 0.10% - - 99.90% 
3661 99.90% - - 0.10% 
3691 - 0.10% - 99.90% 
3695 - 99.90% - 0.10% 
3697 - 0.10% 99.90% - 
Percentage range Number Cumulative SNP 
0.01% 8 8 
0.10% 8 16 
1.00% 2 18 
10.00% 2 20 
Total 20 20 
A 
B 
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2.3.3. RT optimisation 
The RT reaction was optimised in order to produce the highest quantify of cDNA that 
subsequently generate amplicon product. 
Three RT polymerase enzymes (SuperScript III, SuperScript IV (Thermo Fisher Scientific) and 
Transcriptor High Fidelity cDNA Synthesis kit (Roche)) were tested using the ‘High’ and ‘Low’ 
concentrations of the RNA swarm (section 2.3.2). High and Low RNA swarms were reverse 
transcribed in duplicates using each polymerase as per manufactures instructions, with the 
addition of 2µM of a Gene specific primer (GSP) Rev6 (242). A total of 3µl of the resulting 
cDNA was amplified using Platinum SuperFi DNA Polymerase (Thermo Fisher Scientific), as 
per manufacturer’s instructions with the addition of serotype universal FMDV capsid primers 
(243) (Forward: TGG TGA CAG GCT AAG GAT G (GenBank: EU448369 base position: 914) and 
Reverse: GCC CAG GGT TGG ACT C (pT7S3 base position: 3936)). The PCR reaction amplified 
a 2811bp product, containing part of the 5’UTR region, the leader, the capsid and parts of 2A 
encoding regions of FMDV (Figure 2.1). Cycling conditions were as follows: 98⁰C for 30 
seconds, followed by 39 cycles of 98⁰C for 15 seconds, 66⁰C for 15 seconds and 72⁰C for 2 
minutes with a final cycling step of 72⁰C for 5 minutes. Amplicons were purified using the 
Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, Little Chalfont, UK) as per 
manufacturer’s instructions and eluted in 50µl of nuclease-free water prior to quantification 
using the Qubit® dsDNA High Sensitivity Assay Kit. To confirm the correct size of the 
amplicon, each product was subjected to electrophoresis through a 1% agarose gel (Sigma-
Aldrich, Poole, UK) containing GelRed® (Biotium) and visualised by trans illumination with UV 
light.  
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2.3.4. PCR cycling optimisation 
PCR cycling conditions were optimised in order to produce the required input amount of 
nucleic acid template for Illumina sequencing using the Nexteria XT kit (Illumina, San Diego, 
USA) (i.e. 0.2 ng/µl), whilst minimising the number of cycles. In order to identify a broad 
range of where this cycle cut-off may be, eight aliquots of the DNA and cDNA generated from 
the High swarms were amplified (as described in section 2.3.3) with a tube removed every 5 
cycles (between 5 and 40 cycles). These aliquots were purified using the Illustra GFX PCR DNA 
and Gel Band Purification and eluted in 50µl of nuclease-free water, prior to quantification 
using the Qubit® dsDNA High Sensitivity Assay Kit.  
Following this, the experiment was repeated on all swarm populations, with samples being 
processed as above, but with aliquots being removed every two cycles instead of five. This 
was performed to pin-point the number of PCR cycles required for each swarm type and 
abundance (Table 2.2).  
Table 2.2. PCR cycle requirements for artificial swarms. The number of cycles tested for the 
second PCR optimisation experiment. Aliquots from each swarm type and starting input were 
processed every two cycles.  
*Copies/µl 
 Starting template* PCR cycle range 
D
N
A
 High 106 12 - 18 
Medium 104 18 - 26 
Low 102 24 – 34 
R
N
A
 High 106 18 – 26 
Medium 104 24 – 34 
Low 102 28 – 40 
 
2.3.5. Illumina MiSeq sequencing and raw read filtering 
Following PCR optimisation, all RNA and DNA swarms were amplified in quadruplicates (with 
the RT and PCR steps being performed independently) and sequenced on a single HTS 
sequencing run. Samples were diluted to 0.2 ng/µl in nuclease-free water prior to library 
preparation using the Nextera XT DNA sample preparation kit (Illumina) as per 
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manufacturers’ protocol.  Final libraries were multiplexed and diluted to 12.5 pM prior to 
sequencing on an Illumina MiSeq platform using a 2x150 cycle, paired-end sequencing run 
on a version 2 chemistry MiSeq reagent cartridge.  
After sequencing, quality control checks were performed on the raw FASTQ data using 
FastQC (244) (Version 0.11.5). Sections of the reads which were of lower quality or contained 
per base sequence content difference of greater than 10% (FastQC considers this a warning) 
were removed using Prinseq-lite (version 0.20.4) (230). 
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2.4. Results 
2.4.1. Plasmid linearisation 
Plasmids pT7S3 1:5 were linearised (Figure 2.3) using the restriction enzyme HpaI to allow in 
vitro transcription of RNA. A secondary double digestion using restriction enzymes Bsu36I 
and NsiI in order to identify if each plasmid contained the FMDV insert (Figure 2.1) produced 
two fragments of 10,355bp and 767bp (Figure 2.3). Plasmids digested with HpaI were 
quantified using the Qubit DNA HS assay and number of copies/µl estimated, with a mean of 
1.37x1010 copies/µl being produced (Table 2.3).  
 
Figure 2.3. Unlinearised and linearised pT7S3. Agarose gel depicting pT7S3 1-5 which are; 
unlinearised (1), linearised with HpaI (2) and with Bsu36I and NsiI (3).  
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2.4.2. In vitro transcription of RNA 
Following in vitro transcription, each of the plasmids were quantified using the Qubit with an 
estimated mean of 6.78 RNA copies/µl for each sample (Table 2.3). Using this and the 
estimated plasmid size, the estimated copy number per µl was estimated (Table 2.3).  
Table 2.3. DNA and RNA swarm quantification. The estimated nucleic acid length and 
quantification values for each of the DNA and RNA templates.  
* Sample diluted 1/10 prior to quantification 
+ For the RNA samples: Copy number of the 8kb fragments 
 
Samples Template length Qubit (ng/µl)* Copy numbers/µl+ 
D
N
A
 
pT7S3 1 
11278nt 
148.00 1.23x1010 
pT7S3 2 141.50 1.17x1010 
pT7S3 3 152.25 1.65x1010 
pT7S3 4 143.00 1.43x1010 
pT7S3 5 165.25 1.38x1010 
R
N
A
 
pT7S3 1 
8297nt 
75.75 8.46x1010 
pT7S3 2 71.50 7.98x1010 
pT7S3 3 58.00 6.48x1010 
pT7S3 4 72.25 8.07x1010 
pT7S3 5 25.90 2.89x1010 
 
2.4.3. Reverse transcription optimisation 
In order to identify an RT polymerase with the greatest cDNA conversion efficiency, three 
different RT enzymes; SuperScript III, SuperScript IV and Transcriptor High Fidelity Reverse 
Transcriptase were tested in duplicates on the High and Low concentrations of the RNA 
swarm. Following RT, samples were amplified with limited cycles and quantified using the 
Qubit. Quantified cDNA between technical replicates showed that SuperScript III, SuperScript 
IV and Transcriptor HiFi produced on average 31.31 ng/µl, 45.05 ng/µl and 41.75 ng/µl 
respectively for the RNA High sample set and an average of 7.21 ng/µl, 15.49 ng/µl and 4.02 
ng/µl respectively for the RNA Low set. Transcriptor HiFi was selected for future use due to 
its reported increased fidelity and as the quantification values for each replicate were closer 
in comparison for the RNA High data set (between the two replicates, there was a difference 
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of 15.31 ng/µl for SuperScript III, 6.22 ng/µl for SuperScript IV and 0.1 ng/µl for Transcriptor 
HiFi) (Table 2.3). Though Transcriptor HiFi performed poorly on the RNA Low swarm, enough 
DNA was produced for sequencing using the Nextera XT kit. Amplified products were 
visualised on an agarose gel (Figure 2.4).  
Table 2.4. Reverse transcription yields for RNA High and Low swarms. The Qubit yields of 
amplified products following reverse transcription of the RNA High and Low swarms using 
different RT enzymes SuperScript III, SuperScript IV and Transcriptor HiFi. 
 
Input RNA   
Qubit dsDNA HS reading (ng/µl) 
SuperScript III SuperScript IV Transcriptor HiFi 
High 
Replicate 1 38.96 48.15 41.80 
Replicate 2 23.65 41.93 41.70 
Low 
Replicate 1 7.20 14.93 3.64 
Replicate 2 7.22 16.05 4.40 
Negative control 0.00 0.00 0.00 
 
 
Figure 2.4. RT of RNA high and RNA low swarms. Agarose gel depicting the amplified 
products for the RNA High and Low swarms following reverse transcription with SuperScript 
III, SuperScript IV and Transcriptor HiFi. Sizes of the ladder on the gel are indicated.  
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2.4.4. PCR cycling optimisation 
To gain an insight into the number of PCR cycles required to amplify a template for 
sequencing, two experiments were performed. In the first experiment, eight aliquots of the 
DNA and RNA High swarms were amplified (following RT using Transcriptor HiFI for the RNA 
swarm) in singlets with one aliquot removed and quantified every 5 cycles from cycles 10 to 
40. The lowest detectable amount of DNA occurred after 10 cycles for the DNA swarm (0.06 
ng/µl) and 20 cycles (0.28 ng/µl) for the RNA swarm, while visible product on a gel 
electrophoresis was observed from 15 cycles and 25 cycles for the DNA High and RNA High 
swarms respectively (Figure 2.5). The DNA High swarm produced a greater amount of 
amplified product than the RNA High swarm and after 40 amplification cycles there was a 
30.01% difference between the final products (Table 2.4).  
Table 2.5. DNA produced following PCR for DNA and RNA high swarms. The amount of 
amplified product for the DNA and RNA High swarms after different amplification cycles 
between 10 and 40, with Qubit quantification readings taken every 5 cycles.  
 
    Qubit dsDNA HS assay (ng/µl) 
PCR cycle number 10 15 20 25 30 35 40 
DNA 0.06 1.18 7.35 15.15 23.45 32.73 42.15 
RNA 0.00 0.00 0.28 4.13 14.30 18.05 29.50 
Percentage 
difference 
100.00% 100.00% 96.15% 72.74% 39.02% 44.85% 30.01% 
 
Based on these results, a second experiment was undertaken using a narrower range of PCR 
cycles (Table 2.2) on all DNA and RNA swarms with aliquots being removed and quantified 
every 2 cycles. Results reveal that the use above 18, 24 and 32 cycles for the DNA High, 
Medium and Low swarms and above 26, 34 and 40 cycles for the RNA High, Medium and Low 
swarms produced adequate material for sequencing (Table 2.6).  
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Table 2.6. DNA produced following PCR for all swarms. The amount of amplified product for 
all DNA and RNA swarms types between 12 and 40 cycles, with Qubit quantification readings 
taken every 2 cycles. The shaded cells indicate cycles not quantified. 
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Figure 2.5. PCR of DNA and RNA high swarms. An agarose gel image showing the amount of 
amplicon produced for the DNA and RNA High swarms from cycles 5 to 40.  
 
2.4.5. Illumina Sequencing and raw read analysis 
All DNA and RNA swarm populations were processed in quadruplicates and sequenced on an 
Illumina MiSeq platform using the Nextera XT kit on a V2 300 cycle cartridge. Illumina base 
calling revealed that no reads were generated for the DNA Medium swarm data set. As a 
result of this, this population was dropped from future analysis.  
A total of 2.52x107 sequence reads were produced, with each sample having between 
2.71x105 and 1.57x106 reads (mean: 1.26x106, median: 1.36x106). For all samples, a mean of 
85.42% (median: 86.78%) of reads were of a qScore of q30 and above and a mean of 80.57% 
were of a length of 70bp and above. FastQC identified that on average the first 15 and final 
5 bases failed on the per base sequence content analysis and consequently trimmed using 
Prinseq-lite (Figure 2.6). The mean read length after trimming was 131bp in length. Further 
information regarding the qScore and read length properties of the reads for all samples 
sequenced can be found on Table 2.7.  
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Figure 2.6. Per base sequence quality and content. The distribution of qScore for each read 
position is shown by the boxplot with the purple line representing the mean qScore. The Per 
base sequence content percentage for each A (green), C (blue), T (red) and (black) is by the 
coloured lines. The dotted lines indicate the points before (<15bp) and after (>145bp) where 
the reads were trimmed using Prinseq-lite. Data is an example of RNA High replicate one.   
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2.4.6. Data analysis 
Systematic analysis of these data is described in chapter 3. HTS reads were passed through 
in-house BASH and R scripts which assessed genomic type and input, read parameters 
(qScore and read length), short-read aligners, short-read aligners, replicate combinations 
and percentage frequency cut-offs on variant identification accuracy.  
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Table 2.7. Illumina raw read data. The percentage frequency of raw reads from all sample 
types (excluding the DNA Medium swarm in which no reads were generated) which were 
above certain qScore and read length thresholds 
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2.5. Discussion 
A disadvantage of using HTS to identify low frequency variants is the high coverage required 
and as a result PCR is often employed to generate the sufficient template. This factor can be 
problematic for an RNA based genome as the use of a low-fidelity RT polymerase enzyme 
could introduce errors which in turn would be amplified (215), whist a low cDNA converting 
RT polymerase enzyme could theoretically lead to disproportional amplification. Out of three 
enzymes tested, Transcriptor HiFi polymerase was identified to be the most consistence in 
regards to the amount of final product produced between technical replicates, however 
further testing would be required to confirm this. Furthermore, the manufacture has 
reported that this polymerase has between 4 and 7 times the fidelity compared to other 
commonly used RT enzymes (245). While this report stated that Transcriptor HiFi was only 
tested against another ‘commonly used Moloney Murine Leukemia Virus (MMLV) reverse 
transcriptase’, the manufacture of the genetically engineered MMLV based SuperScript III 
(Thermo Fisher Scientific) have quoted an error rate of 1 in 3.5x104 bases (based on email 
correspondence). Based on the reported fidelity (245), this gives an estimated error rate of 
the Transcriptor HiFi polymerase of between 1 in 1.4x105 and 2.45x105. However, further 
testing would be required to confirm this as these numbers are based on manufacture’s 
testing and not independent investigation.  
During the PCR step, the polymerase enzymes utilised can introduce error, although the 
degree of which depends on the fidelity of the particular enzyme used (214). Error in this 
study has been limited by the use of Platinum Taq SuperFi DNA Polymerase, which Invitrogen 
have estimated the fidelity to be greater than 100x the fidelity that of the non-proofreading 
Taq polymerase (1 in 3.7x104 to 1.25x105 errors per nucleotides amplified (246)). This 
estimation gives an error rate for Platinum Taq SuperFi as 1 in 3.7x106 to 1.25x107 errors per 
nucleotides amplified. Although as with Transcriptor HiFi, this number is based on 
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manufacture’s testing and independent investigation would be required to test this. A 
greater number of PCR amplification cycles can lead to other biases, including artefactual 
recombination (214) and skewed allelic frequencies through preferential amplification of a 
small number of variants (223).  
Through the systematic evaluation of the RT and PCR processes a laboratory HTS pipeline 
has been developed. This pipeline utilises a high-fidelity RT and PCR polymerase enzymes as 
well optimised amplification cycles for both DNA and RNA populations at different starting 
inputs.  
Following optimisation of a laboratory based pipeline for HTS, analysis was performed on the 
generated reads. Systematic evaluation of the bioinformatics analysis as described in chapter 
3 demonstrated the influence of genomic type and input, choice of short-read aligner, read 
parameters (qScore and length) and frequency cut-off on the ability to accurately predict 
low-frequency substitutions.   
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Chapter 3  
A systematic evaluation of computational based 
protocols to accurately identify low-frequency variants 
with DNA and RNA templates 
This work, combined with chapter 2 has been submitted to BMC Genomics: 
A systematic evaluation of high-throughput sequencing based approaches for identifying 
low-frequency variants 
David J. King1,2, Graham Freimanis1, Lidia Lasecka-Dykes1, Amin Asfor1, Paolo Ribeca1, Ryan 
Waters1, Donald P. King1 and Emma Laing2 
1The Pirbright Institute, Woking, Surrey, UK 
2Department of Microbial and Cellular Sciences, School of Biosciences and Medicine, Faculty 
of Health and Medical Sciences, University of Surrey, Guildford, UK 
Corresponding author: Emma Laing: e.laing@surrey.ac.uk 
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3.1. Abstract  
Data generated by HTS technologies provide efficient ways of understanding sub-consensus 
population dynamics. However, errors introduced prior to and during sequencing can mask 
true biological variance, limiting the full potential of HTS datasets. In addition to this, specific 
algorithms behind short-read alignment programs can influence variant calling, with each 
program claiming to offer the highest level of accuracy. While previous comparison studies 
have systematically investigated both laboratory and bioinformatics techniques for HTS 
analysis, these have focused on high-frequency variants in intermediate coverage data sets. 
For the first time, this study systematically evaluated the impact of both laboratory 
(described in chapter 2) and computational analysis techniques to identify low-frequency 
variants in high-coverage datasets. Using Illumina sequence data generated from DNA and 
RNA based ‘artificial swarm’ populations (as described in chapter 2), the impact abundance 
and type of starting input material, number of technical replicates, read length and quality, 
choice of short-read aligner, and percentage frequency thresholds on the ability to 
accurately call variants were systematically evaluated.  
Analyses revealed that abundance and type of input nucleic acid had the greatest impact on 
the accuracy of variant calling as measured by Matthews correlation coefficient (MCC). DNA 
and high RNA inputs (107 copies) variants could be called at 0.2% frequency, with a MCC of 
1 and 0.816 respectively, while reduced RNA input (105 copies) required more technical 
replicates to maintain accuracy. Low RNA inputs (103 copies) suffered from non-reproducible 
consensus-level errors. In addition, unique patterns of low-frequency errors were identified, 
which can be used to further limit error and maximise variant calling confidence in HTS 
datasets.  
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3.2. Background and introduction 
Advances in HTS technologies such as those offered by Illumina™ allow for the rapid 
generation of large amounts of deep sequence data. However, in order to obtain high 
coverage, enrichment of the sequencing target is normally required and as a result PCR is 
typically utilised to generate sufficient material for HTS (214). This coupled with the RT (for 
RNA genomes) (215) and the sequencing process (212) can introduce error which can mask 
true biological variance (further information is provided in section 1.6). While these 
laboratory steps do introduce error (see chapter 2), computational analysis of data can lead 
to further biases being introduced (247), such as analysis of low-quality reads, incorrect use 
of mismatch and gap opening penalties, as well as alignment issues with genomic biases such 
as GC content (248). In addition, specific algorithms behind short-read alignment programs 
(249) can also influence variant calling, while an increasing number of available programmes, 
each claiming to offer the highest level of accuracy (250–253), can make it difficult to choose 
an algorithm that introduces the least amount of bias. 
While previous studies have simultaneously and systematically investigated the impact of 
laboratory and bioinformatics protocols on variant calling and error generation (254), the 
focus has always been on intermediate coverage and high-frequency variants data, often 
used in large genome investigations. Here, for the first time, the impact of different 
laboratory (see chapter 2) and bioinformatics approaches have been systematically 
evaluated with which to produce a HTS pipeline for identifying low-frequency variants with 
high confidence.  
In an attempt to establish a systematic approach to generate frequency thresholds above 
which mutations can be called with high confidence, and to characterise potential HTS errors, 
an artificial FMDV DNA and RNA based swarm was created (as described in chapter 2). 
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Following sequencing of the High, Medium and Low RNA swarms and the High and Low DNA 
swarms on an Illumina MiSeq platform, computational analysis was performed to assess the 
influence of genome type and input, different read parameters (qScore and length), choice 
of short-read aligner, number of technical replicates, and percentage frequency cut-offs, on 
variant calling performance. Assessing all possible combinations of approaches, with the 
laboratory analysis (as described in chapter 2) identified key factors that influence the overall 
performance of an HTS pipeline, as well as defining a ‘tailored’ HTS pipelines taking into 
consideration both the type and amount of input material and identified reproducible 
patterns of error.  
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3.3. Materials and Methodology 
Following the evaluation of the laboratory HTS pipelines for each of the DNA and RNA 
artificial swarms and sequencing on an Illumina MiSeq platform (as described in section 
2.3.5), HTS reads were passed through Bash and R based in-house scripts to determine the 
effect of the following on variant calling accuracy:  
 Genome type and starting input 
 Number of technical replicates  
 HTS read parameters (qScore and read length) 
 Choice of short-read aligner and associated parameters 
 Percentage frequency thresholds 
3.3.1. Reference consensus sequence generation 
A de novo assembly was performed on the HTS data from each of the swarm sample using 
IDBA_UD (version 1.1.1) (255). Briefly; each of the paired HTS reads from each sample set 
were trimmed using Sickle (version 1.33) (231) using qScore and read length parameters of 
q35 and length >70bp respectively. Paired trimmed reads were converted into a fasta format 
and merged into a single file using the script fq2fa (downloaded as part of the IDBA_UD 
package). This was followed by trimming all reads to a maximum length of 125bp using 
Prinseq-lite (230) and then running IDBA_UD using a kmer length of intervals of 20 between 
20 and 120 and the short-read parameter setting (defined as reads of 125 and below). The 
resulting contigs was uploaded onto BLAST (using blastn) (256) to confirm identify. Following 
this the primer sequences were removed from the reference sequence.  
Generated sequences from each swarm were then aligned using BioEdit (Version 7.2.5) (257) 
and a consensus sequence generated. The known positions where variants had been 
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introduced (Table 2.1a) were then checked to confirm an accurate consensus sequence. This 
reference sequence can be found in Supplementary sequence 3.1.  
3.3.2. HTS read trimming and alignment pipelines 
Prinseq-lite (version 0.20.4) trimmed reads (section 2.4.5) were passed through an in-house 
bash (version 4.1.2(1)) script. This script iteratively (for each parameter assessed) processed 
reads through Sickle (231) (version 1.33) (which filtered reads according to q quality (qScore) 
and l (length) (Table 3.1)) and then separately through five commonly cited short read 
aligners;  
 BWA-MEM (version 0.7.12-r1039) (250)  
 GEM3 (Version 3.6-2-g77d1) (251) 
 Bowtie2 (version 4.1.2) (Both Local and Global alignment) (252) 
 HiSAT2 (version 4.8.2) (253) 
 SMALT (version 0.7.6) (http://www.sanger.ac.uk/resources/software/SMALT).  
For each set of filtered reads (q) of a given length (l), different sets of parameters of each 
aligner (Table 3.1) were used to map reads to the reference consensus sequence to produce 
a .SAM file. 
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Table 3.1. Program parameters tested for HTS pipeline. A list of programs used for HTS 
read quality control checks and alignment and their parameters used in this study.  
          
    Program options Program code Parameter options 
P
re
-a
lig
n
m
e
n
t 
P
ri
n
se
q
 
5' Trimming -trim_left 15 
3' Trimming -trim_right 5 
Si
ck
le
 qScore -q 0, 10, 20, 25, 30, 35, 38 
Read Length -l 70, 80, 90, 100, 110, 120, 130  
Sh
o
rt
-r
ea
d
 a
lig
n
er
s 
B
W
A
-M
EM
 
Minimum Seed Length -k 10, 20 
Re-seeding -r 1, 1.5, 2 
G
EM
3
 Mapping mode --mapping-mode fast, sensitive 
Maximum alignment error 
--alignment-max-
error 
0.05, 0.10, 0.12, 0.15 
B
o
w
ti
e2
 
Local alignment -- 
very-fast-local, fast-local, sensitive-local, 
very-sensitive-local 
Global alignment -- very-fast, fast, sensitive, very-sensitive 
H
iS
A
T2
 Most distinct primary 
alignment 
-x 0, 1, 3, 5, 7, 10, 13, 15 
Maximum seed length -k 1, 3, 5, 7, 10, 13, 15, 17, 20 
Sm
al
t Length of k-mer word index -k 11, 13, 16, 18, 20 
Sample every # k-mer -s 1, 3, 5, 7, 8, 11, 13, 16, 18, 20 
 
3.3.3. Mathew’s Correlation Coefficient analysis 
Each .SAM file was converted into a .BAM file using SAMTools (Version 1.2)(258), which in 
turn was used to generate a tab-delimited file of the aligned data for each sample set using 
SAMTools mpileup written using R (version 3.3.1) was used to covert the SAMTools mpileup 
file into a human readable file). This file contained the number of A, C, G and T bases at each 
sequenced position. These tab-delimited files were then passed through an in-house R-script 
which computed, for each sequenced position, and all frequency thresholds (between 0.01% 
and 1%, with intervals of 0.01% between 0.01% and 0.1% and intervals of 0.1% between 0.1% 
and 1%), all four elements of a confusion matrix (Figure 3.1).  
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Figure 3.1. Confusion matrix. All four elements of the confusion matrix and their meanings 
generated from each nucleotide position for all HTS pipelines 
 
The calling of a variant is dependent on the frequency threshold being applied, for example, 
at a frequency threshold of 0.5%, known-variants at 0.01% would be considered as a FN as 
they are below the applied threshold.  
This approach was subsequently repeated for all possible duplicate (6 possible 
combinations), triplicate (4 possible combinations) and quadruplicate combinations of each 
singlet samples such that, at the given threshold, the calling of TP and TNs at a position was 
based on 100% agreement, e.g. a TP assigned if all samples in a combination agree a TP if not 
the alternative FN and FP was made. Finally, the TP, TN, FP and FN values across all 
combinations of replicates were used to calculate a micro-averaged Matthew’s correlation 
coefficient (MCC) (i.e. micro-average all singlets, micro-average of all duplicate 
combinations, micro-average of all triplicate combinations, micro-average of quadruplicate 
combination), a measure of classification performance that considers the entire confusion 
matrix and is able to handle an imbalance of classes (i.e. few true variants), for each position:  
𝑀𝐶𝐶 =
∑ 𝑇𝑃𝑐𝑐 ∑ 𝑇𝑁𝑐 − ∑ 𝐹𝑃𝑐𝑐 ∑ 𝐹𝑁𝑐𝑐𝑐
√(∑ 𝑇𝑃𝑐𝑐 + ∑ 𝐹𝑃𝑐𝑐 )(∑ 𝑇𝑃𝑐𝑐 + ∑ 𝐹𝑁𝑐𝑐 )(∑ 𝑇𝑁𝑐𝑐 + ∑ 𝐹𝑃𝑐𝑐 )(∑ 𝑇𝑁𝑐 + ∑ 𝐹𝑁𝑐𝑐 )
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A perfect correlation between the predicted and observed, equivalent to 100% accuracy in 
variant calling, is indicated by a MCC score of 1, random calls by a MCC score of 0, and a total 
discordance by a MCC score of -1.  
The median micro-averaged MCC (MuMCC) across all sequence positions was used to 
represent the average performance of a candidate HTS pipeline comprising a combination of 
experimental and bioinformatic factors (aligners, replicate number and frequency threshold) 
from which the performance assessment was derived.  
The effect of each laboratory and bioinformatic factor on the confidence of variant detection 
was assessed using ANOVA (259) (R (version: 3.3.1), aov). Tukey’s honest significant 
difference (HSD) (260,261) test (R (version: 3.3.1), TukeyHSD) was performed post-hoc for 
factors identified as having a significant effect (ANOVA P-value <0.01). Following these tests, 
the factors that produced the highest MuMCC scores were selected for each swarm type. 
Areas with higher percentages of error were identified and were used to investigate 
sequence patterns along the template which could contribute to reproducible error.  
3.3.4. Percentage critical difference analysis 
In order to confirm the percentage frequency cut-off based on the MuMCC scores for the 
different duplicate inputs of the DNA and RNA swarms, Bland-Altman plots were created. 
These plots describe the agreement between technical replicates by plotting the average of 
variance/error (x-axis) in each technical replicate against the difference in variance/error in 
each technical replicate (y-axis) (Figure 3.2).  
In total, 95% of the data should fall within ± 1.96 standard deviation of the mean (262). From 
this analysis, a percentage critical difference (PCD) score can be calculated, which is equal to 
half the difference of the upper and lower standard deviation limits. Replicate samples with 
a high level of agreement in variant calling would be expected to have a lower critical 
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difference score. Subsequently, samples with a lower critical difference score could be given 
a lower percentage frequency cut-off. An example of a Bland-Altman plot can be found on 
Figure 3.2.  
For each duplicate replicate combination for each swarm type a PCD score was generated. 
The range of scores were then compared with the frequency cut-off established for each 
swarm type using the MuMCC analysis. Bland-Altman and PCD score analysis using the R 
based package BlandAltmanLeh (version 0.31) (263) 
As all datasets presented in chapters 3 and 4 were performed using duplicate technical 
replicates, the PCD score from Bland-Altman analysis was chosen to confirm the percentage 
frequency cut-off for real biological samples.  
 
Figure 3.2. Bland-Altman plot example. A plot of the percentage differences between 
method A and method B vs the mean of the two measurements. The ± 1.96 standard deviation 
from the mean is indicated by the dotted lines, while the double sided arrows between them 
indicate the percentage difference between the mean and ± 1.96 standard deviation. The 
critical difference is equal half the difference of the upper and lower standard deviation limits. 
In this example, the critical difference would be 68.2%. Example generated from previously 
generated FMDV sequence data.   
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3.4. Results 
3.4.1. HTS file output 
DNA and RNA based ‘artificial swarm’ populations were created by introducing a total of 20 
sequence variants at known positions and frequencies between 0.01% and 10% in the 
population (table 2.1). Subsequently, the overall accuracy of candidate HTS pipelines, 
comprising a combination of different laboratory and bioinformatic steps, were assessed. 
The approaches evaluated included: the type (DNA and RNA) of starting material and 
abundance (high, medium (RNA only) and low) and; read length and quality; choice of one of 
five commonly cited short read aligners (i.e. BWA-MEM, GEM3, Bowtie2 (Local and Global), 
HiSAT2 and SMALT) and their related parameters in regards to read alignment; number of 
technical replicates (one, two, three or four); and the frequency threshold (0.01%-1%) 
applied. 
From the loop Bash script (section 3.3.2), a total number of 3.99x106 files were produced, 
each representing a single iteration of the HTS pipeline and containing the number of each 
nucleotides at each site across the sequenced amplicon region. From these files the MuMCC 
values were summarised, whereby the distribution of accuracy for each of the main factors 
of type of input material, abundance of input material, qScore, read length, aligner and 
associated factors on accuracy could be assessed. Accordingly, the influence of each of these 
parameters on the distribution of MuMCC values obtained was assessed by ANOVA and 
TukeyHSD tests. Here, the influence of aligner and then the impact of replicate combinations 
and qScore, read length and percentage frequency cut-off individually is described.  
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3.4.2. The effect of input nucleic acid and aligner choice on the accuracy of 
variant calling 
To assess which of the tested aligners had the greatest influence on the accuracy of variant 
calling, the range of MuMCC scores across all factors tested (aligners, aligner parameters, 
read parameters and cut-off thresholds) was compared. The analysis showed that for all 
aligners tested, the DNA swarms had a greater maximum MuMCC, compared to their 
equivalent RNA swarms (Figure 3.3, Table 3.2). There was a positive relationship between 
the amount of starting input material for both DNA and RNA swarms and the range of 
MuMCC scores, with a greater effect on performance observed for RNA swarms. A TukeyHSD 
test comparing the distributions of MuMCC between input material types showed that DNA 
swarms were significantly different to the RNA swarms (RNA-DNA difference of MuMCC: -
0.088, TukeyHSD P-value = <0.01). Performing the equivalent comparison for the factor 
‘abundance’ highlighted significant differences between the levels of input material, with 
lower MuMCC values as the input levels decreased (TukeyHSD P-value = <0.01).  
Comparing across aligners, GEM3 produced the highest mean MuMCC (RNA High: 0.389, 
RNA Medium: 0.262, Low: 0.131, DNA High: 0.490, DNA Low: 0.394), whilst Bowtie2 Global 
yielded the poorest values across all swarm sets tested (RNA High: 0.213, RNA Medium: 
0.146, Low: 0.072, DNA High: 0.233, DNA Low: 0.172) (Table 3.2). Post-hoc tests showed that 
the use of GEM3 as an aligner for all swarm types (except RNA Low) produced a significant 
(TukeyHSD p-Value = <0.01) difference in accuracy against all aligners with the exception of 
BWA-MEM.  
Although no overall significant differences were found between GEM3 and BWA-MEM (with 
the exception of RNA Low), GEM3 was selected as the aligner on which all downstream 
analysis were based as it produced the higher overall mean MuMCC scores (Table 3.2).  
90 
 
 
 
Figure 3.3. MuMCC distribution range for tested aligners. The range of MuMCC scores of 
each of the tested aligners (including all parameters) used for all singlets swarm types.  
RNA High = Red, RNA Medium = Orange, RNA Low = Light orange, DNA High = Blue, DNA Low 
= Light blue. The mean of the MuMCC range is indicated by the solid black dot within each 
boxplot.  
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Table 3.2. MuMCC distribution range for tested aligners. The range of MuMCC scores 
generated for each artificial swarm type from each HTS pipeline for each of the short-read 
aligners tested.  
 
      Aligners 
  BWA-MEM GEM3 
Bowtie2 
Local 
Bowtie2 
Global 
HiSAT2 SMALT 
R
N
A
 
H
ig
h
 
Minimum 0.009 0.010 0.008 0.010 0.015 0.008 
1st Quartile 0.115 0.151 0.102 0.099 0.139 0.102 
Median 0.347 0.382 0.321 0.254 0.324 0.321 
Mean 0.362 0.389 0.346 0.213 0.362 0.347 
3rd Quartile 0.577 0.577 0.577 0.288 0.577 0.577 
Maximum 0.816 0.855 0.816 0.500 0.855 0.816 
M
ed
iu
m
 
Minimum 0.009 0.007 0.007 0.008 0.007 0.006 
1st Quartile 0.053 0.071 0.051 0.050 0.069 0.051 
Median 0.103 0.103 0.103 0.097 0.103 0.103 
Mean 0.254 0.262 0.248 0.146 0.259 0.249 
3rd Quartile 0.539 0.539 0.512 0.272 0.539 0.539 
Maximum 0.707 0.707 0.707 0.367 0.707 0.707 
Lo
w
 
Minimum -0.004 -0.005 -0.003 -0.004 -0.002 -0.003 
1st Quartile 0.020 0.027 0.018 0.017 0.027 0.018 
Median 0.101 0.096 0.095 0.061 0.101 0.090 
Mean 0.126 0.131 0.122 0.072 0.131 0.122 
3rd Quartile 0.250 0.250 0.250 0.133 0.250 0.250 
Maximum 0.250 0.250 0.250 0.138 0.250 0.250 
D
N
A
 
H
ig
h
 
Minimum 0.008 0.008 0.008 0.008 0.013 0.008 
1st Quartile 0.148 0.202 0.132 0.127 0.193 0.133 
Median 0.568 0.581 0.504 0.288 0.547 0.511 
Mean 0.453 0.490 0.404 0.233 0.463 0.433 
3rd Quartile 0.707 0.707 0.707 0.299 0.707 0.707 
Maximum 1.000 1.000 1.000 0.554 1.000 1.000 
Lo
w
 
Minimum 0.003 0.002 0.004 0.006 0.002 0.005 
1st Quartile 0.058 0.093 0.053 0.052 0.087 0.053 
Median 0.376 0.395 0.327 0.202 0.402 0.327 
Mean 0.368 0.394 0.351 0.172 0.391 0.352 
3rd Quartile 0.707 0.707 0.707 0.288 0.707 0.707 
Maximum 0.707 0.729 0.707 0.301 0.707 0.707 
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3.4.3. The effect of replicate combinations and qScore choice on the accuracy 
of variant calling 
Having set the aligner to GEM3, the impact of qScore threshold and the number of technical 
replicates on the overall accuracy of variant calling was investigated. Figure 3.4 depicts the 
range of MuMCC scores for different qScore thresholds for all population types, showing that 
accuracy increases as the qScore parameter is raised.  
Comparing the distributions for the RNA High population found that a qScore of q38 for 
singlets, either q35 or q38 for duplicate, and q38 for triplicate and quadruplicate technical 
replicates produced the maximum MuMCC scores (0.855, 0.816, 0.894 and 0.894 
respectively). While for the RNA Medium population all qScores tested for all technical 
replicates produced a maximum MuMCC score of 0.707. However differences were 
identified between the mean MuMCC values with a qScore of q35 for singlet and q38 for 
duplicate, triplicate and quadruplicate technical replicates producing the highest mean 
MuMCC (0.279, 0.380, 0.455 & 0.513 respectively). Post-hoc analysis revealed that the 
MuMCC scores produced using a qScore of 38 of all technical replicate combinations in the 
RNA High population were significantly (TukeyHSD P-value = <0.01) higher than the mean 
MuMCC values of other qScore thresholds tested. This was also observed for the RNA 
Medium population, except for duplicate replicate combinations whereby a qScore of q35 
was significantly (TukeyHSD P-value = <0.01) higher. For the RNA Low population, the highest 
MuMCC score was obtained using a qScore of 35 (MuMCC: 0.279). The use of duplicate, 
triplicate or quadruplicate technical replicates reduced the highest MuMCC score to 
between -0.001 and 0.005 for all qScore parameters tested, indicating that the variant calls 
made by such HTS pipelines were no better than random.  
In contrast, the maximum MuMCC scores produced for the DNA High population was 
achieved using a qScore of between q30 and q38 for singlet (Maximum MuMCC: 1.00) and 
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q30 for duplicate, triplicate or quadruplicate technical replicates (Maximum MuMCC: 1.00). 
While for the DNA Low population all qScores tested for all technical replicates produced a 
maximum MuMCC score of 0.707. Differences were identified for the mean MuMCC with a 
qScore of q35 for singlet and duplicate (mean MuMCC: 0.471 and 0.495 respectively) and 
q38 for triplicate and quadruplicate (mean MuMCC: 0.510 & 0.522 respectively) technical 
replicates. TukeyHSD post-hoc analysis indicated that the use of q38 for singlet and duplicate 
and q35 for triplicate and quadruplicate technical replicates produce significantly (TukeyHSD 
P-value = <0.01) different results for the DNA High population compared to other qScore 
thresholds. For the DNA Low population, a qScore of 35 for all replicate combinations had 
the most significant difference (TukeyHSD P-value = <0.01).  
Further information about the range of MuMCC scores for all qScore parameters tested for 
all populations can be found in Supplementary table 3.1, while a full list of qScore parameters 
producing the highest accuracy for variant detection can be found in Table 3.3. 
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Figure 3.4. qScore MuMCC range following GEM3 alignment. The range of MuMCC scores 
for each swarm type of each qScore parameter tested following alignment using GEM3. 
Singlet, duplicate, triplicate and quadruplicate technical replicates for each swarm type are 
represented by a different shade of colour. The solid black dot within each boxplot indicates 
the mean of the MuMCC distribution.   
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3.4.4. The effect of replicate combinations and read length choice on the 
accuracy of variant calling 
Following alignment using GEM3 and chosen qScore (Table 3.3), the influence of read length 
and the number of technical replicates on variant calling accuracy was tested. Although 151 
sequencing cycles were used for each paired-end, the read length profile of each sample set 
varied as a result of the adaptor and quality trimming procedures. The read length parameter 
therefore sets the minimum length of the trimmed reads.  
Figure 3.5 depicts the distribution of the MuMCC scores of different read lengths for all 
swarm types when using GEM3 and the optimised (Table 3.3) qScore parameters as input. 
The figure shows that as the read length increases the mean MuMCC score decreases slightly.  
For the RNA High population a read length of 70bp, 80bp, 90bp and 130bp and above 
produced the highest MuMCC score (maximum MuMCC: 0.816), while for duplicate technical 
replicates all read lengths produced the same highest MuMCC score (maximum MuMCC: 
0.816). For triplicate and quadruplicate technical replicates a read length of 130bp and above 
produced the highest accuracy (Maximum MuMCC: 0.894 for both). Post-hoc analysis 
revealed that for singlets, the mean MuMCC values for a read length of 70bp were 
significantly higher (TukeyHSD P-value =<0.01) against all other parameters except read 
lengths of 80bp and 90bp. For duplicate, triplicate and quadruplicate replicates the MuMCC 
values of 70bp were significantly (TukeyHSD P-value =<0.01) higher against all parameters 
except read lengths of 80bp, 90bp and 100bp. For the RNA Medium population, all read 
lengths tested produced a maximum MuMCC score of 0.707 in all technical replicate 
combinations tested, while differences were identified in the mean MuMCC scores, with 
70bp and above for singlets, duplicate and triplicates and 130bp and above for 
quadruplicates producing the highest mean MuMCC scores (mean MuMCC: 0.282, 0.381, 
0.442 and 0.497 respectively). TukeyHSD post-hoc analysis indicated that the use of a read 
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length of 70bp and above for singlet and duplicate replicates produced significantly 
(TukeyHSD P-value <=0.01) higher MuMCC values compared to all other read length 
thresholds except for a read length of 80bp, whist for triplicate and quadruplicate replicates, 
no significant read length comparisons were identified. While for the RNA Low population, 
only singlet replicates produced a mean MuMCC score above 0.01, with the highest being 
0.149 when a read length of 100 and above was used.  
In contrast, for the DNA High population all read lengths tested for singlets and read lengths 
between 70bp and 110bp and above for duplicate, triplicate and quadruplicate technical 
replicates produced the highest MuMCC scores (maximum MuMCC: 1.00 respectively). 
While, a read length of 70bp and above for singlet, duplicate and triplicate replicates and 
100bp and above for quadruplicates was found to produce the highest mean MuMCC score 
(mean MuMCC: 0.619, 0.654, 0.663 and 0.686 respectively). Post-hoc analysis revealed that 
for single replicates, the mean MuMCC values for a read length of 70bp and above were 
significantly (TukeyHSD P-value =<0.01) higher when compared to all other read length 
parameters except lengths of 80bp and 90bp. For duplicates, the mean MuMCC values for a 
read length of 70bp and above was only significantly (TukeyHSD P-value =<0.01) higher when 
compared to a parameter of 130bp. For triplicate replicates no significant comparisons were 
identified and for quadruplicate replicates, the mean MuMCC values for a read length of 
100bp and above were only significantly (TukeyHSD P-value =<0.01) higher when compared 
against read lengths of 120bp and 130bp.  
For the DNA Low population, the highest MuMCC score obtained was 0.707 regardless of the 
number of technical replicates, whilst the highest mean MuMCC score for singlet and 
duplicate replicates were produced using a read length of 80bp and above (mean MuMCC: 
0.485 & 0.501 respectively) and 100bp and above for triplicate and quadruplicate replicates 
(mean MuMCC: 0.505 & 0.510 respectively). TukeyHSD post-hoc analysis indicated that the 
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use of a read length of 70bp and above for singlet and duplicate replicates produced 
significantly (TukeyHSD P-value <=0.01) higher mean MuMCC scores only when compared to 
read lengths of 120bp & 130bp for singlet replicates and 130bp for duplicate replicates. No 
significant comparisons were identified for triplicate and quadruplicate replicate 
combinations. Further information about the range of MuMCC scores for all swarms can be 
found in Supplementary table 3.2. 
As either multiple or no significant read length parameters were identified for all sample 
types and replicate numbers, the choice of read length was based on the shortest length 
which gave the highest MuMCC scores. A full list of read length parameters producing the 
highest accuracy for variant detection can be found on Table 3.3. 
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Figure 3.5. Read length MuMCC range following GEM3 alignment. The range of MuMCC 
scores for each swarm type for each read length tested following alignment using GEM3 and 
selected qScore parameter. Singlet, duplicate, triplicate and quadruplicate technical 
replicates for each swarm type are represented by a different shade of colour. The solid black 
dot within each boxplot, indicates the mean of the MuMCC distribution.  
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3.4.5. The impact of replicate combination and frequency on variant 
confidence 
Using GEM3 and fixing the qScore and read length parameters to the values indicated in Table 
3.3, the influence of each percentage frequency threshold between 0.01% and 1%, and the 
number of technical replicates on the HTS pipeline performance was assessed. For each 
frequency threshold a single MuMCC value was produced, indicating that the GEM3 
parameters tested; mapping mode (fast & sensitive) and maximum alignment error (0.05, 
0.10, 0.12, 0.15), did not influence variant detection performance. The MuMCC value from 
each replicate number were subsequently visualised to identify an optimal frequency 
threshold (Figure 3.6).  
Within the RNA High population, the maximum MuMCC score obtained was at a frequency 
of 0.2% for all replicate combinations (Maximum MuMCC: 0.756, 0.816, 0.816 & 0.816 
respectively), after which the MCC score decreased. This was due to a smaller number of TPs 
(at a 0.1% frequency dominance) being detected at the 0.2% frequency threshold.  Below 
0.2%, another high MuMCC scores was observed at lower frequency thresholds within the 
duplicate, triplicate and quadruplicate data at 0.06% (MuMCC: 0.535, 0.632 & 0.680 
respectively), suggesting this frequency could be applied to characterise variants below 0.2% 
at the cost of allowing more errors through the analysis process. The MuMCC scores dropped 
after 0.06% due to a decline in the number of TPs (at 0.01% frequency dominance) being 
detected within each set of technical replicates. For the RNA Medium population, 0.8% was 
the most accurate frequency threshold for singlet, 0.5% for duplicates, 0.3% for triplicates 
and 0.2% for quadruplicates (MuMCC: 0.707 for all replicate numbers). For the RNA Low 
population, only the singlet dataset produced MuMCC scores above 0.01, with the highest 
MuMCC score obtained from 0.5% frequency cut-off onwards (MuMCC: 0.250). The MCC 
scores for duplicate, triplicate and quadruplicate combinations ranged from -0.003 to 0.007, 
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implying that these results were no better than random and the low MuMCC score for singlet 
demonstrates that the RNA Low input material was too low for variant analysis.  
Similar to the RNA High population, the DNA High population showed two peaks in the 
MuMCC scores. The highest peak for singlet, and duplicate replicate combinations was 
achieved using a frequency cut-off threshold of 0.2% (MuMCC: 1.000 & 0.933 respectively), 
while smaller peaks were achieved at 0.05% for singlet (MuMCC: 0.764) and 0.04% for 
duplicate (MuMCC: 0.840). For triplicate and quadruplicate technical replicates, a frequency 
threshold of 0.04% produced the highest peak (MuMCC: 0.891 & 0.913 respectively), while a 
cut-off of 0.03% produced MuMCC scores of 0.761 and 0.881 respectively, suggesting that 
with a either triplicate or quadruplicate technical replicates, this threshold could be applied 
at the cost of confidence in variant analysis. For the DNA Low population, the highest MuMCC 
score for all replicate combinations was present at a 0.2% frequency (MuMCC: 0.707 for all 
replicate combinations). 
Analysis of the MuMCC scores showed that a greater abundance of starting material and a 
higher number of technical replicates (except DNA Low and RNA Low) allowed for a reduced 
frequency to be applied for variant calling. Further information regarding each frequency 
threshold can be found within Supplementary table 3.3 and a list of frequency thresholds 
which produced the most accurate MuMCC scores can be found inTable 3.3.  
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Figure 3.6. Percentage frequency cut-off MuMCC range following GEM3 alignment. The 
MuMCC scores for each swarm type for each frequency cut-off parameter tested following 
alignment using GEM3 and fixed qScore and read length parameters. The data is represented 
is stacked, with singlet, duplicate, triplicate and quadruplicate replicates for each swarm type 
represented by a different shade of colour, with a darker colour representing a greater 
number of replicates. 
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Table 3.3. Recommended aligner parameters and percentage frequency cut-offs. A list of 
qScore, read length and frequency thresholds which produced the highest variant detection 
accuracy for all swarm types and replicate numbers following alignment of HTS reads using 
GEM3.  
RNA Low was removed due to its inability to accurately call low-frequency variants.  
 
  
Swarm 
type 
Replicate 
combinations 
qScore 
Read length 
(bp) 
Frequency 
cut-off 
MuMCC 
R
N
A
 
High 
Singlet 38 >=70 0.20% 0.756 
Duplicate 38 >=70 0.20% 0.816 
Triplicate 38 >=80 0.20% 0.816 
Quadruplicate 38 >=80 0.20% 0.816 
Medium 
Singlet 35 >=70 0.80% 0.707 
Duplicate 35/38 >=70 0.50% 0.707 
Triplicate 35 >=70 0.30% 0.707 
Quadruplicate 35 >=130 0.20% 0.707 
D
N
A
 
High 
Singlet 30/35/38 >=70 0.20% 1.000 
Duplicate 35 >=70 0.20% 0.933 
Triplicate 35 >=70 0.04% 0.891 
Quadruplicate 35 >100 0.04% 0.913 
Low 
Singlet 35 >=80 0.20% 0.707 
Duplicate 35 >=80 0.20% 0.707 
Triplicate 35 >=100 0.20% 0.707 
Quadruplicate 35 >=100 0.20% 0.707 
 
3.4.6. False positive patterns and distributions  
Once the HTS pipelines for variant calling given a particular type and abundance of input 
material were defined (to the values indicated in Table 3.3), the patterns and distributions of 
FPs were assessed. Firstly, the type of FPs (regardless of frequency cut-off thresholds) for 
each replicate sequenced from each swarm type was investigated. All swarm types showed 
the same pattern of transition FPs; T to C base change, A to G base change, C to T base change 
and G to A base change. Each of these four base changes represented >10% of all FPs types 
(Figure 3.7).  
After identifying the error type, FPs found above and below the recommended frequency 
threshold for each replicate sequenced for each swarm type were investigated. Within the 
RNA High swarm, a total of 4 FPs were identified above the 0.2% frequency cut-off, all of 
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which were T to C base changes (Table 3.4). Interestingly, the FPs at positions 1135 and 3056, 
were found to occur in all replicates and correspond to the start of a 5-mer homopolymeric 
T region, while the two FPs at positions 1915 and 2300 were present at the start of a 3-mer 
homopolymeric T region. For all technical replicates, at frequency thresholds between 0.01% 
and the ‘optimal’ 0.2%, a mean of 2623 FPs were identified, of which an average of 70.58% 
were transition substitutions. Below a frequency threshold of 0.01%, a mean of 3953 FPs 
were identified and an average of these 20.52% were transitions (Figure 3.8, Table 3.5).   
Within the RNA Medium swarm, only one FP above the 0.8% frequency cut-off was identified 
in a single technical replicate, which was a T to C base change (Table 3.4) and corresponded 
to the start of a 5-mer homopolymeric T region. For all technical replicates between 0.8% 
and 0.01%, a mean of 1706 FPs were identified, of which 75.05% were transition FPs. Below 
0.01%, a mean of 3326 FPs were identified for replicates 1, 2 and 3, of which an average of 
35.27% were transition FPs. No FPs below 0.01% were identified from replicate 4, most likely 
due to the lower number of reads (Table 2.7) sequenced for this sample (Figure 3.8, Table 
3.5).  
Table 3.4. Errors occurring above frequency threshold. The number and type of FPs detected 
above the recommended frequency threshold for all swarm types and replicates. 
     Swarm replicate 
Swarm type Amplicon position Base change 1 2 3 4 
RNA High 
1135 T > C 0.39% 0.35% 0.48% 0.30% 
1915 T > C   0.21%   0.28% 
2300 T > C     0.21%   
3056 T > C 1.06% 0.81% 0.62% 0.87% 
RNA Medium 1135 T > C 1.14%       
RNA Low 
1609 T > C   53.76%     
2933 T > C 9.06%       
3648 T > C   45.06%     
2199 G > T     18.49%   
2744 G > C       99.94% 
DNA Low 605 G > T       0.22% 
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While no recommended frequency cut-off parameters below 1% were identified for the RNA 
Low swarm, five high frequency FPs, including two consensus level changes, unique to a 
single replicate were identified. Three of were T to C base changes, a fourth a G to T base 
change and a fifth a G to C base change (Table 3.4). Between 0.01% and 1%, a mean of 1688 
FPs for all technical replicates were identified, of which an average of 78.97% were transition 
FPs. Below 0.01%, a mean of 4737 FPs for each of the four replicates were identified, of which 
an average of 27.76% were transition FPs (Figure 3.8, Table 3.5). 
For the DNA High swarm, no errors were found in any replicate above the recommended 
frequency cut-off of 0.2%. Below this, from 0.01% to 0.2% for all technical replicates, a mean 
of 1711 FPs were identified, of which an average of 76.35% transition substitutions. Below 
0.01%, for replicates 1 to 4, a mean of 2801 FPs were identified, with an average of 38.38% 
being transition FPs (Table 3.4). Whilst for the DNA Low swarm dataset, a single error G to T 
base change was identified above the 0.2% frequency threshold in replicate 4 (Figure 3.8, 
Table 3.5). For all technical replicates between 0.01% and 0.2%, a mean of 1648 FPs were 
identified, of which an average of 78.77% were transition substitutions. Below 0.01 a mean 
of 2801 errors were identified, with an average of 38.50% of these FPs being transition 
substitutions (Figure 3.8, Table 3.5). 
From analysing the data, the highest frequency FPs occurring above the recommended cut-
off threshold in the RNA swarm sets were T to C base changes and were only present at the 
start of a homopolymeric region of T bases, with a higher number of T bases resulting in a 
higher frequency error. Although a frequency cut-off for these error types wasn’t defined in 
this study, this error pattern was more common and present in more technical replicates in 
the RNA High dataset, suggesting that the T to C base change has reduced confidence with 
more starting RNA used for the sequencing process.   
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Table 3.5. Error types below threshold. The total number of FPs and respective percentage 
of transition FP identified below the recommended frequency threshold.     
* Range from 0.01% to the recommended percentage cut-off threshold for each swarm type 
+ Percentage 
       Swarm replicate 
Swarm type Frequency threshold FP type 1 2 3 4 
R
N
A
 
High 
0.01% - 0.2%* 
Total 2665 2625 2591 2609 
+Transition 74.37% 71.28% 71.09% 65.58% 
Below 0.01% 
Total 4053 3893 5207 2659 
+Transition 18.80% 20.47% 17.25% 25.57% 
Medium 
0.01% - 0.8%* 
Total 1705 1693 1698 1726 
+Transition 77.54% 78.09% 78.80% 65.76% 
Below 0.01% 
Total 3107 3470 3402 0 
+Transition 37.14% 34.32% 34.36% 0.00% 
Low 
0.01% - 1%* 
Total 1803 1653 1636 1658 
+Transition 81.48% 79.19% 75.98% 79.25% 
Below 0.01% 
Total 3896 4873 4174 6006 
+Transition 29.75% 27.05% 31.84% 22.39% 
D
N
A
 
High 
0.01% - 0.2%* 
Total 1789 1758 1713 1585 
+Transition 76.58% 72.64% 76.77% 79.50% 
Below 0.01% 
Total 2464 1988 3505 3248 
+Transition 39.45% 39.59% 37.23% 37.25% 
Low 
0.01% - 0.2%* 
Total 1701 1633 1616 1642 
+Transition 78.60% 79.73% 78.96% 77.77% 
Below 0.01% 
Total 2492 3198 3202 2967 
+Transition 40.61% 36.90% 36.91% 39.57% 
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Figure 3.7. False positive error types in swarm datasets. The different base change error 
types identified for each of the swarm types (without a percentage frequency cut-off). Within 
each base change, each one of the 4 bar plots represents a sequenced technical replicate.   
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Figure 3.8. Transition and Transversion error with swarm datasets. The average number of 
Transition (blue) and Transversion (red) error at each of the percentage frequency cut-offs 
tested between 0.01% and 0.1%, above 1%, above 10% and above 50% for each of the swarm 
types.  
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3.4.7. Percentage critical difference analysis  
Bland-Altman analysis revealed that the replicate combinations of both the DNA High and 
Low swarms had the lowest critical difference scores with a mean of 0.020% and 0.028% 
respectively. Following this, was the RNA High swarm with a mean critical difference of 
0.085%, then RNA Medium with a mean score of 0.153% and finally RNA Low with a mean 
score of 2.307%. The range of critical difference scores identified for each duplicate technical 
replicate can be found on Figure 3.9.  
Based on the range of results for the RNA swarms, real biological data with PCD scores 
ranging from 0.045% to 0.121% would have a similar sequencing profile to the RNA High 
dataset and therefore a 0.2% frequency cut-off would be applied for variant analysis. While 
RNA samples with PCD scores ranging from 0.121% and 0.203% would have similar profiles 
to the RNA Medium dataset, with a 0.5% frequency cut-off being applied for variant analysis. 
While samples with PCD score above 1.521% would be similar to the RNA Low dataset, and 
variant analysis would be discarded. For obtained PCD scores between the RNA High and 
Medium (i.e. between 0.121% and 0.142%) and between RNA Medium and Low (i.e. 0.203% 
and 1.521%) a percentage frequency cut-off would be assigned for a sample based on its 
nearest neighbour. For example, a sample with a PCD score of 0.350% would be assigned a 
variant frequency cut-off of 0.5%. 
Only a 0.008% difference was observed between the DNA High and Low swarms, indicating 
similar sequence profiles for these two datasets.  
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Figure 3.9. The range percentage critical difference (PCD) scores for each swarm type. The 
range of PCD scores for each duplicate replicate combination for each swarm type is given. 
For real biological samples, PCD scores would be assigned and then correlated with the swarm 
profiles to assign a frequency cut-off for variant analysis. Samples with PCD scores in between 
swarm profiles (for example between RNA Medium and Low) would be assigned a frequency 
cut-off based on its nearest neighbour profile.   
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3.5. Discussion  
The use of HTS technologies to identify low frequency variants is limited by the presence of 
process introduced errors and biases that can mask true biological variation. This chapter, 
together with chapter 2, describes a systematic approach to evaluate both the laboratory 
and bioinformatics protocols to define an HTS pipeline(s) able to most accurately identify 
true biological variation.  
By investigating different DNA and RNA starting inputs it became apparent that the type and 
abundance of nucleic acid template affects the accuracy of the variant calls made by an HTS 
pipeline. Overall less error was identified in the DNA swarm types, with this decreasing as 
more starting template was included (Figure 3.3). As only 0.2ng/µl of DNA was required by 
the Nextera XT kit for sequencing on the Illumina MiSeq, the number of PCR cycles of each 
swarm type and abundance was optimised to produce sufficient material, whilst limiting the 
number of cycles. As expected, more PCR cycles were required to accommodate lower 
amounts of starting templates and this may have increased the likelihood of artefactual 
recombination errors being introduced within a sample (214) as well as skewed allelic 
frequencies through preferential amplification of a small number of variants (216). The latter 
of which was seen most clearly in the RNA Low swarm population, with two out of the four 
technical replicates having consensus level error changes. The increased frequency of errors 
in the RNA dataset can be explained by the fidelity (215) and the conversion efficiency of the 
RT enzyme used, with one study finding the conversion efficiency of SuperScript III 
(Invitrogen) on bacteriophage MS2 RNA being between 35% and 69% (264). Inefficient 
conversion of RNA to cDNA, or low amounts of starting RNA template may increase the 
likelihood of preferential amplification of variants during PCR, as reduced cDNA will increase 
the likelihood of the same genome coming in contact with the polymerase more than once. 
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As a result of these factors, the highest amount of available starting template for both DNA 
and RNA is required to maximise HTS pipeline accuracy.  
While some of this error may be contributed from the in vitro transcription of RNA, the 
estimated error rate of the T7 enzyme used in the MEGAScript T7 kit (Thermo Fisher is 
approximately 6x10-6 per nucleotide (265). From each of the plasmids, an average of 
6.78x1010 genomes of RNA per µl were produced, which in turn, following the creation of the 
artificial swarms were diluted to 106/µl, 104/µl and 102µl for the High, Medium and Low 
swarms. The dilution of the plasmids would in turn dilute any errors, limiting their impact of 
the results.  
As different short-read alignment programs can also influence variant calling, five different 
aligners, each employing different alignment algorithms, were tested in order to maximise 
the accuracy of candidate HTS pipelines. This study found that GEM3 produced the highest 
mean MuMCC and was significantly more accurate than the other aligners tested except BWA 
(while not significant the MuMCC score was greater for GEM3 than BWA-MEM), so was 
therefore selected as the aligner on which to base all subsequent investigations. The next 
step was to select the number of replicates required along with the read qScore and length 
that would be passed to GEM3, as well as the frequency cut-off required for variant calling.  
Based on the data for RNA High & Medium and DNA High swarms, the use of multiple 
technical replicates increased the accuracy of variant calling, with an example being the RNA 
High dataset, where the use of duplicates increased MuMCC score from 0.756 to 0.816 when 
compared to singlets (Supplementary table 3.3). An increased number of replicates also 
allowed for lower percentage frequency cut-off to be applied for DNA High and RNA Medium 
datasets. A previous study investigating the role of technical and biological replicates for HTS 
for negating errors caused by the sample preparation and sequencing found that the 
replicates can be used to filter error, increasing confidence in low-frequency variants being 
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called (266). However, in this study the opposite was true for RNA Low swarm, with more 
than one technical replicate resulting in a MuMCC score of almost 0, suggesting that these 
results were no better than random. A possible explanation for this observation is that due 
to the low number of starting templates only a small subsection of the RNA swarm is 
sequenced in each replicate, reducing the overlap of variant calls between replicates, and 
thus variant calling overall. In addition, lower inputs could result in certain genomes being 
preferentially amplified in one replicate and not the other (evident by the high frequency 
errors in single replicates). Due to the low MCC scores, high frequency and consensus level 
errors present and the fact that the use of technical replicates decrease confidence in the 
data, it is suggested that sequencing RNA at the same copy number as RNA Low (102 RNA 
copies/µl) sample on an Illumina MiSeq platform using the HTS pipelines in this study be 
avoided.  
Whilst single replicates could be applied for all sample types to predict low-frequency 
variants, this study shows the use of technical replicates for all swarm types (except RNA 
Low) increases MuMCC scores and therefore the accuracy of variant calling and for the RNA 
Medium and DNA High (Table 2) allows for a lower frequency cut-off (triplicate and 
quadruplicate cut-off of 0.05%) to be applied whist maintaining maximum confidence in 
accuracy.  
In all datasets and replicates (apart from RNA Low duplicate, triplicate and quadruplicate), 
an increase in qScore was found to have a significant effect on the results, with the MuMCC 
score increasing (Figure 3.4). Higher qScore values applied to datasets would lead to a 
reduction to the overall coverage, potentially limiting the detection of various low-frequency 
variants. While in this study the benefits of higher qScore were observed, the impact on lower 
coverage datasets and non-PCR amplified samples would need to be assessed.  
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Whilst in previous studies, where a percentage frequency cut-off was applied across the 
genome (regardless of input abundance) to reduce processed-introduced errors being called 
as real variants (181,267,268), the tailored approach in this study allows for dynamic 
frequency thresholds to be identified in both DNA and RNA sample types and their 
abundance at different frequencies and confidence levels. A frequency cut-off of 0.2% was 
found to be the lowest point, at which variations could be called with the highest confidence 
(with the RNA Medium data requiring 4 replicates for this frequency cut-off), with the 
exception of DNA High, where the use of triplicate and quadruplicate combinations allowed 
for a frequency cut-off as low as 0.04%, which is close to the intrinsic sequencing limit of 
Illumina chemistry (212). The use of more than one technical replicate (Figure 5) for the RNA 
High and DNA High swarms saw a peak in the MuMCC data at frequency thresholds of 0.06% 
and below (Table 2 & Supplementary table 3.4), although not as accurate, variants could be 
called at the risk of allowing more errors through the bioinformatics pipeline. Future studies 
however could improve on this frequency cut-off threshold by introducing more TP as 
different frequency thresholds within the artificial swarms in order to gain a more accurate 
MuMCC results.  
Most of the errors occurring above the percentage cut-off frequency associated with the 
highest MuMCC score were a T to a C base change and found at the start of repetitive T base 
regions, with more T bases resulting in higher percentage frequency errors. A study 
investigating error rates in just Illumina sequencing found that errors were more likely to 
occur in repetitive regions, however at the end of the respective region and T to C base 
change errors were least likely to occur (269), which suggest, that the RT and/or PCR steps 
have a larger influence on error. Another sequencing study that utilised the same FMDV-O 
plasmid sequence used here, found that when just PCR was used, that T to C transitions were 
one of the most abundant errors (along with A to G). This effect was also observed when the 
plasmid RNA was reverse transcribed and amplified (215). Although the same error patterns 
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were observed within the DNA and RNA datasets, greater frequencies of error occurred 
within the RNA swarms, presumably due to the RT step (or possibly the in vitro transcription). 
The use of RT within the RNA High dataset resulted in reproducible error from a T to a C base 
at the start of repetitive T base regions, above the chosen 0.2% frequency cut-off for RNA 
High. A previous study investigating Illumina error identified that A and C bases are more 
prone to substitution errors than T and G bases. During the sequencing process, both A and 
C bases emit high fluorescence intensities and are identified by the same laser sensor (red 
channel). Interference of this signal would result in base errors being introduced (270). With 
the T to C base change occurring in higher percentage frequencies, results indicate a greater 
influence of the RT and PCR approaches in the generation of error. As a result, it is 
recommended that low frequency T to C based variants are treated with caution, as the error 
from this study was found at the highest percentage 1.14%. Interestingly, this reproducibility 
of error is only seen within the RNA High swarm and as the RNA input template is reduced, 
the number of errors identified at similar percentage frequencies in more than one replicate 
decreases, however further work is required to investigate this. 
The use of Bland-Altman analysis showed that there was a relationship between each of the 
swarms, with the PCD score decreasing as the starting RNA input increased (Figure 3.9) (little 
difference was observed between then DNA High and Low swarms). For real biological 
datasets, the PCD scores could be directly compared with the RNA High, Medium and Low 
PCD ranges in order to assign to a bin, with each bin representing a percentage frequency 
cut-off for variant analysis. While for samples with PCD scores outside the range define by 
each of the RNA swarms, frequency cut-offs for variant analysis can be assigned based on its 
closest neighbour bin. In order to further characterise the relationship between PCD and 
frequency cut-offs for variant analysis, additional dilutions of the artificial swarm could be 
sequenced and characterised.  
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In this study a systematic approach has been taken to create a laboratory and bioinformatic 
HTS pipeline, in order to establish a tailored approach which can be applied to any genomic 
material at different input levels in order to maximise the accuracy of variant analysis. 
Analysis identified that the use of different nucleic acid type and starting input has the 
greatest effect on the reliability of calling a true variant and the generation of process 
introduced error. The use of the highest amount of starting template (1x106 copies/μl), 
coupled with the use of more than one technical replicate can lead to the detection of 
variants from 0.2% in frequency and below (depending on the sample type, input and 
replicates used) with high confidence. Furthermore, the use of an RT step on a sample with 
a high RNA copy number (106 RNA copies/μl) can lead to higher frequencies of predictable 
error, which can be used to further exclude real variation from error. As our results do not 
depend on sample origin and can be confidently generalised to the sequencing of any nucleic 
acid material, this model provides an effective means of separating true biological variants 
from process-introduced error in viral, bacterial and eukaryotic datasets.  
This validated HTS pipeline was applied to FMDV samples deriving from both in vivo and in 
vitro studies. These studies explained in chapters 4 and 5 aimed to characterise how FMDV 
populations adapt to immune pressures through the generation of variants associated with 
immune escape.  
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Chapter 4  
Development of foot-and-mouth disease virus immune 
escape variants in vaccinated cattle  
The serology, RT-qPCR and vaccine potency results in this chapter have been published in 
Vaccine.  
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4.1. Abstract  
Specific polyclonal antibody responses are hypothesised to act as an evolutionary driver on 
FMDV swarms leading to the accumulation of non-synonymous substitutions at critical 
antigenic sites located on the surface of the viral capsid. However, little is known about sub-
consensus level changes present in vaccinated animals recently exposed to FMDV. This study 
characterised FMDV swarm populations in seven foot epithelium samples derived from five 
vaccinated cattle, as well as two non-vaccinated control animals.  
Following Illumina sequencing of extracted viral nucleic acid (using the optimised HTS 
pipeline described in chapters 2 and 3), no amino acid changes were identified at a consensus 
level; however, a total of 27 low-frequency substitutions were detected within samples from 
vaccinated animals. Of these, a total of seven non-synonymous substitutions were identified 
within the capsid encoding region, all of which were below 1.6% in frequency. Six of these 
substitutions were predicted to be located on the FMDV capsid surface, with two, at sites 
VP183 and VP195 correlating to previously identified epitope regions in proximity to antigenic 
site one, while another substitution was identified at VP2134, which could be associated with 
antigenic site two. Interestingly, none these variants were shared between samples, which 
indicate that either FMD viral immune escape evolution is non-deterministic in nature, or the 
responses in each host are specifically shaped by the spectrum of the different polyclonal 
sera.  
This study provides new insights into the process of immune escape that occurs in FMDV 
populations within vaccinated hosts with a partially protective immune response.   
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4.2. Background and introduction 
Polyclonal antibodies generated from vaccination and previous FMDV infection acts as a 
selective evolutionary pressure on the population dynamics of FMDV (271). The poor-proof 
reading ability of the RdRP allows FMDV populations to rapidly adapt to new external 
environments and in the case of antibody polyclonal host immune pressure, through amino 
acid substitutions. Most of these substitutions are present at critical epitope sites on the 
surface of the viral capsid (190,272) (Figure 1.6).  
FMDV serotype A is considered to be the most genetically and antigenically diverse serotype 
(273), comprising of 26 genotypes based on >15% VP1 coding sequence difference (274). 
Serotype A is found in Pools 1, 2 and 3 located on the Asia continent (Figure 1.2), with the 
Indian subcontinent (pool 2) historically containing two co-circulation genotypes of serotype 
A, G-VII and G-XVI. However since 2001, G-VII has been exclusively responsible for all field 
outbreaks (274). While a year later, a variant within G-VII emerged having an amino acid 
deletion at an antigenically critical site within the VP3 coding region (VP359), which had a poor 
antigenic match to vaccines (275).  It is speculated that preventive vaccination used within 
the Indian subcontinent (189) led to sub-neutralising immunity which in turn may have acted 
as a selective pressure on the viral populations, leading to this deletion at VP359.  
In 2015, the G-VII strain emerged from the Indian subcontinent and spread rapidly to Saudi 
Arabia, Iran, Armenia, Israel and Turkey (276) (Figure 4.1), most probably due to cultural and 
trade links and possibly due to the export of meat from the Indian sub-continent to the 
Middle East (277). From the second half of 2015, VP1 sequences of isolates from Saudi Arabia 
and Iran revealed amino acid differences within the G-H loop of antigenic site one of the VP1 
coding region (17,276). Again, it was speculated that variation within this region may had 
arisen as a consequence of an immune escape from heavily vaccinated cattle in Saudi Arabia 
(154).  
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Figure 4.1. FMDV spread throughout Asia, the Middle-east and north-east Africa. Long 
distance spread of FMDV revealed by sequence analysis within Asia, the Middle-east and 
north-east Africa. The spread of lineages normally contained within the Indian subcontinent 
(pool 2) including A/ASIA/G-VII are shown in brown. Areas displayed in green indicate FMD-
free (without vaccination) regions, amber areas indicate FMD sporadic regions and red areas 
indicate FMD endemic regions. Map generated by Dr. Antonello Di Nardo (the Pirbright 
Institute).   
 
 
While multiple field studies have identified the presence of nucleotide substitutions at 
antigenic sites, these have been characterised from consensus sequences derived from FMD 
viral populations which have undergone multiple rounds of replication through multiple 
hosts. Little is known about the generation of potential immune escape variation at a sub-
consensus level in FMDV populations derived from vaccinated animals which have been 
recently infected.  
This study characterised the generation of potential immune escape variants from a group of 
vaccinated cattle during infection with FMDV. The samples tested were collected from an in 
vivo study which was undertaken to assess the performance of a hexavalent vaccine against 
a field virus from the A/ASIA/G-VII lineage (278). Samples used here were taken from a total 
of 16 vaccinated cattle and two unvaccinated cattle, with the vaccine protecting only 56% of 
animals, with the remaining unprotected animals having varying degrees FMDV-specific 
antibody levels. Epithelium foot lesions from the unprotected animals were sequenced to 
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characterise how sub-neutralising immune pressure might influence the FMDV swarm 
structure. Substitutions identified in unprotected vaccinated animals were compared to 
control samples and previously identified epitope regions of FMDV to establish the presence 
of potential immune escape variants.     
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4.3. Materials and Methodology 
4.3.1 In vivo study design and setup 
The design and implementation of the animal experiment has been published (278), with all 
animal work conducted by the animal servicing unit (The Pirbright Institute) and compliant 
with the Animals (Scientific Procedures) Act 1986, EU Directive 2010/63/EU, and licenced by 
The Home Office after local ethical review.  Briefly; a PPG study design involved 18 cattle, 
with animals being split into five different groups (Table 4.1). Animals in groups one to four 
(16 in total), were vaccinated with a full dose multivalent vaccine containing seven FMD 
vaccine strains; O1Manisa, O-3039, O-PanAsia-2, A/IRN/05, A/SAU/95, SAT2 Eritrea and 
Asia1-Shamir. In vitro vaccine matching data generated by WRLFMD (The Pirbright Institute) 
indicated that the A/IRN/05 vaccine strain is antigenically very distinct to A/ASIA/G-VII field 
viruses, while the A/SAU/95 component is poorly matched to these viruses (278). The two 
animals in group five were left unvaccinated and served as a control group. Animals were 
challenged with a field isolate from the A/ASIA/G-VII lineage (IRN/22/2015 at 105 TCID50/ml)) 
21 days post vaccination, with each animal being checked daily for clinical signs. Animals were 
culled at one of the following end-points:  
1. A control animal with lesions on at least three feet 
2. A vaccinated animal with lesions on at least one foot (these animals were classed as 
unprotected) 
3. Humane welfare grounds for the animal (defined by veterinary care personnel) 
4. The end of the study on day 29 (eight days post-challenge) 
Serum from each animal was collected, at day 1 (before vaccination), day 21 (before 
challenge) and every day post-challenge until the end of study. Following culling of an 
unprotected or control animal, lesion material was removed from the affected feet using 
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separate scalpels and tweezers to avoid cross-contamination and stored at -80µl in glycerol 
phenol red solution (49.5% glycerol (Sigma-Aldrich), 49.5% M25 phosphate buffer (The 
Pirbright Institute) and 1% phenol red (Sigma-Aldrich)). Epithelium samples were given the 
following identification depending on what foot it was collected from; FRF (Front Right Foot), 
FLF (Front Left Foot), BRF (Back Right Foot) and BLF (Back Left Foot).  
Table 4.1. In vivo study layout. Animals were assigned unique identification tags and were 
separated into different groups, with groups 1 to 4 receiving the full dose of the multivalent 
vaccine and group 5 acting as the unvaccinated controls. All animals were infected with the 
challenge virus 21 days following vaccination. 
                
    Group 1 Group 2 
  
V
ac
ci
n
at
e
d
 3918, 4945, 4933, 4932 3920, 4942, 4921, 4916 
  
  Group 3 Group 4 
  
4921, 4917, 4914, 4910 4944, 4935, 4930, 4926 
  
  
C
o
n
tr
o
l Group 5 
  
4939, 4919 
  
 
VNT serology tests were performed by Ginette Wilsden from the Serology Section within the 
Vesicular Disease Reference Laboratory at The Pirbright Institute on serum samples collected 
21 days post vaccination and before challenge. Anti-FMDV neutralising antibodies against 
each of the component strains within the vaccine were measured. In addition, specific VNT 
responses to A/ASIA/G-VII field isolate (SAU/2/2015) and the challenge virus (IRN/22/2015) 
were also determined.  
4.3.2. Viremia quantification from serum samples 
A total of 55µl of serum from each of the time points was added to 143µl of MagMAX 
Lysis/Binding Solution Concentrate (Thermo Fisher Scientific, Waltham, USA). Viral RNA 
extraction was performed on the MagMAX™ Express-96 Deep Well Magnetic Particle 
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Processor (program: AM1836_DW_50_V2) using the MagMAX™ 96 viral RNA isolation kit 
(Thermo Fisher Scientific) as per manufacturer’s instructions.  
Following RNA extraction, viremia was determined by quantification of viral RNA on a 
Mx3000P qPCR System (Agilent technologies, Santa Clara, USA) using a FMDV specific RT-
qPCR assay (241) with an RNA standard curve generated from 10-fold dilution series of RNA 
belonging to the 3D region of FMDV isolate UKG/35/2001 (GenBank Accession: AJ539141). 
The 3D region of UKG/35/2001 was compared to two G-VII field isolates (A/IRN/8/2015 
(unpublished, isolate sequenced at The Pirbright Institute) and A/SAU/1/2015 (GenBank 
Accession: KU127247)). This was done to confirm that the forward, reverse and probe 
binding sites targeted by the RT-qPCR were identical (Supplementary figure 4.1), so that viral 
RNA quantification of samples collected from the G-VII challenge study was not impacted by 
any sequence changes. 
RNA from each day belonging to the same animal were extracted on the same plate and 
quantified on the same RT-qPCR run to limit bias. Each extraction run contained a number of 
negative controls (MagMAX lysis only, MagMAX master mix (minus input RNA), nuclease-free 
water and FMDV negative serum) and a positive control consisting of FMDV O UKG/35/2001 
with an expected viral RNA concentration of 105 RNA copies/µl. 
As stated in (278), in order to compare the overall serum levels of FMDV, the area under the 
curve (AUC) was calculated by applying the trapezium rule to the time-course of FMDV RNA. 
AUCs for three groups of animals (controls, unprotected vaccinated and protected 
vaccinated) were compared using Kruskal-Wallis tests, followed by pairwise rank-sum tests 
to identify differences between groups.  
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4.3.3. Viral RNA extraction, quantification, RT and PCR amplification 
4.3.3.1. RNA extraction from epithelium tissue and quantification 
Viral RNA was collected by homogenising FMDV infected epithelium tissue using the 
TissueLyser LT instrument (Qiagen). Briefly; approximately 25mg (previous optimised at The 
Pirbright Institute in unpublished work) of epithelium tissue (less than 1mm in size) was 
added to 500µl of TRIzol reagent (Thermo Fisher Scientific) in a 2ml microcentrifuge tube 
containing a single 5mm steel bead (Qiagen). Samples were then placed in the TissueLyser LT 
(Qiagen) instrument and then homogenised at 20 oscillations per second for two minutes. 
This was followed by a 5-minute incubation at 4°C and centrifugation for 10 minutes at 
8,000g.  
Supernatant was then transferred into a Phasemaker tube (Thermo Fisher Scientific) with an 
additional 1.25ml of TRIzol reagent (Thermo Fisher Scientific) and 300µl of chloroform 
(Sigma-Aldrich) and incubated at room temperature for 15 minutes. Following this, samples 
were centrifuged for 5 minutes at 14,000xg at 4°C which separated the sample into a lower 
red phenol-chloroform phase, an interphase and a colourless upper aqueous phase with the 
gel in the Phasemaker tubes forming a barrier between the upper and lower phases. The top 
aqueous phase was combined with 1µl of 20mg/ml RNA grade glycogen (Thermo Fisher 
Scientific) and 1ml of isopropanol (Sigma-Aldrich) in a fresh DNA Low bind tube (Eppendorf, 
Hamburg, Germany), incubated at room temperature for 10 minutes and then centrifuged 
for 15 minutes at 12,000xg at 4°C. The supernatant was removed and the resulting RNA pellet 
(made visible by the presence of GlycoBlue™ Coprecipitant (15mg/ml) (Thermo Fisher 
Scientific)) was washed twice with pre-chilled 70% ethanol and the eluted in 28µl of nuclease-
free water (Ambion). RNA was then split into three aliquots, with 21µl being used for 
sequencing, 1.2µl being used for quantification by RT-qPCR (this was diluted 1 in 10 in 
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nuclease-free water) and the remaining 5.8µl being used for Qubit (RNA HS Assay (Thermo 
Fisher Scientific)) quantification.  
Viral RNA was quantified using the same method and RNA standards as described in section 
4.3.2. 
4.3.3.2. RT, PCR and sequencing of samples 
Based on the optimised HTS pipeline as described in chapter 2, samples were diluted to 106 
viral RNA copies/µl in nucleic acid template extracted from FMDV negative bovine tongue 
epithelium tissue (collected from Newman’s Abattoir, Farnborough, UK). Following this, 
technical replicates from each RNA sample were reverse transcribed using the Transcriptor 
High Fidelity cDNA Synthesis Kit (Roche) (as described in section 2.3.3) and amplified using 
the defined number of PCR cycles required for the input template (as described in section 
2.3.4). If the recommended number of PCR cycles didn’t produce enough amplicon material 
for sequencing, then amplification was repeated with an increased cycle number. All 
amplicon material from each sample was subjected to electrophoresis through a 1% agarose 
gel (containing GelRed® (Biotium)) and visualised by illumination with UV light. A 3kb FMDV 
RT-PCR fragment capsid was excised from the gel and purified using the QIAquick Gel 
extraction kit (Qiagen, Manchester, UK). Finally, amplicon samples were quantified using the 
Qubit® dsDNA High Sensitivity Assay Kit and diluted to 0.2 ng/µl in nuclease-free water.  
4.3.4. Illumina sequencing and analysis 
Technical replicates from each sample were sequenced on the Illumina MiSeq platform, using 
on a 300 cycle v2 cartridge using the Nextera XT kit. The run produced paired-end reads of 
approximately 151bp in length.   
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4.3.4.1. Reference sequence generation  
In order to obtain a reference sequence which could be used to align HTS reads obtained in 
this study, a de novo assembly using IDBA_UD (Version 1.1.1) (255) was performed on the 
starting challenge virus. Reads from both technical replicates were first merged and then 
passed through a de novo assembly pipeline as described in section 3.3.1.  
4.3.4.2. Read trimming and alignment 
The quality of raw reads was examined using FastQC (version 0.11.5) (244) which resulted in 
15 bases and 5 bases from the 5’ and 3’ of each read respectively being trimmed using 
Prinseq-lite (version 0.20.4) (230) (as described in section 2.3.5). Alignment was performed 
using the optimised HTS pipeline (Table 3.3), with reads filtered using Sickle (version 1.33), 
with a qScore of 38 and a read length of 70 (Table 3.3). Following this, GEM3 (version 1.843) 
(251) was used to map the reads to the reference sequence.  
Following alignment, the output .SAM file was converted into a .BAM file using SAMTools 
(version 1.2) (258) and in-house R scripts were used to generate variant and read coverage 
depth data and consensus sequences.  
4.3.4.3. Variant analysis  
As described in sections 3.3.4 and 3.4.7, Bland-Altman analysis was performed on each of the 
technical replicates in order to ascertain a percentage critical difference (PCD) score from 
each sample. PCD scores were used to assign a percentage frequency cut-off for variant 
analysis. Samples with a PCD score of below 0.121% were assigned a frequency cut-off of 
0.2%, while samples with PCD scores between 0.121% and 0.203% were assigned a 0.5% 
frequency cut-off. Samples with PCD score 1.521% and above were discarded, due to the low 
associated accuracy for variant analysis and the risk of consensus level errors being present 
within a technical replicate. Samples with PCD scores outside an optimised ranged were 
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assigned a percentage frequency cut-off based on its nearest neighbour (e.g. a sample with 
a PCD score of 0.40% were assigned a 0.5% frequency cut-off). 
To be classed as a true biological substitution, variants within a sample had to be present in 
both technical replicates either equal or above the assigned frequency cut-off. Based on the 
error profiles identified as described in section 3.4.6, C>T base changes, present at the start 
of a homopolymeric region of T bases, identified with samples assigned a 0.2% frequency 
cut-off were removed due to the likelihood of these being errors.   
4.3.4.4. Shannon’s Entropy  
Shannon’s entropy (H’) (279) was used to measure the levels of variation at each genome 
position for each sample:  
𝐻′ =  − ∑ 𝑝𝑏 log2(𝑝𝑏)
𝑏𝜖{𝐴,𝐶,𝐺,𝑇}
 
Whereby pb represents the proportion of each of A, C, G and T bases present in each technical 
replicate from each sample set. Only variants present in both technical replicates, above the 
percentage cut-off frequency thresholds and not associated with error profiles were 
included. Scores for each nucleotide position ranged from 0 to 2, with higher scores indicating 
more levels of diversity.  
4.3.4.5. FMDV capsid structures mapping 
To identify if any substitutions were predicted to be located on the capsid surface of the virus, 
non-synonymous variants were mapped to a FMDV serotype A crystallised structure using 
RasMol (Version 2.7.5) (280,281). As no crystallised structure of A/IRN/22/2015 was 
available, substitutions belonging to the capsid encoding regions were mapped to the 
crystallised recombinant FMDV A22-H2093F empty capsid structure (282). The amino acid 
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sequences of A/IRN/22/2015 and A22-H2093F were compared and were found to have 100% 
identity in the VP4 region, 93% in both the VP3 and VP2 regions and 91% in the VP1 region.  
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4.4. Results 
4.4.1. Clinical observations and viremia  
4.4.1.1. Serology results 
VNT were performed on serum samples collected from all animals at 21 days post vaccination 
to determine the level of specific antibodies generated from each component of the vaccine. 
Against the vaccine component A/IRN/05, all animals except 4942 had positive VNT titres 
(>32), while against the A/SAU/95 vaccine component, all animals with the exception of 
animals 4932 and 4914 tested positive. VNT tests against the two G-VII field isolates revealed 
that against SAU/2/15, all animals had inconclusive titres (>11 & <32), while against 
IRN/22/2015 animals 4932, 4917, 4910 and 4944 tested negative (<8), while all other animals 
had inconclusive titres. Sera from unvaccinated control animals tested negative (<8) for 
specific antibody responses against all vaccine components and field viruses. Table 4.2 
displays the VNT scores from serum collected from all unprotected animals against 
A/SAU/95, SAU/2/2015 and IRN/22/2015.  
4.4.1.2. Lesion generalisation  
After challenge, all animals developed primary lesions at the site of inoculation. Within 
groups one to four, seven of the animals (43.8%) displayed lesions on at least one foot (Table 
4.2). All protected cattle were euthanised on day 29 of the study, with the exception of 
animals 3918, 4945 and 4933 in group one which were culled on day 27 due to ethical 
reasons.  Both control animals also developed lesions on all feet, with these animals being 
culled on day 29 (Table 4.2). 
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Table 4.2. VNT scores and lesion location from unprotected animals.  VNT results for serum 
samples collected 21 days post-vaccination from all unprotected animals against the 
A/IRN/05 and A/SAU/95 components of the hexavalent vaccine and two field strains from the 
A/ASIA G-VII FMDV lineage. Green indicates a positive titre, yellow indicates inconclusive and 
red indicates a negative titre. Each animal is separated by their respective group and animal 
tag. Samples from selected cattle (numbers highlighted in blue) were sequenced. The location 
of the foot lesions and the day of the study of when each animal was culled is also given.   
     VNT     
      Vaccine components Field strains Clinical signs 
    Group A/IRN/05 A/SAU/95 A/SAU/2/15 A/IRN/22/15 Foot lesions 
Day 
culled 
V
ac
ci
n
at
ed
 
4932 1 32 32 11 8 FLF 27 
3920 2 90 128 32 16 FRF 26 
4921 3 178 45 22 22 FLF & BLF 25 
4917 3 45 32 16 8 FRF & BRF 27 
4910 3 64 64 22 8 FRF 29 
4944 4 45 45 11 8 BRF & BLF 29 
4930 4 90 64 22 22 BRF & BLF 29 
C
o
n
tr
o
l 
4939 5 <8 <8 <8 <8 All feet 29 
4919 5 <8 <8 <8 <8 All feet 29 
 
4.4.1.3. Viremia 
Viremia data was classified into three groups; animals with lesions (n=7), animals without 
lesions (n=9) and control animals (n=2). The highest peak of viremia occurred within the 
unvaccinated controls (4939 (Day 23): 1.48x104 RNA copies/µl, 4919 (Day 24): 5.82x103 RNA 
copies/µl). Overall, vaccinated animals had a lower peak in levels of viremia after challenge 
compared with unvaccinated animals. While protected animals had a lower peak than 
unprotected animals, but displayed higher viremia levels than the protected animals (Figure 
4.2). AUC analysis showing a significant difference between groups (Kruskal-Wallis test: 
P=0.003). While pairwise comparisons of the groups showed significant differences in the 
AUC between the control and the unprotected groups (Wilcoxon rank-sum test: P=0.04) and 
between the unprotected and protected groups (Wilcoxon rank-sum test: P=0.02). No 
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significance was identified between the control and unprotected groups (Wilcoxon rank-sum 
test: P=0.06).  
 
Figure 4.2. Mean viremia levels for the control, protected and unprotected groups. The 
levels of mean viremia for the control animals (Red), animals with lesions (Green) and animals 
without lesions (Blue). Error bars represent the range of differences between samples at each 
time point. Each quantification value was determined using singlet replicates.  
 
4.4.2. Sequencing setup 
4.4.2.1. Samples for sequencing selection 
Epithelium samples obtained from vaccinated and unprotected animals with the highest VNT 
titres against the A/IRN/05 and A/SAU/95 vaccine components and the two field strains from 
the A/ASIA G-VII lineage (Table 4.2) were selected for sequencing. The following samples 
were selected to characterise immune variation both within and between hosts, with lesion 
material from vaccinated and control animals being selected: 
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 Challenge virus 
 4939 (Control) BRF 
 4919 (Control) FLF 
 3920 FRF 
 4921 FLF and BLF 
 4930 BLF 
 4944 BRF 
 4917 FRF and BRF 
 
4.4.2.2. Viral RNA extraction and quantification 
Following tissue homogenisation and total RNA extraction using the TRIzol reagent, total RNA 
from each sample was quantified using the Qubit. From all the samples, a mean of 44 ng/µl 
total RNA was obtained, with this ranging from 19.75 ng/µl (4921 BLF) and 75.75 ng/µl (4921 
FLF). Following RT-qPCR quantification, the lowest FMD viral RNA was found in the sample 
prepared from the challenge virus (4.48x104 FMD viral RNA copies/µl) and the highest found 
in 4921 BLF (2.7x107 FMD viral RNA copies/µl). An average of 5.57x106 FMD viral RNA 
copies/µl was extracted for all samples. All information regarding the Qubit and RT-qPCR 
analysis of the samples can be found in Table 4.3. 
4.4.2.3. PCR amplification  
Based on the PCR cycle number optimisation (as described in section 2.4.4), six samples were 
expected to require a total number of 26 cycles (as their corresponding FMD viral RNA 
copies/µl inputs were diluted to 106 viral RNA copies/µl) (Table 4.3). However, only two 
samples (4921 FLF and 4917 BRF) matched this, with the other three requiring a further 10 
or more cycles to produce enough amplicon for sequencing (0.2 ng/µl) (Table 4.3).  
For the four samples with a starting FMDV input of below 106 copies/µl, only two samples 
(4930 BLF and 4939 BRF) produced enough material for sequencing following the expected 
number of PCR cycles (Table 4.3). The other two samples (challenge virus and 4944 BRF 
required a total of 39 cycles.  When amplicon products were run on an electrophoresis gel, a 
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clear 3kb band was visible for samples; 4921 FLF, 4930 BLF, 4917 BRF, 4949 BRF (samples 
with matching expected and required PCR cycles), 4919 FLF and the challenge virus (example 
in Figure 4.3a), whilst for the remaining samples, the 3kb band as well as multiple smaller 
bands were detected (examples of these post-amplification agarose electrophoresis gels are 
shown in Figure 4.3b).  
Table 4.3. RNA extraction PCR amplification information of the samples. The expected and 
required number of PCR cycles and the average quantification between technical replicates 
for each amplified sample.  
$Copies/µl, *Expected number of PCR cycles was optimised as described in section 2.4.4, 
+Average between two technical replicates (ng/µl) 
      Qubit RT-qPCR PCR amplification Qubit   
  Lesion site 
Total 
RNA$ 
Copies/µl Expected*  Required  
Total 
DNA+ 
Multiple 
bands? 
U
n
p
ro
te
ct
ed
  
3920 FRF 31.33 1.20x107 26 36 3.24 Yes 
4921 FLF 75.75 2.00x106 26 26 6.14 No 
4921 BLF 19.75 2.70x107 26 36 3.70 Yes 
4930 BLF 46.35 2.00x105 26-32 30 0.27 No 
4944 BRF 23.25 8.50x105 26-32 39 1.40 Yes 
4917 FRF 22.3 1.59x106 26 39 0.59 Yes 
4917 BRF 73.5 2.30x106 26 26 1.87 No 
C
o
n
tr
o
l 
4939 BRF 67.5 1.20x105 26-32 32 0.82 No 
4919 FLF 56.3 9.60x106 26 32 1.32 No 
Challenge virus 24.31 4.48x104 32 39 0.42 No 
  
 
 
 
 134 
 
 
Figure 4.3. PCR amplification products of in vivo samples. Examples of amplicons which 
produced a single 3kb band (A) and a 3kb band plus multiple smaller amplicon products (B). 
L: 1kb Hyperladder – sizes displayed on the left of the figure 
+: 3kb positive control (shows the correct size of the FMDV capsid PCR amplicon) 
R1/R2: Technical replicates 1 and 2 
 
4.4.3. Illumina Sequencing 
4.4.3.1. Reference generation by De Novo assembly 
A total of 1.01x105 reads from the two challenge virus replicates were passed through the de 
novo assembler pipeline (section 4.3.4.3). Following trimming of data to a qScore of q38 and 
a read length of 70 using Sickle, a total of 6.92x105 paired reads were used for de novo 
assembly producing a contig 3038nt in length. BLASTn analysis revealed the closest alignment 
to FMDV A SAU/1/2015 (GenBank accession number: KU127241) with a nucleotide identify 
of 99.20%.  
4.4.3.2. Raw read filtering and alignment 
Following Illumina sequencing, a total of 3.53x107 reads were produced, with a mean of 
1.77x106 generated for each sample. Following trimming based on qScore of 38 and read 
length of 70 using Sickle, a mean of 6.31x104 reads remained for each sample, of which an 
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average of 96.29% aligned to the reference genome producing a mean coverage depth per 
nucleotide across the sequenced amplicon of 2.07x103 (Figure 4.4).  
Based PCD scores generated from Bland-Altman analysis between technical replicates (Table 
4.4), variants within samples from 4921 FLF and 4917 BRF were analysed using a frequency 
cut-off of 0.2% (Table 4.4). While all other samples were assigned a frequency cut-off of 0.5% 
for variant analysis (Table 4.4). 
 
Figure 4.4. Coverage profiles across the sequenced amplicon. Read coverage plots across 
the sequenced amplicon region for each sample. Within the vaccinated group; 4917 BRF is 
shown in red, 4917 FRF in orange, 4921 FLF in blue, 4921 BLF in light red, 3920 FRF in purple, 
4944 BRF in pink and 4930 BLF in green. Within the control group; 4939 BRF is shown in black 
and 4919 FLF in grey. The challenge virus coverage depth is shown in Yellow 
 
 
 
 
 
 
 
 
 
 
 136 
 
Table 4.4. Read statistics for the sequenced in vivo samples. Alignment parameters and 
results for all sequenced samples. 
* Total reads after trimming using Prinseq and before sickle trimming 
+ Between technical replicates 
  Lesion site Replicate 
Total 
reads* 
Reads 
mapped 
Mean 
coverage 
Critical 
difference+ 
Frequency 
cut-off 
V
ac
ci
n
at
e
d
  
3920 FRF 
1 4.95x104 99.25% 1.66x103 
0.173% 0.50% 
2 9.23x104 99.80% 3.18x103 
4921 FLF 
1 4.61x104 99.53% 1.56x103 
0.120% 0.20% 
2 5.96x104 99.57% 2.02x103 
4921 BLF 
1 9.78x104 99.51% 3.28x103 
0.208% 0.50% 
2 7.58x104 99.48% 2.54x103 
4930 BLF 
1 5.39x104 91.77% 1.67x103 
0.502% 0.50% 
2 4.61x104 94.83% 1.49x103 
4944 BRF 
1 9.70x104 98.96% 3.19x103 
0.619% 0.50% 
2 2.44x104 98.54% 8.04x102 
4917 FRF 
1 4.57x104 98.65% 1.52x103 
0.145% 0.50% 
2 2.96x104 97.94% 9.81x102 
4917 BRF 
1 1.07x105 97.63% 3.66x103 
0.081% 0.20% 
2 7.69x104 97.36% 2.49x103 
C
o
n
tr
o
l 4939 BRF 
1 6.34x104 96.58% 2.02x103 
0.303% 0.50% 
2 6.94x104 93.31% 2.23x103 
4919 FLF 
1 9.22x104 96.82% 3.10x103 
0.168% 0.50% 
2 3.31x104 94.71% 1.06x103 
Challenge virus 
1 4.64x104 73.30% 1.14x103 
0.173% 0.50% 
2 5.45x104 98.35% 1.80x103 
 
4.4.3.3. Consensus changes 
A single synonymous consensus change was present within sample 4930 BLF present at 
VP1195. This mutation was at a frequency of 98.14% resulted in a codon change from GTC to 
GTT (amino acid: valine). This change was not found in any other sample as a consensus 
change or low-frequency variant.  
4.4.3.4. Low-frequency variant substitutions 
For the inoculum virus, 4921 BLF, 4944 BRF and 4930 BLF, no variants above the percentage 
frequency threshold and in both technical replicates were identified. For the remaining 
samples, a total of 51 sub-consensus variants were identified (present in both technical 
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replicates of each sample), of which 30 were synonymous and 21 were non-synonymous in 
nature.     
Within the two control samples, a total of 27 substitutions were identified with sample 4939 
BRF containing the most variants (n=24) (Figure 4.5). While within the seven samples from 
vaccinated animals, a total of 24 substitutions were identified, with sample 4921 FLF having 
the highest number (n=10). The highest frequency variant identified within the control group 
was within sample 4939 BRF, which was a non-synonymous substitution (10.93%) found at 
Lpro9 (Table 4.5). While for the vaccinated group, sample 4921 FLF contained the highest 
frequency variant, which was synonymous in nature (5.15%) and located at VP3173 (Table 
4.6). The highest frequency non-synonymous substitutions within the vaccinated group was 
also found in sample 4921 FLF (1.74%) at VP195 (Table 4.5). Further information regarding 
the position and frequency of the non-synonymous and synonymous changes can be found 
on Table 4.5 and Table 4.6 respectively.  
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Figure 4.5. Summary of variant positions across the RT-PCR amplicon. The location of 
identified synonymous (cross) and non-synonymous (dot) substitutions found above the 
percentage frequency threshold and in both technical replicates along the sequenced 
amplicon region. Variants within the vaccinate groups belonging to; 4917 BRF are shown in 
red, 4921 FRF in blue, 3920 FRF in purple and 4930 BLF in green. Variants with the control 
group belonging to; 4939 BRF are shown in black and 4919 FLF in grey. 
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Table 4.5. Non-synonymous substitutions. The total number of non-synonymous variants 
(average of technical replicates) identified within the control and samples from vaccinated 
animals. Variants identified with sample 4944 BRF have been removed due to the likelihood 
of being errors.   
*Amplicon 
+Amino acid 
      Vaccinate Control 
*Position Region +Change 
3920 
FRF 
4917 
BRF 
4917 
FRF 
4921 
FLF 
4939 
BRF 
4919 
FLF 
167 Lpro9 Ile > Thr         10.93%   
236 Lpro32 Phe > Ser         0.84%   
472 Lpro111 Leu > Met         2.07%   
575 Lpro145 Lys > Arg       0.36%     
624 Lpro161 Tyr > Try         0.61%   
643 Lpro168 Phe > Leu           0.69% 
724 Lpro195 Ala > Thr         2.31%   
983 VP479 Leu > Pro 0.60%           
1244 VP281 Leu > Ser         1.00%   
1399 VP2133 Thr > Ala     1.54%       
1623 VP2207 Tyr > Try         1.26%   
1669 VP35 Val > Ile   0.27%         
2281 VP3209 Phe > Leu   0.43%         
2380 VP121 Thr > Ala       0.23%     
2419 VP134 Ile > Val         2.94%   
2567 VP183 Gly > Asp 1.05%           
2603 VP195 Ala > Val       1.74%     
2644 VP1109 Ala > Pro         1.32%   
2935 VP1206 Ala > Thr         3.32%   
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Table 4.6. Synonymous substitutions. The total number of synonymous variants (average of 
technical replicates) identified within the control and samples from vaccinated animals. 
Variants identified with sample 4944 BRF have been removed due to the likelihood of being 
errors.   
*Amplicon 
+Amino acid 
 
      Vaccinate Control 
*Position Region +A.A 
3920 
FRF 
4917 
BRF 
4917 
FRF 
4921 
FLF 
4930 
BLF 
4939 
BRF 
4919 
FLF 
60 5'UTR Ser   0.23%           
120 5'UTR Leu           2.82%   
177 Lpro12 Leu           1.03%   
267 Lpro42 Phe         1.87%     
273 Lpro44 Ser           1.56%   
285 Lpro48 Asn           3.21%   
447 Lpro102 Ala           3.19%   
498 Lpro119 Ala     0.53%         
543 Lpro134 Cys     0.53%         
576 Lpro145 Lys     0.50%         
579 Lpro146 Gly     0.65%         
630 Lpro163 Ile       0.30%       
633 Lpro164 Asp           1.76%   
708 Lpro189 Leu           5.34%   
825 VP426 Tyr           2.02%   
1155 VP251 Leu           2.00%   
1416 VP2138 Try           0.70%   
1500 VP2166 Asn           2.01%   
1581 VP2193 Gly       0.33%       
1638 VP2212 Gly   0.37%           
1728 VP324 Pro             0.54% 
1761 VP335 Thr           0.96%   
1779 VP341 Phe       0.36%       
2175 VP3173 Asp       5.15%       
2181 VP3175 Ala           0.93%   
2289 VP3211 Leu             3.11% 
2343 VP18 Asp       0.28%       
2373 VP118 Gly       2.57%       
2832 VP1171 Ile           14.18%   
2856 VP1179 Lys 1.35%             
2901 VP1194 Val         1.86%     
2946 VP1209 Lys       0.43%       
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4.4.3.5. Shannon’s entropy  
Shannon’s entropy analysis revealed that the control sample 4939 BRF exhibited the highest 
total global entropy score across the sequenced amplicon region, with an accumulative 
entropy score of 4.044. The vaccinated sample 4921 FLF had the second highest entropy 
across the sequenced amplicon with an accumulative entropy score of 0.823 (Table 4.7). 
These two samples also showed the highest entropy scores within the capsid encoding 
region. However, 91.83% of the overall entropy for sample 4921 FLF was present within the 
capsid, with 47.13% and 40.33% of present within VP1 and VP3 respectively (Table 4.7). These 
results were in comparison to the data for control sample 4939 BRF, where 47.10% of the 
overall entropy was present within the capsid encoding region. In this sample, with the region 
encoding the leader protein containing the highest proportion (48.34%) of the overall 
entropy (Table 4.7). A total of 80.69% of the total entropy for the other control sample, 4919 
FLF, was present within the capsid encoding region, of which all of it was present within the 
VP3 encoding region (Table 4.7).  
All but two of the samples from vaccinated animals contained more than 80% of the total 
entropy within the capsid encoding region, while samples 4930 BLF and 4917 FRF had 50.33% 
and 35.95% respectively of their overall entropy present within the capsid (Table 4.7). Within 
the samples from vaccinated animals, VP3 and VP1 displayed the highest entropy 
percentages of the entire capsid encoding region. Figure 4.6 shows entropy levels at 
nucleotide positions as well as accumulative entropy scores across the sequenced amplicon 
regions for all samples.  
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Table 4.7. Global entropy scores across the sequenced amplicon region. The total global 
entropy amount is given within the sequenced amplicon region for all vaccinated and control 
samples. This is further split into entropy levels and percentages for the entire capsid encoding 
region and individual.  
*Percentage of overall entropy 
                      
  Sample  Amplicon Capsid Capsid*  5'UTR Lpro VP4 VP2 VP3 VP1 
V
ac
ci
n
at
ed
 
3920 FRF 0.241 0.241 100%   21.80%   78.40% 
4917 BRF 0.127 0.102 80.52% 19.49%   27.63% 52.89%  
4917 FRF 0.317 0.114 35.95%  64.02%  35.99%   
4921 FLF 0.823 0.756 91.83%  8.14%  4.38% 40.33% 47.13% 
4930 BLF 0.264 0.133 50.33%  49.82%    50.18% 
C
o
n
tr
o
l 
4939 BRF 4.044 1.905 47.10% 4.58% 48.34% 3.40% 12.93% 3.86% 26.95% 
4919 FLF 0.307 0.248 80.69%  19.31%   80.69%  
 
Entropy scores equal to or greater than 10% of the overall non-synonymous diversity were 
investigated further. A total of 6 sites were identified within five samples deriving from 
vaccinated hosts, all within the capsid encoding regions. One site each was identified within 
both control samples, both of which were present within the leader encoding region (Figure 
4.6 and Table 4.8).   
Table 4.8. Substitutions representing >10% Entropy within a population. Substitutions found 
in the vaccinated and control animals with entropy scores representing equal or greater than 
10% of the total sequenced diversity.  
+Control animals 
*Amplicon 
Sample Encoding region % frequency Entropy score Entropy % 
4939 BLF+ Leader9 10.93% 0.498 12.30% 
4919 FLF+ Leader168 0.69% 0.059 19.31% 
3920 FRF VP479 0.60% 0.053 21.80% 
4917 FRF VP2133 1.54% 0.114 35.99% 
4917 BRF VP35 0.27% 0.027 21.16% 
4917 BRF VP3209 0.43% 0.040 31.72% 
3920 FRF VP183 1.05% 0.085 35.38% 
4921 FLF VP195 1.74% 0.126 15.32% 
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Figure 4.6. Shannon entropy scores of in vivo data. (Top) Accumulative Shannon’s entropy 
scores. (Middle and bottom) Percentage entropy scores across the sequenced amplicon region 
for the two control and seven samples from vaccinated animals respectively. Entropy scores 
within the vaccinate groups belonging to; 4917 BRF are shown in red, 4921 FRF in blue, 3920 
FRF in purple, 4917 FRF in orange and 4930 BLF in green. Entropy scores with the control 
group belonging to; 4939 BRF are shown in black and 4919 FLF in grey. 
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4.4.4. Surface exposed non-synonymous substitutions  
The non-synonymous substitutions identified within the capsid encoding region were 
mapped to a crystalized structure of FMDV A (A22-H2093F) to assess if they were located on 
the capsid surface and mapped to previously identified epitope regions. Information 
regarding the non-synonymous substitutions can be found on Figure 4.7 and Table 4.9.  
For the samples from vaccinated animals, from the six non-synonymous substitutions 
identified within the capsid, four were predicted to be exposed on the surface of the virus. 
No surface exposed substitutions were identified for sample 4930 BLF, while one substitution 
each was identified for samples 3920 FRF, 4917 BFR, 4917 FRF and 4921 BLF. The mean 
frequency of the identified substitutions was 1.15%. Of the seven variants identified within 
the control samples, two (VP281 and VP1109) were predicted to be on the surface of the capsid. 
These two substitutions were found exclusively in sample 4939 BRF and had a mean 
frequency of 1.16%.  
Table 4.9. Surface exposed non-synonymous substitutions. The location, amino acid change 
and frequency of the non-synonymous substitutions identified within the capsid encoding 
regions from the vaccinated and control animals. 
+Control     
Sample 
Amplicon 
position 
Encoding region  
Amino acid 
change 
Frequency 
+4939 BRF 1244 VP281 Leu > Ser 1.00% 
4917 FRF 1399 VP2133 Thr > Ala 1.54% 
4917 BRF 1669 VP35 Val > Ile 0.27% 
3920 FRF 2567 VP183 Gly > Asp 1.05% 
4921 FLF 2603 VP195 Ala > Val 1.74% 
+4939 BRF 2644 VP1109 Ala > Pro 1.32% 
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Figure 4.7. Surface exposed non-synonymous substitutions for samples from vaccinated 
animals. A crystallised structure showing the predicted VP1 (Blue), VP2 (Sea-green), VP3 
(Pink-tint) and VP4 (Yellow). Non-synonymous substitutions identified within the vaccinated 
group are shown in red while previously identified epitope regions of FMDV type A are 
highlighted in grey.   
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4.5. Discussion  
In order to characterise immune escape substitutions that were generated during the initial 
stages of FMDV infection in vivo, FMDV infected epithelium tissue collected from a cattle 
vaccination challenge study (278) were sequenced.       
Serology results showed differing titres of FMDV-specific neutralising antibodies between 
unprotected and protected vaccinated cattle, while viremia analysis demonstrated that 
animals that were protected had lower concentrations of FMD viral RNA in their blood (Figure 
4.2). These results indicate that the FMD viruses recovered from the unprotected vaccinated 
animals had replicated in the presence of a partial immune response against the virus. These 
conditions mimicked the situation in the Middle East where the vaccine used in this study is 
widely deployed and anecdotal data from field outbreaks in vaccinated regions (154) suggest 
this vaccine is ineffective against the G-VII lineage of FMDV.  
Technical issues with the laboratory HTS pipeline (chapter 2) were identified, with six samples 
requiring extra PCR amplification cycles to produce enough template material for 
sequencing. One reason for this inconsistency in the required PCR cycles could be the quality 
of the RNA material extracted from each of the epithelium samples. Overall, samples which 
amplified correctly with expected number of PCR cycles produced a single 3kb amplicon 
product, while samples in which extra cycles were required produced multiple shorter 
amplicon products (Figure 4.3). These PCR differences could be due to necrosis at the site of 
infection, which could lead to viral RNA being degraded in some of the samples. These issues 
might be overcome by using the Bioanalyser in order to obtain RIN values for samples sets, 
giving an indication of RNA quality, which could be used as an alternative method to estimate 
the number of PCR cycles required. Necrotic tissue (and bacterial from a secondary infection) 
could also lead to the presence of inhibitors, for example; cell debris, salts, proteins and 
polysaccharides (283), which would affect the PCR reaction. These problems could be 
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overcome by performing further purification steps after RNA extraction or RT to remove 
potential inhibitors, however this may come at a loss of genomic material.  
Alignment using GEM3 revealed large drops in sequence coverage at multiple positions along 
the amplicon. Further analysis of these positions revealed overrepresented GC or AT base 
motifs, consistent with previously published studies (284). Following filtering based on 
frequency cut-off, no substitutions were identified in the starting inoculum virus and samples 
4921 BLF, 4944 BRF and 4930 BLF. The lack of variability in the clinical samples could be due 
to a lack of viral diversity caused by low extent of viral replication or reduced immune or 
other environmental pressures acting on the viral swarms. An alternative reason could be 
due to the HTS pipeline used to sequence was not sensitive enough to detect generated low-
frequency variants, either because the percentage frequency cut-off isn’t low enough or 
certain genomes are being preferentially amplified.  
Shannon’s entropy analysis revealed that the control sample 4939 BRF had the highest 
diversity within the sequenced amplicon region. While the control samples were not 
subjected to immune pressure, the high entropy score within sample 4939 BRF could be the 
result of other factors acting on the viral swarm. Evidence to suggest this comes from the 
fact that 48.34% of the overall diversity within control 4939 BRF was identified within the 
Leader encoding region (Table 4.8), which isn’t impacted by the humoral antibody response. 
While in the FLF sample from the vaccinated animal 4921 (which displayed the second 
highest entropy score), 91.83% of the overall entropy was identified within the capsid 
encoding regions, which would be subjected to antibody induced immune pressure. The 
experiment design may have influenced viral swarm diversity, as control animals were 
enthused following viral generalisation to three feet, compared with only one foot for the 
vaccinated animals. Sample 4939 BRF may have been collected from the first lesion to 
generalise (data was not recorded in the in vivo study) and therefore the viral population may 
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have more time to replicate and generate diversity. In contrast, sample 4919 FLF may have 
been collected from a foot lesion which was last to generalise, which could explain the lower 
diversity within the second control sample (Table 4.7). Differences in viral entropy were 
observed in samples 4917 BRF and 4917 FRF which derived from the sample animal, which 
displayed 80.52% and 35.95% of overall entropy within the capsid encoding region. These 
differences could be due to variance in the replication site, local immune pressures, 
differences in transmission bottlenecks or the time point in which generalisation occurred.  
Sample 4921 FRF contained the highest entropy from the samples from vaccinated animals, 
with the highest percentage of entropy occurring within the VP3 and VP1 encoding regions. 
The highest entropy score was associated with the change at VP195, which was exposed on 
the capsid surface (Figure 4.7, Table 4.9). The VP195 substitution (present at a 1.74% 
frequency) was investigated further and was found to match a potential antigenic site in 
serotype A, due to its close proximity to the C-terminus of VP1, which forms part of antigenic 
site one of FMDV (285). While this change was identified in the FRF of sample 4921, no low 
frequency variants were identified in another sample (BLF) derived from the same animal. 
Another VP1 surface exposed non-synonymous substitution was also identified within 
sample 3920 FRF at VP183 (present at a 1.13% frequency). Previous studies (275,286,287) 
have identified VP183 (as well as adjacent site VP185) as an antigenic site with serotype A BAR-
08 and A12 lineages (288). Further evidence that these substitutions are associated with 
immune escape comes from the serology (Table 4.2). VNT titres of the two serotype A vaccine 
components revealed that animal 3920 had the highest A/SAU/95 titre (128), while animal 
4921 had the highest A/IRN/05 titre (178). These higher antibody titres could explain the 
presence of immune escape substitutions within these two viral swarms. Finally, VP2134 has 
previously been reported to influence the binding of antigenic site 2 mAbs in serotype O 
viruses (289), the similar amino acid positions of antigenic sites between serotypes O and A 
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(Figure 1.8) could mean that the mutation at VP2133 (adjacent to VP2134) in the vaccinated 
sample 4917 FRF (Table 4.9) could act as a immune escape variant.  
All identified variants were unique to individual samples which indicates that FMDV evolution 
is non-deterministic in nature, whereby different swarm populations explore different paths 
to immune escape. A second explanation could be due to the differences in the polyclonal 
antibody spectrum present in the different sera and their influence on the viral swarm, 
leading to a unique evolutionary response. A previous study (182) hypothesised that a lack 
of shared diversity between sample sets is due to the evolutionary bottlenecks within the 
host causing a small viral founder population and that variants are generated at the local site 
of replication. An immune pressure could act as an additional bottleneck restriction further 
limiting founder viral diversity. This factor as well as the different environmental pressures 
at each replication sites (e.g. different animals, different sites of replication, different 
immune responses) could be causing the unique diversity between viral swarms.  
This study identified three unique amino acids substitutions which have potential impact on 
immune escape phenotype within FMD viral swarms derived from three vaccinated animals, 
however all were low in frequency and not shared within or between hosts. These low 
frequency substitutions could be due to limited rounds of viral replication, as there was no 
transmission chain and vaccinated animal were quickly euthanised following the 
development of vesicular lesions one foot. In order to further characterise immune escape 
evolution in FMDV populations, an in vitro study was performed. Whereby the same FMD 
virus was exposed to sub-neutralising levels of serum generated from protected animals in 
this study as well as from field animals inoculated with the same hexavalent vaccine. The in 
vitro study is presented in chapter 5.  
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Chapter 5  
The characterisation of immune escape substitutions 
with in vitro FMDV populations subjected to sub-
neutralising antibodies 
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5.1. Abstract  
Being an RNA virus, FMDV rapidly adapts to external environmental pressures such as from 
an immune response. However, observing the initial stages of immune escape in vivo is 
problematic, due to the restricted rounds of viral replication in infection experiment and 
limited access to transmission chain data from field samples. In order to better understand 
the development of immune escape substitutions, a serotype A FMDV was passaged for four 
cycles in LFBK-αVβ6 cells in the presence of sub-neutralising serum antibodies derived from 
vaccinated cattle which increased the time taken for cytopathic effect (CPE) to occur in the 
cell cultures. Three experimental conditions were tested; “Challenged”, representing an 
immune response from vaccinated and infected cattle, “Field” representing an immune 
response from vaccinated and uninfected cattle and “Control”, which was used to measure 
background variation. Cell cultures were monitored until complete CPE had occurred at 
which point viruses were harvested.  During the passage series, time to complete CPE was 
found to decrease in two out of three of the Challenged and Field group serum experiments. 
HTS analysis identified three surface exposed non-synonymous substitutions at VP266, VP280 
and VP1155, in unique viral populations in the Field and Challenged groups, which correlated 
to with previously identified FMDV serotype A epitope regions. Immune escape associated 
changes only occurred in experiments in which the serum exhibited the strongest 
neutralisation effect. While lower frequency variants, generated in viral populations 
subjected to a reduced immune pressure, were hypothesised not to be passed on due to the 
MOI dilution between passages.  This suggests that level of immune response acting on a 
small genetic bottleneck between passages influences the development of immune escape 
variants. This study identified potential immune escape substitutions increasing in frequency 
following each passage, giving an understanding of FMDV evolution during the initial stages 
of immune pressure exposure.   
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5.2. Background and introduction 
At each site of replication, RNA viruses such as FMDV exist as a heterogeneous population 
comprising closely related genomes. This population complexity is due to a combination of 
factors, including; the large viral population size, the high replication rate and the poor proof 
reading ability of the viral RdRP (17). Due to this, it is hypothesised that during each 
transcription event, a least one nucleotide variant arises in each genome (~7.8x10-4 
nucleotides errors per replication) (177). Such factors allow for FMDV populations to rapidly 
generate variation when exposed to selective pressure such as an immune response 
(190,272). For the most part, these positively selected changes can be observed influencing 
a small number of codons sites within the capsid encoding regions (175), for example; the 
five antigenic sites (each with multiple residues) for serotype O (31,159) (Figure 1.6).   
While immune escape variants can be investigated in vivo, such experiments have limitations. 
For example in the case of a vaccination experiment, animals are culled (due to ethical 
reasons) if the virus generalises to at least one foot (278), which imposes limits on the extent 
of viral replication that occurs in the presence of specific antibodies. To overcome this, an in 
vitro based model can be employed, whereby viral replication and antibody dilutions can be 
more easily modelled under more stringently controlled conditions. Previous studies using 
cell culture models have identified amino acid substitutions associated with either immune 
or antiviral escape. Examples include; immune escape associated substitutions within the 
hemagglutinin protein of avian influenza virus (290) and E2 envelope protein of hepatitis C 
virus (291) as well as antiviral associated variants in the RdRP protein of influenza A virus, 
leading to favipiravir resistance (197). In vitro based studies have also been performed with 
FMDV, to investigate immune escape evolution (189,190), with one study passaging FMDV 
type O in IBRS-2 cells in the presence of sub-neutralising polyclonal serum leading to the 
identification of two novel neutralising epitope regions at VP3116 and VP3195 (292).   
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In this study, a field FMDV isolate from the A/ASIA/G-VII lineage was passaged in LFBK-αVβ6 
cells with serum derived from either; vaccinated cattle (“Field”), vaccinated/challenged cattle 
(“Challenged”) or unvaccinated/unchallenged cattle (“Control”) in order to measure the 
effect that sub-neutralising antibodies had on the evolution of the viral swarm. The vaccine 
and challenge induced serum for the Challenged group derived from vaccine protected 
animals from a previous in vivo vaccine study (278) (as described in chapter 4), while the 
vaccine-induced serum for the Field group derived from vaccinated and uninfected cattle 
from Saudi Arabia (154). In both cases the same hexavalent vaccine, containing the FMDV 
A/SAU/95 component (which can be used to induce protection against the A/ASIA/G-VII 
lineage) was used (described in section 4.3.1). In total, four viral passages with serum were 
performed, with viral populations being sequenced using the optimised HTS pipeline (as 
described in chapters 2 and 3), with the aim of testing three interconnected hypotheses 
(Figure 5.1):  
 The time to CPE of FMD viruses exposed to sub-neutralising serum would increase 
during the initial passages but would decrease in later passages as the virus evolved 
immune escapes variants.  
 Sequence data would identify viral capsid surface amino acid substitutions in the 
initial passages as the virus population explores possibilities of immune escape.  
 Generated immune escape variants match (or neighbour) previously identified 
epitope regions (276)  
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Figure 5.1. FMDV immune escape evolution in vitro and in vivo. FMDV population exposed 
to a sub-neutralising antibody response or serum are hypothesised to developed non-
synonymous substitutions associated with immune escape that are located on the viral capsid 
surface. Blue circles indicate viruses that are neutralised by antibodies, while orange circles 
indicate viruses which have ‘escaped’ the immune response and have become dominate in 
the viral swarm. The crystallised structures of FMDV shows the potential location of surface 
exposed variants (in red). 
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5.3. Materials and Methodology 
5.3.1. Virus, cells and serum 
5.3.1.1. LFBK-αVβ6 cells maintenance and passaging 
An immortalised line of foetal porcine kidney (LFBK) cells expressing bovine αV and β6 integrin 
subunits (LFBK-αVβ6) previously identified as the cellular receptor for FMDV (293), was used 
in this study.  
Monolayers of LFBK-αVβ6 cells were maintained in high glucose Dulbecco's Modified Eagle 
Medium (DMEM) (Thermo Fisher Scientific) supplemented with 10% foetal bovine serum 
(negative for FMDV-specific antibodies) (Thermo Fisher Scientific), penicillin-streptomycin 
solution (100 SI Units/ml penicillin and 100µg/ml streptomycin) (Thermo Fisher Scientific) 
and amphotericin B (2.5µg/ml) (Life Technologies). Cultures were split twice weekly to 
maintain cell populations in T175 flasks.  
For each passage, a total of 106 cells were seeded onto Falcon 6-well clear flat bottom TC-
treated multiwall cell culture plates (Scientific Laboratory Supplies). Briefly; DMEM from each 
fully confluent T175 flask was removed and cells washed using 10ml of Dulbecco’s Phosphate 
Buffered Saline (DPBS) (Sigma-Aldrich). The cell monolayer was then removed by incubation 
at 37°C for 10 minutes with of 6ml of pre-warmed 0.05% trypsin-EDTA phenol red solution 
(Thermo Fisher Scientific). After incubation, the trypsin was neutralised by the addition of 
10ml of DMEM, and the supernatant was added to a 50ml Falcon tube before being spun at 
50xg for 5 minutes at 10°C. The supernatant was then removed, and the resulting cell pellet 
re-suspended in 10ml of DMEM with 9µl of cells being added to a haemocytometer for cell 
counting. Following this, cells were further diluted in DMEM to 2.5x105 cells/ml with 4ml 
being added to each cell culture plate well. Plates were incubated in a 37°C in a 5% CO2 
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incubator for 6 hours to allow a monolayer of cells to become established. Prior to infection, 
DMEM from each well was removed and cell monolayers washed twice using DPBS.  
5.3.1.2. Virus isolate 
The FMDV virus (Isolate IRN/22/15) used in these experiments was prepared for use in a PPG 
in vivo study (278) (described in chapter 4) directly from bovine tongue lesion material 
collected from a field case of FMD in Iran. Briefly; the virus material was a 10% suspension 
(w/v in M25 PBS) of homogenised tissue and titred on bovine thyroid (BTY) cells (294) to give 
a final titre of 105 TCID50/ml.  
In order to establish a stable starting FMDV population which was adapted to the LFBK-αVβ6, 
the FMDV isolate was first passaged independently a total of five times using MOI 
concentrations of 0.1 and 0.01. Lower MOI concentrations were tested due to the increased 
likelihood of the formation of defective interfering particles in viral populations passaged 
using a high MOI (295). Briefly; the time to CPE and the amount of virus produced (as 
measured by viral PFU) for both viral MOI populations was found to reach equilibrium 
following the third passage. For the main passage series, an MOI of 0.01 was chosen, as 
theoretically the MOI: 0.01 viral population would of had more rounds of replication to reach 
the same amount as the MOI: 0.1 virus. Hypothetically, this would make the MOI of 0.01 viral 
population more adapted to the LFBK-αVβ6 cells. In addition to this, some serum sample 
volumes were found to be limited and lower MOI of virus would require less volumes of sub-
neutralising levels of serum. Further information regarding this preliminary optimisation 
experiment can be found in Appendix A. 
Following adaptation to the LFBK-αVβ6 cell line, 100µl of virus at a MOI of 0.01 was combined 
with 1ml of the required dilution of serum (see below) and incubated at room temperature 
for 1 hour. The virus/serum mix was then added onto the cells, with the addition of 2.9ml of 
DMEM.  
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In order to monitor the development of CPE, the IncuCyte® Live-cell analysis system 
(Sartorius, Michigan, USA) was used, which allowed for the visualisation and quantification 
of cell death over time. For each experiment, a total of 36 images per well were taken every 
30 minutes using an x10 magnification, which resulted in a total of 48 daily scans. The scans 
were stopped following complete CPE of the cells. In order to avoid bias, a blind approach to 
observing images was taken, with each sample being given a randomised name. The 
estimated CPE percentage for these randomised images (from each time point) were 
manually recorded, allowing for the generation of ‘kill curves’, showing the decline in the 
number of living cells over time. Typical examples of such images are shown on Figure 5.2.  
 
Figure 5.2. IncuCyte images of cell CPE. Representative IncuCyte images taken from a plate 
containing LFBK-αVβ6 cells infected with IRN/22/2015 at two different time points after 
infection; (A) mid-infection (i.e. partial CPE), taken after 7 hours and (B) complete cell death 
(i.e. full CPE), taken after 11 hours.  
 
5.3.1.3. Serum  
Three different sera groups from were used in this study, which all derived from individual 
Holstein Friesian cattle.  
Group one (Field) consisted of serum derived from vaccinated and uninfected animals (as 
tested by NSP ELISA) from Saudi Arabia (154) and were used to represent a vaccine induced 
immune response. Serum from group two (Challenged) derived from protected vaccinated 
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and infected animals obtained from an in vivo vaccine potency study (278) and was used to 
represent both a vaccine and host specific generated immune pressure. Serum collected 
from cattle in group’s one and two were vaccinated using the Aftovaxpur® multivalent 
vaccine (Boehringer Ingelheim), consisting the A/SAU/95 and A/IRN/05 components, which 
were demonstrated to provide protection against the A/ASIAG-VII lineage (278). Serum used 
in groups one and two tested positive for neutralising antibodies as measured by VNT (Table 
5.1). Group three (Control) was the control group, consisting of serum collected from the 
same cattle in group one prior to vaccination and challenge and was used to measure neutral 
variation.  
In order to estimate the amount of antibody pressure acting on the viral population, a 
preliminary experiment testing the CPE delay from an infection with the starting virus with 
all serum samples was measured. Plates were monitored for 3 days using the IncuCyte, with 
the results recorded on Table 5.1. 
Table 5.1. Serum VNT scores and CPE times for 1/10 serum dilution. VNT scores of A SAU/95 
(a vaccine component) for the three serum groups tested as well as the CPE delay on the 
starting virus by a 1/10 dilution of the serum.  
NB: Serum used in the challenged and control group derived from the same animals. ‘C’ is 
added to control group tag names to differentiate between the two groups.  
ND: Not done 
Neutralised: No CPE recorded after three days   
Group Animal tag 
VNT - A SAU/95 
(titre) 
1/10 dilution CPE 
(time to CPE (hours)) 
O
n
e 
Field 
3159 708 23 
3157 >/= 512 16 
3817 >/= 1413 25 
Tw
o
 
Challenged 
4942 1024 Neutralised 
4926 ND Neutralised 
4914 >/= 1413 59 
Th
re
e 
Control 
4942C <8 14 
4926C <8 14 
4914C <8 14 
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Following this, the sub-neutralisation dilution of serum required for viral culture was 
previously determined by passaging virus in the presence of a log dilution series of serum (as 
described in Appendix B). These preliminary studies indicated that a 1/10 dilution of the Field 
serum group and 1/50 dilution for the Challenge serum group was the optimum dilution of 
serum which didn’t neutralise the entire virus population. For the controls, a 1/10 dilution of 
serum was used.    
5.3.2. Virus harvesting and quantification  
Following CPE, plates were frozen at -20oC to lyse any remaining cells. This was subsequently 
thawed, and contents transferred to a 10ml Falcon tube, which was then centrifuged at 
1000xg for 3 minutes at room temperature to pellet cell debris. For storage, 500µl aliquots of 
virus supernatant were made in 2ml Nunc tubes (Thermo Fisher Scientific), which were then 
frozen at -80oC.  
In order to quantify the amount of FMD virus produced from each experiment, plaque assays 
were performed to define the number of viral plaque forming units (PFU) present. Briefly; 
each virus sample was diluted in a 10-fold dilution series in DPBS from a neat concentration 
to a 10-10 dilution. Next, a total of 100µl of each viral dilution was then added to 106 LFBK-
αVβ6 cells in duplicates and incubated at 37°C in a 5% CO2 incubator for 15 minutes to allow 
viruses to infect the cells. Following this, 4ml of molten Eagle’s overlay/agarose mixture 
(containing 72% Eagle’s overlay (CSU, The Pirbright Institute), 5% tryptone phosphate broth 
(Sigma-Aldrich), 1% FMDV negative foetal calf serum, 25% agarose indubiose A37 (MP), 1ml 
of penicillin and streptomycin (100 SI Units/ml penicillin and 100µg/ml streptomycin) and 
1ml of amphotericin B (2.5µg/ml)) was added to each well and left to set by incubation at 
room temperature for 5 minutes. After this step, plates were placed back in the incubator for 
24 hours. Viruses in each well were then inactivated by incubation at room temperature for 
30 minutes with 4ml of 0.8% citric acid (Sigma-Aldrich) (diluted in PBS). Agar from each well 
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was removed and 2ml of dye (made up from 500ml of 0.85% saline (The Pirbright Institute), 
2g of citric acid and 1g of Naphthol Blue Black (Sigma-Aldrich)) was added. Following 
incubation for 1 hour at room temperature, the dye was removed and the estimated PFU 
was calculated using the following equation:  
𝑃𝐹𝑈 𝑝𝑒𝑟 𝑚𝑙 = 𝑃𝑁 × 10 
Where 𝑃𝑁 is the number of plaques in a dilution (a well with more than 10 plaques was 
selected). The value was multiplied by 10, to generate PFU/ml (as 100µl of virus was added 
to each well). The PFU/ml was used to dilute the virus to a MOI of 0.01 for each passage, 
using the following equation;  
𝑀𝑂𝐼 =
𝑃𝐹𝑈
106
 
Here, 106 represents the total number of cells used for each infection experiment.  
5.3.3. Serum passage series 
Viruses were passaged in the presence of each respective serum for a total of four passages 
(labelled as P1, P2, P3 and P4) (except for Field-3157, whereby only two passages were 
performed due to limited serum volume). Following each passage, viruses were harvested 
and quantified via plaque assay before being diluted to a MOI of 0.01. Harvested viral samples 
were stored at -80oC. The workflow can be found in Figure 5.3.  
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Figure 5.3. The work flow of the FMDV in vitro immune escape study. FMDV A ASIA/G-
VII/IRN/22/2015 was passaged in LFBK-αVβ6 cells with the presence of sub-neutralising 
antibody serum over four passages. After CPE was observed in cells, virus samples were 
harvested for PFU quantification by plaque assay and for sequencing on an Illumina MiSeq 
platform.  
 
5.3.4. RNA extraction and sequencing setup 
Total RNA from each passage series was extracted using the TRIzol reagent (Invitrogen). 
Briefly; a total of 420µl of virus was added to 980µl of TRIzol, which was then added, with 
200µl of chloroform (Sigma-Aldrich), to a Phasemaker tube (Invitrogen) and incubated for 15 
minutes at room temperature. Each tube was centrifuged for 5 minutes at 14,000xg at 4°C, 
which separated the sample into a lower red phenol-chloroform phase, an interphase and a 
colourless upper aqueous phase with the gel in the Phasemaker tubes forming a barrier 
between the upper and lower phases. The top aqueous phase was combined with 1ml of 
isopropanol (Sigma-Aldrich) in a fresh DNA Low bind tube (Eppendorf, Hamburg, Germany), 
incubated at room temperature for 10 minutes and then centrifuged for 15 minutes at 
12,000xg at 4°C. The supernatant was removed and the resulting RNA pellet (made visible by 
the presence of GlycoBlue™ Coprecipitant (15mg/ml) (Thermo Fisher Scientific)) was washed 
twice with pre-chilled 70% ethanol and the eluted in 28µl of nuclease-free water. RNA was 
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split into two aliquots, with 21µl being used for sequencing and 7µl being used for 
quantification by RT-qPCR (this was diluted 1 in 10 in nuclease-free water).  
Viral RNA was quantified via RT-qPCR (as described in section 4.3.2.2) after which the 
optimised HTS pipeline was applied (as defined in chapter 2), with samples first being diluted 
to 106 viral RNA copies/µl. Technical replicates from each RNA sample were reverse 
transcribed using Transcriptor HiFi polymerase (Roche) (as described in section 2.3.3) and 
amplified using Platinum™ SuperFi™ PCR Master Mix (Invitrogen) using the defined number 
of PCR cycles required to produce enough material for sequencing (as described in section 
2.3.4) using the Nextera XT kit (1ng total) (x26 for 106 RNA copies/µl, x32 for 104 RNA 
copies/µl and 39 for 102 RNA copies/µl). If the recommended number of PCR cycles failed to 
produce enough material for sequencing, then PCR was repeated with an increased cycle 
number. All amplicon material from each sample was subjected to electrophoresis through 
a 1% agarose gel (containing GelRed® (Biotium, Fremont, USA)) and visualised by trans-
illumination with UV light to confirm the presence of the 3kb amplicon. The starting virus was 
extracted a total of three times, with each one being processed and sequenced separately. 
The viruses were given the names SV1, SV2 and SV3.  
PCR amplicons were then quantified using the Qubit® dsDNA High Sensitivity Assay Kit and 
diluted to 0.2 ng/µl in nuclease-free water.  
5.3.5. Illumina Sequencing 
Duplicate technical replicates of each sample were processed for sequencing using the 
Nextera XT kit on a Hamilton NGSstar, using official Illumina certified protocols in the HTS 
unit at the Pirbright Institute.  
Pooled libraries were sequenced on an Illumina MiSeq platform on a 300 cycle v2 cartridge. 
A total of three MiSeq runs were performed, with each containing a passage series from a 
Control, Field and Challenge serum group as well as tone of the starting viruses. For data 
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analysis, each of the Field, Challenged and Control samples were compared with a Start virus 
which was present on their corresponding MiSeq run (Table 5.2). 
Table 5.2. MiSeq samples. Each MiSeq run contained a single Field, Challenged and Control 
passage series sample, as well as a Starting virus which was processed separately.  
 
    
Starting 
virus 
Field Challenged Control 
M
iS
eq
 Run1 One 3157 4926 4926C 
Run2 Two 3817 4914 4914C 
Run3 Three 3159 4942 4942C 
 
5.3.5.1. Reference sequence generation 
Reads from each of the three starting viruses were merged and passed through a de novo 
pipeline (as described in section 4.3.4.1) in which assembly was performed using IDBA_UD 
(version 1.1.1) (255) to generate a reference sequence. This sequence was compared to other 
FMDV sequences using BLASTn (256), as well as with the reference sequence generated from 
the in vivo study (chapter 4).  
5.4.5.2. Read trimming and alignment 
The quality of raw reads was examined using FastQC (version 0.11.5) (244) which resulted in 
15 bases and 5 bases from the 5’ and 3’ of each read respectively being trimmed using 
Prinseq-lite (version 0.20.4) (230) (as described in section 2.3.5). Alignment was performed 
using the optimised HTS pipeline (Table 3.3), with reads filtered using Sickle (version 1.33), 
with a qScore of 38 and a read length of 70 (Table 3.3). Following this, GEM3 (version 1.843) 
(251) was used to map the reads to the reference sequence.  
Following alignment, the output .SAM file was converted into a .BAM file using SAMTools 
(version 1.2) (258) and in-house R scripts were used to generate variant and read coverage 
depth data and consensus sequences.  
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5.3.5.3. Variant and Shannon’s entropy analysis 
As described in sections 3.3.4 and 3.4.7, Bland-Altman analysis was performed on each of the 
technical replicates in order to ascertain a percentage critical difference (PCD) score from 
each sample. PCD scores were used to assign a percentage frequency cut-off for variant 
analysis. Samples with a PCD score of below 0.121% were assigned a frequency cut-off of 
0.2%, while samples with PCD scores between 0.121% and 0.203% were assigned a 0.5% 
frequency cut-off. Samples with PCD score 1.521% and above were discarded, due to the low 
associated accuracy for variant analysis and the risk of consensus level errors being present 
within a technical replicate. Samples with PCD scores outside an optimised ranged were 
assigned a percentage frequency cut-off based on its nearest neighbour (e.g. a sample with 
a PCD score of 0.40% would be assign a 0.5% frequency cut-off). 
To be classed as a true biological substitutions, variants within a sample had to be present in 
both technical replicates either equal or above the assigned frequency cut-off. Based on the 
error profiles identified as described in section 3.4.6, C>T base changes, present at the start 
of a homopolymeric region of T bases, identified with samples assigned a 0.2% frequency 
cut-off  were removed due to the likelihood of these being errors. Identified non-synonymous 
substitutions identified between each sequenced population were compared and visualised 
in the form of a Heatmap generated in Rstudio (R version 3.5.2) using the pheatmap (version 
1.01.12).  
Shannon’s’ entropy analysis was performed as described in section 4.3.4.4, with substitutions 
present in both technical replicates, above the percentage cut-off frequency thresholds and 
not associated with error profiles being included.  
5.4.5.4. FMDV capsid structure mapping 
To identify if any substitutions were predicted to be located on the capsid surface of the virus, 
non-synonymous variants were mapped to a FMDV serotype A crystallised structure using 
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RasMol (Version 2.7.5) (280,281). This was performed using the crystallised recombinant 
FMDV A22-H2093F empty capsid structure (282) due to the unavailability of a crystallised 
structure of A/IRN/22/2015 as described in section 4.3.4.5. 
5.4. Results 
5.4.1. Passage series 
During the first passage, the addition of serum was found to increase the time to CPE in all 
cell cultures except for the three Control samples and Field-3157. Each passage within the 
control serum group required a time of between 10 hours and 15 hours (mean: 13.6 hours) 
to generate complete CPE of the cultures. Within the second passage, the CPE time was found 
to be delayed in the same samples, however in all these samples, except for Challenged-
4914, a reduction in CPE time was observed between passages one and two. Only Challenged 
4942 saw a continuous decline in CPE between each passage, with all other samples 
exhibiting increases in time to CPE between passages one to four. The total time until 
complete CPE for each passage can be found on Table 5.3 while ‘kill curve’ plots for each 
sample set showing the estimated CPE percentage at bi-hourly time point can be found in 
supplementary figures 5.1, 5.2 and 5.3.  
Estimating the PFU via plaque assay of the output FMD viruses generated by these cultures 
revealed similar viral PFU/ml for each sample within the Field and Control group, producing 
an average of 3.12x107 PFU/ml and 2.42x107 PFU/ml for each group respectively for all 
passages. All samples within the Challenged group saw an increase in viral PFU between the 
start and the end of the passage series, with an average of 3.63x106 PFU/ml in passage one 
and 1.95x107 PFU/ml in passage four. The estimated PFU of each virus passage can be found 
in Supplementary table 5.1.  
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Table 5.3. Total time to CPE. The time (hours) to total CPE for each sample set for each of the 
passages. Only two passages were performed for Field sample 3157 due to limited serum 
availability.  
    Passage 
    P1 P2 P3 P4 
Fi
el
d
  3159 23 19 24 16 
3157 16 15   
3817 25 23 21 23 
C
h
al
le
n
ge
d
 
4942 44 25 23 20 
4926 32 21 22 23 
4914 24 25 20 23 
C
o
n
tr
o
l 4942C 14 14 13 12 
4926C 14 14 14 10 
4914C 14 15 15 14 
 
5.4.2. Pre-sequencing processing of viral RNA 
5.4.2.1. Viral RNA quantification and PCR amplification  
Following total RNA extraction, an average of 1.48x108 viral RNA copies/µl obtained from RT-
qPCR quantification for all samples. Quantification ranged from 7.09x107 viral RNA copies/µl 
(Challenged-4942-P2) and 2.75x108 viral RNA copies/µl (Control-4942C-P1)) (Table 5.4). 
Based on the optimisation of the PCR cycle number (as described in section 2.4.4), all samples 
were expected to require a minimum of 26 amplification cycles (as their corresponding inputs 
were diluted to 106 viral RNA copies/µl). However, only PCR replicates from three sample 
sets produced enough amplicon material for sequencing using 26 cycles. Three more datasets 
required a total of 32 amplification cycles, with another three datasets requiring a total of 36 
cycles to reach the DNA threshold required for the Nextera XT kit (Table 5.4). Control-4942C-
P3 and P4 did produce enough amplicon for sequencing using 26 cycles, however 36 cycles 
were applied so that they matched the required cycle amount for Control-4942C-P1 and P2. 
(Table 5.4). The three independently processed starting viruses were found to require a total 
of 26, 32 and 36 cycles respectively.  
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All samples were run on an agarose gel to confirm the amplicon size product prior to 
sequencing, with a single band approximately 3kb in length being visible (an example can be 
found on Figure 5.4).  
 
Figure 5.4 PCR amplification gel of in vitro products. PCR amplification products of the viral 
passage series with Field-3817. All other samples amplified produced similar 3kb bands.  
The 1kb hyperladder is shown in the first column (L), alongside a 3kb positive control (M) 
which was amplified using the universal FMDV capsid PCR reaction on the plasmid pT7S3 
(section 2.3.4).  
P1-4: Passages one to four 
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Table 5.4. RT-qPCR and PCR data. The FMDV RT-qPCR quantification and PCR results for all 
samples processed for Illumina sequencing (Nextera XT threshold for sequencing is 0.2 
ng/µl). 
* DNA ng/µl 
+ FMDV genome copies  
     RT-qPCR HTS PCR amplification   
  Sample Passage +Copies/µl Expected  Required Qubit* 
Start1 
Start2 
Start3 
 
N/A 
1.01x108 
1.51x108 
2.30x108 
26 
26 0.42 
32 0.71 
36 2.02 
Fi
el
d
 s
e
ru
m
 
3159 
1 1.04x108 26 36 2.19 
2 1.20x108 26 36 1.51 
3 2.55x108 26 36 0.75 
4 1.07x108 26 36 1.50 
3157 
1 2.30x108 26 26 0.21 
2 8.81x107 26 26 0.66 
3817 
1 1.81x108 26 32 0.20 
2 1.81x108 26 32 0.19 
3 1.55x108 26 32 0.27 
4 1.24x108 26 32 0.39 
C
h
al
le
n
ge
 s
er
u
m
 
4942 
1 1.78x108 26 36 1.88 
2 7.09x107 26 36 2.54 
3 1.10x108 26 36 0.93 
4 1.28x107 26 36 2.94 
4926 
1 1.38x108 26 26 0.69 
2 8.08x107 26 26 0.31 
3 1.29x108 26 26 0.76 
4 9.17x107 26 26 0.27 
4914 
1 1.42x108 26 32 0.28 
2 2.00x108 26 32 0.61 
3 2.08x108 26 32 0.40 
4 1.27x108 26 32 0.49 
C
o
n
tr
o
l s
er
u
m
 
4942C 
1 2.74x108 26 36 0.87 
2 8.66x107 26 36 0.20 
3 1.48x108 26 36 32.03 
4 9.05x107 26 36 24.51 
4926C 
1 1.04x108 26 26 0.51 
2 2.46x108 26 26 1.54 
3 1.68x108 26 26 1.17 
4 2.41x108 26 26 1.27 
4914C 
1 1.30x108 26 32 0.36 
2 1.82x108 26 32 0.32 
3 1.96x108 26 32 0.35 
4 1.65x108 26 32 0.33 
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5.4.3. High-throughput sequencing 
5.4.3.2. Reference sequence generation 
The consensus sequence generated from the starting viruses was compared with the 
reference sequence generated in a previous study (section 4.4.3.1). A comparison between 
the two revealed a synonymous substitution present at VP237 (TCC (in vivo) > TCT (in vitro). 
Blastn analysis revealed that FMDV A SAU/1/2015 (GenBank Accession: KU127247) had the 
closest match to the generated reference sequence with a percentage identity of 99.16% 
across the sequenced amplicon of IRN/22/2015.  
5.4.3.3. Read analysis and alignment   
Technical replicate two for Field-3817-P2 was found to produce 2.31x103 HTS reads, of which 
only 3.45% aligned to the reference genome, resulting in an average coverage of 2.64 
(supplementary table 5.4) across the amplicon. As a result, this replicate was removed and 
only replicate one was considered for downstream analysis.  
Following sequencing a mean of 3.72x105 reads were produced for all samples. Of this an 
average of 97.98% aligned to the reference sequence producing a mean coverage depth per 
position across the sequenced amplicon of 1.37x104. Further information regarding aligned 
read data for each sample can be found in supplementary tables 5.1 – 5.4 and coverage plots 
can be found on supplementary figures 5.4 - 5.7.  
Based on the PCD scores identified from Bland-Altman analysis of each sample 
(supplementary tables 5.2 – 5.4), a percentage frequency cut-off for variants analysis of 0.2% 
was applied for samples; SV1, all passages of Field-3157, Challenged-4926 and Control-4926C 
and Control-4942C-P3 and P4. For all other samples, a frequency cut-off of 0.5% was used for 
variant analysis except for Field-3817-P2, where a 0.8% frequency cut-off (Table 3.3) was 
applied as only one technical replicate was available.  
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5.4.3.4. Consensus changes 
A total of six unique consensus changes (five non-synonymous, one synonymous (Table 5.5)) 
were identified between the Field, Challenged and Control groups, the most common of 
which, found in all viral populations was identified within Lpro192. This non-synonymous 
change was found to reach consensus level in all sample sets with the exception of the three 
sequenced starting viruses. Another consensus change was found at Lpro29 (Field-3159), 
while three changes were found within the VP2 encoding region (VP237, VP266, VP280), all 
within Field samples. A further change was identified at VP1155 with Challenged-4942.  
Table 5.5. Accumulation of consensus-level changes within the samples. The percentage 
frequencies of consensus-level changes identified following each passage. 
 
  
 
 
 
        Passage 
Region 
Amplicon 
position 
Amino acid 
substitution 
Sample 1 2 3 4 
Leader29 227 Lys > Arg Field 3159 4.45% 22.84% 55.98% 74.39% 
Leader192 718 Trp > Arg 
Control 4942C 5.84% 28.46% 44.14% 53.30% 
Control 4926C 12.74% 29.63% 49.74% 58.64% 
Control 4914C 3.81% 22.40% 35.12% 31.14% 
Field 3159 12.06% 46.39% 80.50% 93.84% 
Field 3157 12.18% 52.28%   
Field 3817 3.50% 15.31% 52.20% 71.21% 
Challenged 4942 15.57% 47.17% 69.96% 91.74% 
Challenged 4926 25.36% 73.50% 91.96% 97.07% 
Challenged 4914 4.87% 38.63% 71.33% 93.92% 
VP237 1113 Ser Field 3159 10.93% 33.43% 62.52% 78.53% 
VP266 1200 Leu > Phe Field 3817 2.76% 11.35% 35.70% 60.95% 
VP280 1240 Lys > Glu Field 3159 2.84% 21.08% 54.08% 71.96% 
VP1155 2782 Ala > Thr Challenged 4942 10.49% 34.44% 52.37% 76.38% 
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5.4.3.5. Sub-consensus changes     
Identified low-frequency non-synonymous substitutions variants identified within the 
Challenged and Field group viral populations were assessed and compared to substitutions 
identified within the Starting virus (sequenced on the same MiSeq run (Table 5.2)) and the 
control samples. A heatmap displaying the shared non-synonymous substitutions identified 
within each sequence population can be found on Figure 5.5.  
Overall, virus populations belonging to the Challenged group were the most diverse with a 
total of 107 unique substitutions identified, of which 62 were non-synonymous in nature, 
with Challenged-4942 containing the highest (n=27). Of these non-synonymous 
substitutions, a mean of 17.40% identified within each virus passage series were also 
identified within other viral passages belonging to the Challenged group. In all three 
Challenged samples, all substitutions identified within passages two, three and four within 
an individual viral passage series, were found to be shared within all passage series and found 
only within the Lpro and VP4 encoding regions. Between the variants identified within each of 
the SV populations and the Control group samples, a mean of 30.02% and 31.47% of non-
synonymous substitutions respectively were also shared within the Challenged group shared. 
For the Field group, a total of 84 substitutions were identified, of which a total of 38 unique 
were non-synonymous in nature, with Field-3817 containing the highest (n=23). Of these 
non-synonymous substitutions, 30.43%, 72.22% and 62.5% identified in Field-3817, Field-
3157 and Field-3159 respectively were identified within other viral passages belonging to the 
Control group. The number of non-synonymous substitutions within each Field virus 
population shared between the SV and the Control group samples varied. A mean of 77.78% 
of non-synonymous substitutions identified within Field-3157 were also found within the SV 
and control groups, in contrast to 53.13% in Field-3159 and 26.09% in Field-3817. 
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Figure 5.5. Heatmap of shared non-synonymous substitutions between all sequenced 
samples. The number of shared non-synonymous substitutions between each sample set is 
indicated by the colours. Darker colours indicate more shared variants between sample sets.   
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5.4.3.6. Shannon’s entropy 
For each of the Starting viruses, a mean total entropy score of 2.60 was identified across the 
sequenced amplicon region. Two substitutions sites were found to have entropy scores 
representing greater than 10% of the overall diversity. The first being a non-synonymous 
substitution found at Lpro29, while the second was identified at VP237.  
Overall the highest level of diversity across the sequenced amplicon region occurred with the 
Control group, followed by the Field group and finally the Challenged group. For the Control 
group, the highest level of diversity measured across the sequenced amplicon was found in 
the Control-4914C sample set, with an overall accumulative entropy of 6.23 in passage four 
(Table 5.6). All three sample sets saw an increase in accumulative entropy levels as the 
passage series increased (except for passages three and four in the Control 4926 sample set) 
(Table 5.6). A total of six sites were identified to have diversity representing more than 10% 
of the total entropy across the sequenced region; three non-synonymous sites located within 
the Leader encoding region (Lpro192, 196 & 197) and three synonymous sites located at VP426, 
VP237 and 2C8. 
Within the Field group, the highest level of diversity measured across the sequenced 
amplicon was found within the Field-3159, with an overall accumulative entropy score of 
5.58 being generated in passage two (Table 5.6). After peak accumulative entropy was 
reached in Field-3817 and Field-3159, entropy across the amplicon began to decrease, which 
correlated with substitutions becoming fixed at consensus level, with three consensus 
changes being identified Field-3159-P3 and two in Field-3817-P2. Six sites (four non-
synonymous, two synonymous) were found to have entropy levels representing more than 
10% of the total diversity across the sequenced amplicon region. Five of these substitutions 
reached consensus level (Table 5.5), with the sixth site being a synonymous low-frequency 
change found at VP226 in Field-3159-P2-4.    
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For the Challenged group, the highest level of diversity measured across the sequenced 
amplicon region was found with the Challenged-4942, with an overall accumulative entropy 
score of 4.91 being generated in passage two.  As with the Field group, following peak 
accumulative entropy in all Challenged samples, entropy scores across the amplicon began 
to decrease (Table 5.6), which correlated with substitutions becoming fixed at consensus 
level (Table 5.5). A total of eight sites (four non-synonymous, four synonymous) in 
Challenged-4926 and four sites each (three non-synonymous, one synonymous) in 
Challenged-4926 and 4942 were found to have entropy levels representing more than 10% 
of the total diversity across the sequenced amplicon region. Three of these non-synonymous 
changes were found to cause consensus level changes (Table 5.5).  
Overall, greater diversity was measured within the capsid encoding regions for the Field and 
Challenged groups. The percentage of overall entropy within the capsid region for all samples 
within these groups (except for Field-3157) was found to increase following the first passage. 
Field-3817-P3 and Challenged-4942-P4 saw the highest percentage share of capsid diversity 
within their respective groups (65.38% and 73.48%, respectively). While within the capsid 
region, the opposite trend of observed, whereby capsid percentage diversity dropped 
following passage one. Control-4914C-P1 saw the highest capsid entropy percentage within 
the Control group, with diversity accounting for 49.65% 
Further information regarding entropy scores can be found on supplementary figures 5.8 – 
5.14 and Table 5.6.   
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Table 5.6. Maximum entropy scores across amplicon and percentage entropy within the 
capsid. Maximum entropy accumulation score obtained across the amplicon regions for the 
three sequenced starting viruses and all passages of the three serum groups. The percentage 
of overall entropy measured within the capsid encoding region is also given for each sample.   
      Passage 
    Starting One Two Three Four 
St
ar
ti
n
g 
One 
2.80         
54.46%         
Two 
2.66         
47.71%         
Three 
2.34         
50.73%         
Fi
el
d
  
3159 
  3.28 5.58 4.72 4.62 
  37.80% 46.61% 55.81% 62.88% 
3157 
  2.85 3.42   
  43.72% 38.22%     
3817 
  2.00 2.77 2.08 2.77 
  39.70% 57.51% 73.51% 65.38% 
C
h
al
le
n
ge
d
 4942 
  4.37 4.91 3.57 4.31 
  58.12% 64.42% 62.58% 73.48% 
4926 
  2.82 2.09 2.49 2.02 
  35.99% 37.18% 46.99% 46.78% 
4914 
  2.54 2.88 2.09 1.49 
  61.34% 39.06% 52.58% 63.15% 
C
o
n
tr
o
l 
4942C 
  3.00 3.06 4.89 5.08 
  47.17% 44.28% 32.68% 40.10% 
4926C 
  2.85 3.96 4.29 4.20 
  42.56% 35.18% 27.83% 27.90% 
4914C 
  3.42 4.09 5.46 6.23 
  49.65% 39.10% 34.76% 32.30% 
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5.4.3.7. Surface exposed non-synonymous substitutions  
In total, five surface bound substitutions were located within the SV populations, while nine 
were identified within the Control group, eight within the Field Group and 16 within the 
Challenged group. Figure 5.6 displays the predicted location of these substitutions, with one 
identified or adjacent to known serotype A epitope regions highlighted.  
All substitutions identified within the three SV populations were below 1.60% in frequency, 
with one variant at VP280 was located on a known epitope region. While for the Control 
group, the mean frequency of all substitutions was 0.93% in all three samples, with one 
substitution at VP1199 within Control-4914C-P1 was found adjacent to an epitope region.  
Within the Field group, two substitutions at VP266 and VP280 were identified to reach 
consensus level in Field-3817-P4 and Field-3159-P3/P4 respectively, with both of these 
identified at known epitope regions. The VP280 change was also located within Field-3159-
P2, however only as a minor variant (0.28%). Two other substitutions (VP1176, VP1197), located 
within Field-3817-P1 and Field-3817-P3, were also identified, with a mean frequency of 
0.88%.    
All substitutions predicted to be surface bound within the Challenged group were all unique 
to their respective virus populations. In total, four substitutions within all three viruses were 
found to be located at or adjacent known epitope regions, with one at VP1155 reaching 
consensus level by passage three in Challenged-4942. The two substitutions within 
Challenged-4926 (VP1174 and VP1207) and the one within Challenged-4914 (VP1196) existed as 
low frequency variants, with a mean frequency 0.92%.  
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Figure 5.6. Surface exposed non-synonymous substitutions at or adjacent to known epitope 
regions. A crystallised structure showing the predicted VP1 (blue), VP2 (sea-green), VP3 (pink-
tint) and VP4 (yellow). Non-synonymous substitutions identified within all sequenced groups 
(in all passages) of viruses are shown in red while previously identified epitope regions of 
FMDV type A are highlighted in grey.    
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5.4.4. Discussion  
This study was conducted in order to characterise immune escape diversity generated at a 
sub-consensus level FMDV populations in the face of a vaccine induced immune pressure. An 
FMDV isolate (A/ASIA/G-VII/IRN/22/2015) was passaged in cells in the presence of three 
different serum conditions, representing no immune pressure, a vaccination-induced 
immune response and an immune response after vaccination and challenge with the specific 
FMDV isolate used in this study. Three biological replicates (i.e. sera from different animals) 
were used for each of these in vitro culture experiments. 
No measurable delay was observed in the time to CPE when the virus was passaged in the 
presence of the control serum. While, all experiments preformed using the Field (except 
Field-3157) and Challenged serum saw a CPE delay greater than two hours. As expected, this 
delay in CPE was greater with the Challenged serum (Table 5.3), as antibodies generated after 
vaccination and subsequent challenge were specific to the FMDV isolate used in this study. 
In contrast, the serum used for the Field group was derived from cattle vaccinated with 
A/SAU/95 and A/IRN/05, which produced weakly cross-reactive antibodies against G-
VII/IRN/22/2015 (154,278). Samples; Field-3159, Challenged-4942 and Challenged-4926 all 
saw a decrease in the time to CPE between passages one and two (Table 5.3), indicative of 
viral evolution in the presence of an immune pressure. Despite having a high VNT titres 
measured against the A/SAU/95 vaccine component (Table 5.1) a possible reason why the 
CPE time failed to decrease further following passage two in samples; Field-3817 and 
Challenged-4914, could be that antibodies levels weren’t high enough to induce further viral 
evolution.   
Another possible reason of why the time to CPE didn’t decrease for some sample sets could 
be due to constraints arising from the transmission bottleneck between each passage. It 
might be expected that viruses exposed to a higher concentration of antibody could generate 
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higher frequency variants, which after the virus population has been diluted to a MOI of 0.01, 
would be carried over in the inoculum for the next passage. However, FMD viruses exposed 
to lower FMDV-specific antibody concentrations might be expected to generate immune 
escape substitutions at a lower frequency which could be lost when the virus is diluted to a 
MOI of 0.01. Evidence in the data for this comes from samples; Field-3817, Field-3159 and 
Challenged 4942 which developed surface exposed high frequency substitutions at VP266, 
VP280 and VP1155 respectively in the initial passage, that were carried over to the second 
passage.  
This study used a low MOI since high MOIs within a passage series have been shown to lead 
to the dominance of encapsulated defective RNA genomes (296). As discussed above, a 
consequence of using a low viral MOI of 0.01 is that it may be more difficult for immune 
escape sequence variants to become established in the viral population (especially when the 
antibody concentrations are low (Figure 5.7). Previous studies have demonstrated that the 
use of larger MOI concentrations leads to RNA virus population between passages having 
higher levels of population complexity (297–300). Future studies investigating the impact of 
an higher MOI could make use of Droplet digital PCR in order to quantify the number of 
encapsulated defective RNA genomes (301). 
A principle aim of this study was to investigate sequence evolution of the viral capsid, 
however the targeted amplicon used in the NGS analysis also contained sequences that 
encoded for Lpro192. This substitution was identified in all datasets and was found to increase 
in frequency over each passage until the point it reached consensus-level (Table 5.5). The 
leader protein is recognised as having a role to supress the host innate intra-cellular antiviral 
responses (302,303), suggesting that the substitution identified may have the potential role 
in influencing the intracellular response to infection. This doesn’t immediately explain why 
this variant only exists at a mean frequency of 1.96% within all starting viruses sequenced, 
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which was generated after five neutral passages in LFBK-αVβ6 cells (Appendix A). A possible 
explanation for this is the addition of the sub-neutralising antibody serum during the main 
passage series. Cells were equilibrated in DMEM with 1% bovine serum so that they were 
‘starved’ to prevent cellular replication during infection, however increasing the serum 
concentrations in the experiment may have up-regulated cellular innate factors, which in 
turn could act as a pressure on the virus. Performing an RNAseq experiment on the LFBK-
αVβ6 could be performed to assess which pathways associated with the cellular innate 
immunity are upregulated and downregulated under different serum conditions.  
Evidence to suggest that the immune pressure from the serum is acting on the capsid 
encoding region can be found by investigating entropy levels. The percentage proportion of 
entropy identified for the first passage within the capsid encoding region was found to be at 
similar levels in all viral populations from the Control, Field and Challenged groups. Over each 
passage series, the percentage proportion of entropy within the capsid encoding region was 
found to increase for viral populations in the Field (except for Field-3157) and the Challenged 
groups, while it was found to decrease within the Control group (Table 5.6).     
Three surface exposed consensus-level non-synonymous substitutions accumulated with 
samples Challenged-4942 (VP1155), Field-3917 (VP266) and Field-3159 (VP280), which were not 
found at consensus-level in the Control Serum group. A cross literature search revealed the 
VP1155 consensus change to be adjacent to substitutions identified in antigenic site one 
(VP1138-154) found in FMD viruses from the A/ASIA/G-VII strain recovered from vaccinated 
cattle in Saudi Arabia (276), where vaccination was heavily practiced (154). As for the VP266 
substitution change found with Field-3917, a previous study (304) identified VP264 (which is 
in close proximity to VP266) to be an antigenic variable site within serotype A FMD viruses 
derived from the Middle-East. While the substitution identified at VP280, also identified as a 
low-frequency variant in Field-3157 was previously characterised as an epitope region with 
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FMDV serotype A10 viruses (162), while nearby antigenic sites have been confirmed at VP279 
in A5 viruses (285) and VP282 in A22 viruses (39). A more recent study (288) identified an 
adjacent amino acid substitution on the capsid surface (VP278) as a predicted epitope site. 
Further evidence to suggest that these substitutions could be due to selective pressure is the 
fact the changes either don’t appear or are present a very low frequencies in the Control 
group samples. Only VP280 was identified in Control-4942C-P4 at a frequency of 0.37% and 
could had been present there due to random chance.  
A reason why three unique potential immune escape variants were identified in three 
separate samples could be explained by non-deterministic evolution within FMDV, with virus 
swarms generating multiple surface exposed non-synonymous substitutions, allowing for 
multiple options of immune escape. Evidence for this comes from the fact that not a single 
variant from any of the three Challenged samples were found to be shared with one another. 
Investigating the low-frequency substitutions further revealed that the samples with the 
strongest immune pressure acting on them (Challenged-4942 and Field-3817 (measured by 
the time delay in CPE (Table 5.3))), had the lowest number of surface exposed sub-consensus 
variants. This could be explained by the rapid generation of the immune escape variant, 
which negates the need for further viral mutations. This indicates that diversity generated by 
the initial rounds of viral replication in the first passage was missed when the virus was 
sequenced at the end of a passage, and viral sample sequenced had already selected the 
immune escape variant. Future studies could harvest virus after individual rounds of 
replication during the first passage, however a challenge with this would be to obtain enough 
viral RNA for sequencing. The same effect can be seen in the samples which were exposed to 
the weakest immune pressure (Challenged-4914 and Field-3157). Here, the pressure acting 
on the viral populations may not appear strong enough to generate higher frequency 
immune escape and these would be removed as the virus is diluted to a MOI of 0.01 following 
each passage. 
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Evidence of low frequency surface exposed non-synonymous substitutions associated with 
immune escape can be found on the passage series of Challenged-4914, Challenged-4926 
and Field-3157. No consensus level substitutions were identified within these samples, 
possibly due to low levels of antibody pressure acting on the viral populations (as discussed 
above). However, substitutions located at or adjacent to known epitope regions were 
identified at frequencies below 1.60% (Figure 5.6). These substitutions could had been 
generated through the immune pressure, however would had been removed from swarm 
following dilution to an MOI of 0.01. Following dilution, the resulting viral population, 
without the presence of an immune escape, would had been exposed again to the antibody 
serum in the following passage. This can be seen more notably in the Challenged-4926 
passage series, in which a substitution at VP1174 first developed in passage two (frequency: 
0.46%), was removed in passage three and before appearing again in passage four 
(frequency: 0.97%) (Figure 5.6).    
This study has highlighted the benefits of using an in vitro model to identify the generation 
of immune escape variants from low-frequency to consensus-level, under different serum 
conditions through a passage series. In total two potential immune escape variants were 
identified within the Field group within the VP2 encoding region and one within the 
Challenged group within the VP1 encoding region. The fact that multiple potential immune 
escape substitutions which were unique to individual viral populations leads to one of two 
conclusions; either FMD virus immune escape evolution is non-deterministic in nature or 
differences in the spectrum of antibodies produced by individual hosts leads to the unique 
development of immune escape substitutions.  
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Figure 5.7. FMDV immune escape evolution under higher and lower amount of sub-
neutralising antibodies. For higher amounts of neutralising serum, more virus particles are 
neutralised, however as the selective pressure is stronger, higher frequency immune escape 
variants are produced. These substitutions are more likely to be present in the viral swarm 
following dilution to an MOI of 0.01. The opposite is predicted when the viral swarm is 
exposed to lower amounts of neutralising serum, which results in the removal of any 
generated immune escape variants following dilution of the virus population.  
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Chapter 6  
Discussion  
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6.1. Overview of thesis  
RNA viruses such as FMDV exist within a single replication site as a heterogeneous swarm, 
consisting of similar but none identical genomes. This genetic diversity is caused by factors 
including (but not exclusive to); the large viral population size, the high replication rate and 
the poor proof reading ability of the viral RdRP. Such diversity allow FMDV populations to 
rapidly adapt to selection pressures, for example from an immune response and can be 
characterised by the use of sequencing.  
HTS technologies allow for the identification of both common and rare variants, with 
important implications for both human and animal health. Nevertheless, challenges exist to 
distinguish true biological variation from processed-introduced error. Moreover, further bias 
can be introduced by the computational analysis steps, for example, multiple different short-
read aligners are available, with each claiming to offer the highest level of accuracy. In order 
to establish an accurate HTS pipeline for variant identification, both the laboratory and 
bioinformatics approaches were systematically evaluated by the use of DNA and RNA 
‘artificial swarms’ created by introducing substitutions at known positions and frequencies 
into template nucleic acid. 
Chapter 2 described the use of these swarms to optimise the laboratory pipeline. Firstly, the 
RT step was optimised, which resulted in the selection of the high-fidelity RNA polymerase 
Transcriptor HiFi.  Following this, each of the swarms were amplified using Platinum Taq 
SuperFi polymerase to determine the number of amplification cycles required for each 
swarm dilution. Following this, swarms were sequenced on a MiSeq in quadruplicates. 
Chapter 3 describes the use of in-house Bash and R scripts to determine the effects of 
abundance and type of starting input material, number of technical replicates, read length 
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and quality, choice of short-read aligner, and percentage frequency thresholds on the ability 
to accurately call variants.  
Results identified that GEM3 was the most accurate aligner for these datasets, while the 
abundance and type of input nucleic acid had the greatest impact on the accuracy of variant 
calling as measured by Matthews correlation coefficient (MCC). Variants within all DNA 
populations and high RNA inputs (107 copies) could be called at a frequency of 0.2% (with a 
MCC of 1 and 0.816 respectively), while reduced RNA inputs (105 copies) required more 
technical replicates to maintain accuracy. Lower RNA inputs (102 copies) were found to 
produce non-reproducible consensus-level errors, while the use of more than one technical 
replicate produced results that were considered random (MCC ~0). Analysis also identified 
T>C patterns of error within high RNA datasets (107 copies) which can be excluded to increase 
variant calling accuracy.  
This optimised HTS methodology was applied to epithelium samples derived from vaccinated 
cattle infected with an isolate from A/ASIAG-VII lineage (chapter 4). The hexavalent vaccine 
employed in this PPG in vivo study only protected 59% of the 16 cattle and contained FMDV 
A/SAU.95 and A/IRN/05 components. Sequencing analysis revealed that no non-synonymous 
changes were present at consensus level and all substitutions identified were unique to their 
respected replication site indicating that FMDV diversity is random in nature. In total, three 
surface exposed low-frequency non-synonymous substitutions were identified, which 
correlated to previously known epitope regions. A possible reason for why these potential 
immune escape substitutions only reached 1.74% could be the fact that vaccinated animals 
were culled following generalisation of FMD to generate lesion only on a single foot. This and 
the lack of a transmission chain would limit the rounds of viral replication in the presence of 
FMDV-specific antibodies.  
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To overcome the issues of an in vivo study, an in vitro study was setup (chapter 5) whereby 
viral replication and antibody dilutions could be more easily modelled under more stringently 
controlled conditions. Here the same FMDV isolate from the A/ASIA/G-VII lineage was 
passaged four times in LFBK-αVβ6 cells in the presence of sub-neutralising levels of antibody 
serum. All serum was derived from cattle vaccinated with the same hexavalent vaccine 
comprising of the FMDV A/SAU/95 and A/IRN/2005 components. In total three different 
experiment conditions were applied, representing a vaccine only response, and vaccine and 
challenge response and a control condition with no specific FMDV antibodies.  
These experiments identified three consensus level surface exposed non-synonymous 
substitutions at VP1155, VP266 and VP280 which were associated with previously identified 
epitope regions. Further analysis also indicated that the virus bottleneck between each cell 
passage also played a role, with evidence that lower frequency variants were diluted out of 
the viral population due to the low MOI (0.01) used between each passage.  
6.2. Laboratory methodology issues and improvements 
It became apparent that the correlation between starting viral input and the number of PCR 
cycles wasn’t accurate for some viral samples and further amplification was required. A 
possible cause was the poor sample quality resulting in the presence of fragmented RNA 
genomes (e.g. possibly due to necrotic tissue at lesion sites). In future studies, the 2100 
Bioanalyzer System (Agilent) could be used on extracted RNA samples to obtain an RNA 
integrity number (RIN) which could be used to evaluate and remove low quality samples. 
Further modifications could also be made to the RT step, whereby instead of using REV6 
primer (which binds at the PolyA tail of FMDV), a GSP could be designed to bind closer to the 
capsid encoding region. This could result in more focused cDNA products, containing the 
capsid encoding region, being amplified from fragmented RNA molecules.  
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Studies could also be employed which aim at improving the quantification method of cDNA 
molecules following RT. The Callahan assay (241) used in this thesis quantifies an 
approximate 100bp region of the 3D polymerase, however the unsuitability of this became 
apparent, with some genomes requiring further amplification cycles to produce enough 
material for sequencing. The use of a non-specific intercalating dye, such as SYBR green 
(ThermosFisher Scientific) and EvaGreen® (Biotium) could be used to quantify larger genomic 
products, however a previous studies have shown that there is an accuracy cost in their use 
(215).  
To overcome this and to assess the quality of a sequenced sample, computational analysis 
was performed, resulting in the generation of PCD scores (sections 3.3.4 and 3.4.7). PCD 
scores based on the artificial swarms allowed for biological samples to be assigned a 
percentage frequency cut-off for variant analysis, instead of relying on input RNA and PCR 
amplification data. However, gaps in the PCD score ranges were observed between the RNA 
High and Medium datasets and RNA Medium and Low datasets (Figure 3.9). Samples with 
PCD scores in-between the swarm profiles would be assigned a percentage frequency cut-off 
based on its nearest neighbour profile. To overcome this, further dilution points of the RNA 
swarm (i.e. 106, 104, 103 total RNA copies) could be sequenced. This would allow for a 
percentage frequency cut-off to be defined for these dilution points (based on MuMCC 
analysis) and PCD scores to be confirmed allowing biological data to be assigned a percentage 
frequency cut-off with higher accuracy.  
While the HTS pipeline was used to assess the impacts of the protocols used for sequencing 
the RNA (RT, PCR and sequencing) and DNA (PCR and sequencing) swarms, the impact of the 
MiSeq alone remains unknown. Sequencing of the DNA swarms, without PCR, would had 
allowed for a more precise estimation of this and at what stage of the overall pipeline that 
the most error was introduced. Furthermore, this information analysis of the swarm 
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structure prior to the creation of the main DNA and RNA swarms would had allowed for the 
investigation of any biases within the in vitro transcription and PCR processes.  
The use of HTS analysis to identify biological variant has been of major importance to this 
thesis, with only 2.5% and 3.5% of the total variation identified within the in vivo and in vitro 
virus populations respectively being above consensus level (Figure 6.1). Calling variants 
below a 0.5% frequency cut-off (to 0.2%) allowed for an additional 20% and 28% substitutions 
being identified in the in vivo and in vitro studies respectively, demonstrating the importance 
of lower frequency cut-offs. Examining substitutions below the established frequency cut-off 
becomes unreliable due to the presence of processed introduced errors masking true 
biological variation. The HTS pipeline established in this thesis demonstrates that higher 
amounts of starting RNA results in a lower frequency cut-off which can be applied for variant 
analysis. Higher concentrations of the RNA artificial swarm (i.e. 108 total RNA copies and 
above) could be sequenced to establish if variants could be accurately be examined below 
0.2%. However the practically of this maybe limited due to the difficulty of extracting enough 
high quality FMDV genome in some sample types. Alternatively, further computational 
techniques could be applied to the generated swarm datasets. While the model presented in 
this thesis identified C>T error base changes in the RNA High datasets, it was advised that 
this error be removed, however a consequence of this is that true biological variance in turn 
could be removed. A computational model could be applied to this error pattern (and any 
other errors patterns currently not identified) to artificially reduce the base change. 
Currently, there is a threshold horizon (<0.2%) beyond which viral variants cannot be 
characterised with current technologies. As the fidelity of enzymes improve and more 
accurate sequencing platforms develop, it may be possible to lower the frequency threshold 
further.     
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In future experiments, the use of both positive and negative controls for each sequencing 
run can be used for characterising error and bias. With the positive control being used to gain 
an understanding of biases between each sequencing run and the negative control being 
used to assess cross-contamination between samples on the same run.   
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Figure 6.1. The frequency of substitutions identified in all samples from the in vivo and in 
vitro viral populations and hypothetical variants below the frequency cut-off. The total 
number of variants is plot against their frequency for every sample in the in vivo samples (red) 
and in vitro samples (blue). The vertical dotted lines indicate the cut-off for consensus-level 
substitutions (50%) as well as the 0.5% and 0.2% frequency cut-offs applied in this thesis for 
variant analysis. The black dots represent hypothetical substitutions which could exist in both 
datasets but can’t be called due to the presence of processed-introduced errors.      
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6.3. Comparison between in vivo and in vitro datasets 
A principle objective for this thesis was to characterise substitutions associated with immune 
escape within both in vitro and in vivo models. As described in chapters 4 and 5, this has been 
achieved, with potential immune escape variants identified both within the in vivo and in 
vitro studies. Both studies highlight that immune pressure influences evolution by causing 
mutations in the FMDV capsid encoding region.  
The next logical step would be to compare the results of each study to identify a correlation 
between substitutions and determine if immune escape evolution in FMDV is deterministic 
or stochastic in nature. None of the potential immune escape variants, or indeed any other 
of the capsid surface exposed non-synonymous substitutions identified in either study were 
found in the other. However, investigating other low-frequency non-surface exposed non-
synonymous substitutions identified five non-synonymous variants which were present 
within both studies; two within the Leader encoding region, and one each in VP4, VP3 and 
VP1 (Table 6.1). Four of these variants however were found in at least one control sample 
and therefore considered not to be associated with immune escape. The final non-
synonymous variant was identified in samples Challenged-4942-P2 (in vitro) and 4917 BRF (in 
vivo) at VP3209 (Table 6.1) (samples subjected to lower immune pressure, based on CPE 
profiles. This variant however probably wasn’t associated with immune escape due its 
predicted buried location within the capsid structure.  
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Table 6.1.Shared non-synonymous substitutions between the in vitro and in vivo studies. 
The percentage frequency of each mutation at an amino acid position is given for the sample. 
The value given for a variant for the in vitro study is the maximum percentage obtained in the 
passage series (P1-P4).  
  Sample Lpro168 Lpro195 VP479 VP3209 VP134 
in
 v
it
ro
 
Challenged-4914         3.42% (P3) 
Challenged-4942       0.64% (P2)   
Control-4914C 0.85% (P4)   0.67% (P2)     
Control-4926C   0.38% (P3)       
in
 v
iv
o
 
3920 FRF     0.60%     
4917 BRF       0.43%   
Control-4929 BRF   2.31%     2.94% 
Control 4919 FLF 0.69%         
 
The lack of shared immune escape substitutions between the two studies could be due to a 
number of reasons, with the first being the differences between the in vivo and in vitro 
models. These differences, for example cell-to-cell transmission and in the case of an in vivo 
model, dissemination throughout the host could itself act as an evolutionary bottleneck, 
leading to differing amounts of virus populations being transmitted, which in turn could 
affect immune escape evolution. Although, this bottleneck was controlled in the in vitro study 
by using a viral MOI of 0.01, it is unknown what the equivalent is in an in vivo model and how 
much viral diversity is being disseminated throughout the host. Previous studies investigating 
intra-host diversity in unvaccinated cattle have identified differences between the genetic 
distance of FMDV populations between replication sites (181,182). It seems reasonable to 
suggest immune escape variation occurs in a similar way, in that different immune escape 
substitutions could evolve in one replication site and not another, with potential evidence 
coming from the vaccinated animal 4921 (used in the in vivo study (chapter 4)). Virus was 
found to generalise to two feet, however sequencing analysis of each identified a potential 
immune escape substitution in the FRF but not the BLF.  
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Evidence from both studies point to FMDV immune escape evolution being stochastic in 
nature, as all variants identified within the in vivo were not shared with any other sample and 
all potential immune escape associated substitutions were unique to individual viral 
populations in both studies. Genetic diversity within influenza virus, which is subjected to 
seasonal vaccine-driven selection (305), has been determined to be dominated by 
stochasticity at an intra-host scale and by positive selection on a global scale (306). This 
evolution could be occurring with FMDV, whereby different immune escape variants are 
generated within different hosts, however at a herd/region level the substitution which 
produces the fittest viral swarm survives overall (Figure 6.2). An immune escape variant 
identified in one passage series/host could be out competed by another immune escape 
variant deriving from a different viral population. This could explain why none of the immune 
escape variants identified in both in vivo and in vitro studies match any identified from 
vaccinated cattle infected with FMDV G-VII in the field (276).  
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Figure 6.2. Potential stochastic and positive immune escape evolution at different infection 
scales. FMDV populations (blue dots) subjected to immune pressure may develop different 
solutions to immune escape (coloured dots) between different replication sites and hosts. 
However, each of these generated immune escape viruses would be subjected to competition 
from other immune escape viruses. The ‘fittest’ virus would outcompete all other immune 
escape viruses and transmit from cell-to-cell, host-to-host and farm-to-farm.    
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6.4. Future work  
The main results discussed in this thesis were generated on an Illumina MiSeq platform. As 
described, future work could entail improving on the HTS pipeline to improve the accuracy 
of variant calling. Moreover, each of the swarm populations could be sequenced and 
analysed again on a second MiSeq run or another HTS platform (e.g. HiSeq) in order to assess 
the bias between multiple sequencing runs and platforms. Analysis of the effect of strand 
bias, where variants inferred from both the positive and negative read strands are different 
(307), was not undertaken during this thesis. Further analysis of the artificial swarm datasets 
could be completed to assess the effect of strand bias on the generation of errors. However, 
as pre-existing filters focus on homopolymer regions (308), the effect of strand bias could be 
limited, as variants (above the percentage frequency cut-off) at the start of homopolymer 
regions are flagged as potential errors in the analysis pipeline (see T>C base error, section 
3.4.6).  
A capsid based PCR was utilised for this study as it was hypothesised that immune escape 
substitutions would occur on the capsid encoding region. While potential immune escape 
substitutions were identified within the capsid encoding region, most of the 5’UTR and non-
structural genome regions were not sequenced, which could contain important associated 
substitutions. A PCR assay could be designed to include the entire viral polyprotein to obtain 
more sequencing resolution.  Further improvements to the pipeline could be made to the 
quantification of both the artificial swarm populations. The Qubit DNA and RNA HS assays 
were selected to quantify the DNA and RNA swarms respectively, as the intercalating dyes 
are specific to the target of interests. Studies investigating the accuracy of quantification 
methods have determined that qPCR techniques are more accurate than using the Qubit 
(309,310). Future studies could utilise qPCR/RT-qPCR to quantify plasmids and in vitro 
transcribed RNA, however at the expense of increase cost and time efficiency.   
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Although substitutions identified in these studies were located at previously known epitope 
regions, it is important to recognise that the work undertaken in this thesis does not 
confirmed whether they solely influence the immune escape phenotype. Recombinant 
viruses expressing the surface bound non-synonymous changes could be produced and 
exposed to the sera used in the in vivo and in vitro studies. Resistance of these viruses to 
neutralisation by sera would confirm these specific mutations as response for the immune 
escape phenotype. For example, a previous study used recombinant infectious clones of 
FMDV serotype A to characterise novel epitope regions (288).  
HTS identified multiple potential immune escape substitutions which weren’t shared 
between sample sets. To determine if FMDV immune escape evolution is deterministic or 
stochastic in nature, the in vitro study could be repeated with multiple technical replicates of 
passages. If FMDV evolution was truly stochastic, then different mutations would appear 
within each technical replicate. Moreover, viruses could also be passaged in the presence of 
sub-neutralising levels of antibodies at higher or lower MOIs to determine what effect the 
transmission bottleneck has on immune escape evolution. Viruses which developed immune 
escape substitutions could also be exposed with higher concentrations of sub-neutralising 
levels of antibodies to determine what further mutations along the capsid encoding region 
could occur.  
In order to determine a generated immune escape substitution is specific to a host serum 
immune pressure, viral swarms expressing the immune escape could be exposed to 
vaccinated sera derived from the same study, but from a different animal. (Figure 6.3). This 
approach could be used to determine if an immune escape substitution generated from 
antibody serum from one animal would allow for evasion of immune pressure from serum 
from another animal. If the differing spectrums from a host antibody response dose influence 
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immune escape variation, then either the viral populations won’t evade the secondary serum 
pressure or additional immune escape substitutions will develop in the viral population.  
 
Figure 6.3. An experiment outline of exposing a viral population with an immune escape 
variant generated from one sera and exposing it to another. Immune escape populations 
generated from serum A or B would be exposed to serum generated from the same 
vaccination response but from another animal.  
 
A limitation of using the Illumina MiSeq platform is the short-read length, which makes 
linkage between genomes difficult. The use of long-read sequencers such as those offered by 
Pacific Biosciences and Oxford Nanopore Technologies (ONT) potentially would allow 
genome linkage and would enable the investigation of the interaction between dominant 
and minor substitutions (i.e. does a viral genome within immune escape variation (which is 
dominant in the swarm) require other mutations (which are minor in the swarm) to fully 
escape an immune response?). Moreover, ONT offers direct RNA sequencing which would 
negate the RT and PCR steps limiting the biases introduced here. However, such technologies 
will require further improvement, namely; to reduce the required input and the sequencing 
error rate. For this later point, the artificial swarm model could be employed to develop an 
acute long-read sequencing protocol.       
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6.5. Concluding remarks 
This study describes the development of a HTS pipeline would could be applied to any DNA 
and RNA genome in order to accurately determine low-frequency variants. This methodology 
was applied to in vivo and in vitro generated samples to identify substitutions associated with 
immune escape. These studies demonstrate that HTS can be used to characterise the 
development of immune escape substitutions and has shed light on the evolutionary nature 
of FMDV.  
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Appendix A  
FMDV A/G-VII/IRN/22/2015 adaptation to LFBK-αVβ6 
cell 
A.1.1. Background 
In order to avoid cell culture adaptation based substitutions occurring in the in vitro study as 
described in chapter 5, FMDV A/G-VII/IRN/22/2015 (the challenge virus used in the in vivo 
study (chapter 4) was passaged five times in LFBK-αVβ6 (total of 106 cells). For this passage 
series, two different viral MOIs were used; MOI:0.1 (105 viral PFU) and 0.01 (104 viral PFU), 
in order to determine which concentration of virus was suitable for use. Following five 
passages, the virus concentration which showed the most signs of being fully adapted to the 
LFBK-αVβ6 (i.e. lowest time to CPE, highest viral PFU) was selected for use in the serum in 
vitro study (Chapter 5).  
A.1.2. Methodology  
LFBK-αVβ6 were maintained and seeded onto Falcon 6-well clear flat bottom TC-treated 
multiwall cell culture plates (Scientific Laboratory Supplies) as stated in section 5.3.1. FMDV 
A/G-VII/IRN/22/2015 PFU was quantified via plaque assay as described in section 5.3.2) to 
two MOI concentrations of 0.1 and 0.01. Each viral MOI population was passaged 
independently five times. Following each passage, virus was harvested (as described in 
section 5.3.3) and virus PFU quantified before being diluted to their respective MOI 
concentrations. During infection, cells were maintained in DMEM supplemented with 1% 
bovine serum.  
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Following infection, cells were incubated at plus 37°C in a 5% CO2 incubator and visually 
checked every 6 to 12 hours to monitor signs of CPE.  
A.1.3. Results 
The PFU of the FMDV A/G-VII/IRN/22/2015 in vivo challenge virus was found to be 7x106 
PFU/ml, which was diluted to 1x105 PFU/ml and 1x104 PFU/ml to represent the two MOI 
populations (0.1 and 0.01 respectively) to be tested. For both MOI populations, time to CPE 
decreased for each passage while the MOI concentration was found to increase (Table A.1.1).  
Table A.1.1. CPE time and estimated PFU for each viral MOI population. Each viral MOI 
population (MOI: 0.1 and 0.01) was passaged five times on LFBK-αVβ6.  
*Estimated 
 
    MOI: 0.1 MOI: 0.01 
    Hours to CPE *PFU/ml Hours to CPE *PFU/ml 
P
as
sa
ge
 s
e
ri
es
 
1 35 4.5x106 51 5.0x106 
2 24 5.5x106 31 8.5x106 
3 20 4.0x106 20 2.0x106 
4 14 2.0x107 15 4.3x107 
5 14 2.0x107 15 3.0x107 
 
 
A.1.4. Discussion 
While both virus populations displayed similar PFU and time to CPE results, a starting MOI of 
0.01 was chosen for the serum in vitro study. This was due to concerns about serum 
availability (reduced virus MOI would require less serum) and the fact that the MOI: 0.01 
population would of had more rounds of replication to reach the same amount as the MOI: 
0.1 virus, which hypothetically would make this population more adapted to the LFBK-αVβ6 
cells. 
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Appendix B  
Sub-neutralising serum optimisation  
A.2.1. Background 
Following adaptation to the LFBK-αVβ6 cell line and selection of the MOI concentration, the 
dilution factor for each of the serums used in the Challenged and Field groups needed to be 
determined. The serum dilution factor needed to be strong enough to drive immune escape 
and not neutralise the entire viral population. To test this FMDV A/G-VII/IRN/22/2015 
populations were independently exposed to a 10-fold dilution series of each serum.  
A.2.2. Methodology 
To determine a suitable sub-neutralisation point for each of the serums, a 10-fold log dilution 
ranging from; 1 in 10 dilution to 1 in 1000 for the Field group (3917, 3159, 3157) and 1 in 50 
dilution to 1 in 5000 for the Challenged group (4942, 4926, 4914) were setup. A higher serum 
dilution was tested for the Challenged group, as preliminary infection experiments using a 
1/10 concentration of all serum in the Challenged group was found to completely neutralise 
the virus (Table 5.1).  
Independent infections of LFBK-αVβ6 cells (106 total) using a viral MOI of 0.01 was performed 
in the presence of each dilution of serum (as described in section 5.3.1.2). Plates were 
incubated at plus 37°C in a 5% CO2 incubator with CPE being monitored using the IncuCyte® 
Live-cell analysis system (Sartorius, Michigan, USA) (as described in section 5.3.1.2).  
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A.2.3. Results 
For the Field group, the 1 in 10 dilution of serum was found to delay CPE when compared 
with a control, with Field-3817 serum having the greatest effect on CPE delay, with a total 
time to CPE of 25 hours. The 1 in 100 dilution of each of the serum was found to delay CPE 
by between two and three hours when compared with the control, with the 1 in 1000 dilution 
had no measurable effect. The times to CPE for each dilution of the Field group serum 
samples can be found on Table A.2.1. 
Table A.2.1. CPE times for different sub-neutralising of the Field group serum samples. Each 
of the time points (in hours) is given for each of the serum dilutions as well as for a control 
passage (which contained no serum).  
    Serum dilution 
Samples   1/10 1/100 1/1000 
Control 15       
3817   25 17 14 
3159   24 18 14 
3157   17 16 14 
 
While for the Challenged group, all serum dilutions were found to have a measurable effect 
on the time to CPE, with the greatest effect being seen the 1 in 50 dilution of Chalenged-
4942, in which CPE occurred following 43 hours of incubation. The times to CPE for each 
dilution of the Challenged group serum samples can be found on Table A.2.2. 
Table A.2.2. CPE times for different sub-neutralising of the Challenged group serum 
samples. Each of the time points (in hours) is given for each of the serum dilutions as well as 
for a control passage (which contained no serum). 
 
    Serum dilution 
Samples   1/50 1/500 1/5000 
Control 14       
4942   43 24 17 
4926   35 21 17 
4914   27 20 15 
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A.2.4. Discussion 
The concentrations of serum which delayed CPE for the greatest amount of time) were 
selected. FMDV A/G-VII/IRN/22/2015 would be passaged four times in the presence of a 1/10 
dilution for each Field group serum and 1/50 dilution for each Challenged group serum to 
characterise the generation of immune escape variants (Chapter 5).  
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Supplementary tables   
Supplementary table 3.1. MuMCC distribution of different qScore parameters. The 
distribution of median micro-averaged MCC scores generated from testing different qScore 
parameters for each swarm type replicate combinations following alignment of reads using 
GEM3.  
Singlets 
  0 10 20 25 30 35 38 
R
N
A
 
H
ig
h
 
Minimum 0.010 0.010 0.022 0.025 0.041 0.048 0.053 
1st Quartile 0.054 0.054 0.084 0.151 0.229 0.252 0.201 
Median 0.096 0.096 0.115 0.205 0.360 0.434 0.375 
Mean 0.236 0.236 0.286 0.352 0.415 0.435 0.423 
3rd Quartile 0.439 0.439 0.538 0.577 0.577 0.577 0.642 
Maximum 0.642 0.642 0.707 0.707 0.756 0.756 0.855 
M
ed
iu
m
 
Minimum 0.007 0.007 0.012 0.015 0.027 0.021 0.029 
1st Quartile 0.021 0.021 0.022 0.047 0.083 0.098 0.093 
Median 0.034 0.034 0.051 0.084 0.101 0.103 0.102 
Mean 0.215 0.215 0.234 0.258 0.271 0.279 0.264 
3rd Quartile 0.408 0.408 0.512 0.538 0.538 0.538 0.512 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Lo
w
 
Minimum -0.005 -0.005 -0.004 0.003 0.008 0.011 0.004 
1st Quartile 0.003 0.003 0.004 0.015 0.037 0.069 0.047 
Median 0.014 0.014 0.016 0.036 0.082 0.108 0.108 
Mean 0.092 0.092 0.102 0.119 0.137 0.148 0.139 
3rd Quartile 0.209 0.209 0.250 0.250 0.250 0.250 0.250 
Maximum 0.250 0.250 0.250 0.250 0.250 0.250 0.250 
D
N
A
 
H
ig
h
 
Minimum 0.008 0.008 0.019 0.033 0.056 0.062 0.074 
1st Quartile 0.053 0.053 0.073 0.143 0.356 0.547 0.322 
Median 0.071 0.071 0.099 0.185 0.435 0.707 0.642 
Mean 0.258 0.258 0.311 0.393 0.510 0.600 0.533 
3rd Quartile 0.500 0.500 0.707 0.707 0.707 0.707 0.707 
Maximum 0.447 0.447 0.634 0.564 0.351 0.160 0.385 
Lo
w
 
Minimum 0.002 0.002 0.006 0.015 0.025 0.032 0.021 
1st Quartile 0.012 0.012 0.017 0.052 0.125 0.275 0.174 
Median 0.018 0.018 0.042 0.114 0.326 0.455 0.417 
Mean 0.209 0.209 0.271 0.339 0.415 0.471 0.438 
3rd Quartile 0.427 0.427 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
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Duplicates 
  0 10 20 25 30 35 38 
R
N
A
 
H
ig
h
 
Minimum 0.013 0.013 0.028 0.035 0.056 0.068 0.078 
1st Quartile 0.065 0.065 0.092 0.173 0.296 0.340 0.369 
Median 0.109 0.109 0.124 0.232 0.377 0.475 0.543 
Mean 0.265 0.265 0.303 0.371 0.437 0.467 0.504 
3rd Quartile 0.500 0.500 0.577 0.590 0.642 0.642 0.707 
Maximum 0.707 0.707 0.707 0.707 0.786 0.816 0.816 
M
ed
iu
m
 
Minimum 0.009 0.009 0.008 0.018 0.036 0.025 0.032 
1st Quartile 0.017 0.017 0.022 0.046 0.097 0.162 0.169 
Median 0.024 0.024 0.040 0.091 0.173 0.197 0.192 
Mean 0.254 0.254 0.286 0.322 0.357 0.378 0.380 
3rd Quartile 0.555 0.555 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Lo
w
 
Minimum -0.013 -0.013 -0.011 -0.010 -0.008 -0.002 -0.010 
1st Quartile -0.008 -0.008 -0.008 -0.005 -0.002 -0.002 -0.003 
Median -0.001 -0.001 -0.006 -0.003 -0.001 0.002 -0.002 
Mean -0.001 -0.001 -0.003 -0.002 0.000 0.005 -0.002 
3rd Quartile 0.006 0.006 0.000 -0.001 -0.001 0.010 -0.001 
Maximum 0.018 0.018 0.019 0.022 0.027 0.023 0.001 
D
N
A
 
H
ig
h
 
Minimum 0.011 0.011 0.023 0.042 0.077 0.094 0.137 
1st Quartile 0.057 0.057 0.083 0.153 0.398 0.577 0.577 
Median 0.076 0.076 0.101 0.195 0.494 0.707 0.707 
Mean 0.272 0.272 0.325 0.407 0.535 0.645 0.608 
3rd Quartile 0.538 0.538 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.711 1.000 0.933 0.854 
Lo
w
 
Minimum 0.001 0.001 0.004 0.012 0.030 0.036 0.038 
1st Quartile 0.011 0.011 0.015 0.036 0.121 0.408 0.370 
Median 0.019 0.019 0.031 0.088 0.288 0.408 0.408 
Mean 0.227 0.227 0.280 0.340 0.409 0.495 0.490 
3rd Quartile 0.500 0.500 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
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Triplicates 
  0 10 20 25 30 35 38 
R
N
A
 
H
ig
h
 
Minimum 0.015 0.015 0.030 0.039 0.063 0.078 0.085 
1st Quartile 0.070 0.070 0.090 0.169 0.299 0.347 0.468 
Median 0.114 0.114 0.133 0.252 0.412 0.500 0.577 
Mean 0.276 0.276 0.314 0.383 0.455 0.486 0.540 
3rd Quartile 0.500 0.500 0.577 0.618 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.816 0.816 0.894 
M
ed
iu
m
 
Minimum 0.003 0.003 0.008 0.010 0.033 0.027 0.049 
1st Quartile 0.018 0.018 0.021 0.046 0.136 0.273 0.288 
Median 0.027 0.027 0.046 0.109 0.246 0.333 0.333 
Mean 0.265 0.265 0.297 0.340 0.394 0.442 0.455 
3rd Quartile 0.610 0.610 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Lo
w
 
Minimum -0.016 -0.016 -0.012 -0.010 -0.006 -0.004 -0.007 
1st Quartile -0.009 -0.009 -0.008 -0.005 -0.002 -0.003 -0.002 
Median -0.001 -0.001 -0.005 -0.003 -0.001 -0.001 -0.001 
Mean -0.002 -0.002 -0.004 -0.003 0.000 0.000 -0.002 
3rd Quartile 0.005 0.005 -0.001 -0.002 -0.001 0.000 0.000 
Maximum 0.020 0.020 0.020 0.017 0.021 0.012 0.000 
D
N
A
 
H
ig
h
 
Minimum 0.011 0.011 0.025 0.047 0.091 0.119 0.211 
1st Quartile 0.060 0.060 0.086 0.155 0.408 0.577 0.577 
Median 0.079 0.079 0.103 0.205 0.530 0.707 0.707 
Mean 0.279 0.279 0.332 0.415 0.547 0.657 0.634 
3rd Quartile 0.577 0.577 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.756 1.000 0.913 0.897 
Lo
w
 
Minimum -0.002 -0.002 -0.001 0.008 0.027 0.050 0.042 
1st Quartile 0.011 0.011 0.016 0.040 0.139 0.408 0.408 
Median 0.021 0.021 0.033 0.095 0.333 0.408 0.408 
Mean 0.235 0.235 0.286 0.347 0.418 0.503 0.510 
3rd Quartile 0.538 0.538 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
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Quadruplicates 
  0 10 20 25 30 35 38 
R
N
A
 
H
ig
h
 
Minimum 0.017 0.017 0.031 0.044 0.071 0.089 0.105 
1st Quartile 0.072 0.072 0.093 0.174 0.308 0.347 0.480 
Median 0.119 0.119 0.141 0.262 0.454 0.529 0.577 
Mean 0.279 0.279 0.316 0.387 0.462 0.495 0.564 
3rd Quartile 0.500 0.500 0.577 0.632 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.816 0.816 0.894 
M
ed
iu
m
 
Minimum 0.005 0.005 0.009 0.012 0.041 0.023 0.067 
1st Quartile 0.019 0.019 0.023 0.051 0.165 0.408 0.408 
Median 0.029 0.029 0.051 0.121 0.288 0.408 0.408 
Mean 0.269 0.269 0.303 0.349 0.418 0.493 0.513 
3rd Quartile 0.610 0.610 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Lo
w
 
Minimum -0.015 -0.015 -0.012 -0.009 -0.006 -0.011 -0.005 
1st Quartile -0.009 -0.009 -0.008 -0.005 -0.002 -0.002 -0.001 
Median -0.001 -0.001 -0.005 -0.003 -0.001 -0.001 0.000 
Mean -0.001 -0.001 -0.004 -0.002 0.000 -0.001 -0.001 
3rd Quartile 0.005 0.005 -0.001 -0.002 -0.001 0.000 0.000 
Maximum 0.022 0.022 0.020 0.016 0.019 0.002 0.000 
D
N
A
 
H
ig
h
 
Minimum 0.013 0.013 0.027 0.051 0.100 0.151 0.311 
1st Quartile 0.061 0.061 0.088 0.164 0.408 0.577 0.577 
Median 0.081 0.081 0.109 0.214 0.539 0.707 0.707 
Mean 0.282 0.282 0.337 0.418 0.555 0.667 0.649 
3rd Quartile 0.577 0.577 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.756 1.000 0.913 0.913 
Lo
w
 
Minimum -0.006 -0.006 -0.006 0.008 0.027 0.058 0.056 
1st Quartile 0.011 0.011 0.016 0.044 0.153 0.408 0.408 
Median 0.022 0.022 0.036 0.103 0.333 0.408 0.408 
Mean 0.236 0.236 0.288 0.348 0.424 0.507 0.522 
3rd Quartile 0.577 0.577 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
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Supplementary table 3.2. MuMCC distribution of different read length parameters. The 
distribution of median micro-averaged MCC scores generated from testing different read 
length parameters for each swarm type replicate combinations following alignment of reads 
using GEM3 and chosen qScore parameter. 
Singlets 
  70 80 90 100 110 120 130 
R
N
A
 
H
ig
h
 
Minimum 0.053 0.048 0.048 0.050 0.050 0.054 0.055 
1st Quartile 0.265 0.253 0.248 0.242 0.232 0.234 0.210 
Median 0.469 0.447 0.424 0.414 0.427 0.380 0.354 
Mean 0.448 0.445 0.436 0.435 0.431 0.431 0.423 
3rd Quartile 0.577 0.577 0.577 0.577 0.577 0.642 0.577 
Maximum 0.756 0.756 0.756 0.756 0.756 0.756 0.756 
M
ed
iu
m
 
Minimum 0.039 0.034 0.034 0.029 0.024 0.023 0.021 
1st Quartile 0.099 0.098 0.098 0.097 0.097 0.095 0.094 
Median 0.103 0.103 0.103 0.103 0.103 0.103 0.103 
Mean 0.282 0.281 0.278 0.282 0.278 0.275 0.275 
3rd Quartile 0.577 0.577 0.539 0.539 0.539 0.539 0.539 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Lo
w
 
Minimum 0.020 0.012 0.011 0.017 0.018 0.015 0.022 
1st Quartile 0.067 0.069 0.069 0.068 0.061 0.062 0.057 
Median 0.101 0.101 0.117 0.109 0.109 0.109 0.109 
Mean 0.148 0.147 0.148 0.149 0.149 0.146 0.146 
3rd Quartile 0.250 0.250 0.250 0.250 0.250 0.250 0.250 
Maximum 0.250 0.250 0.250 0.250 0.250 0.250 0.250 
D
N
A
 
H
ig
h
 
Minimum 0.069 0.066 0.065 0.062 0.067 0.066 0.070 
1st Quartile 0.590 0.577 0.547 0.553 0.541 0.507 0.526 
Median 0.707 0.707 0.707 0.707 0.707 0.699 0.706 
Mean 0.619 0.604 0.599 0.601 0.601 0.588 0.588 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 1.000 0.933 0.854 1.000 1.000 0.854 1.000 
Lo
w
 
Minimum 0.039 0.039 0.032 0.032 0.036 0.040 0.045 
1st Quartile 0.296 0.282 0.281 0.260 0.245 0.216 0.208 
Median 0.455 0.455 0.455 0.455 0.433 0.433 0.433 
Mean 0.483 0.485 0.477 0.469 0.467 0.459 0.459 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
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Duplicates 
  70 80 90 100 110 120 130 
R
N
A
 
H
ig
h
 
Minimum 0.084 0.084 0.078 0.081 0.088 0.086 0.101 
1st Quartile 0.480 0.466 0.436 0.400 0.344 0.305 0.256 
Median 0.577 0.541 0.543 0.547 0.513 0.456 0.417 
Mean 0.524 0.525 0.515 0.515 0.503 0.482 0.466 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.816 0.816 0.816 0.816 0.816 0.816 0.816 
M
ed
iu
m
 
Minimum 0.040 0.036 0.040 0.033 0.034 0.028 0.025 
1st Quartile 0.165 0.158 0.165 0.161 0.159 0.160 0.153 
Median 0.203 0.197 0.197 0.197 0.197 0.197 0.187 
Mean 0.381 0.378 0.379 0.378 0.378 0.376 0.374 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Lo
w
 
Minimum -0.002 -0.002 -0.002 -0.002 -0.002 -0.002 -0.002 
1st Quartile -0.001 -0.001 -0.001 -0.001 -0.002 -0.001 -0.002 
Median 0.003 0.003 0.003 0.003 0.010 0.001 0.016 
Mean 0.006 0.005 0.004 0.004 0.009 0.001 0.008 
3rd Quartile 0.010 0.009 0.008 0.008 0.017 0.006 0.016 
Maximum 0.023 0.015 0.015 0.014 0.018 0.006 0.020 
D
N
A
 
H
ig
h
 
Minimum 0.096 0.094 0.098 0.096 0.101 0.098 0.103 
1st Quartile 0.577 0.577 0.577 0.577 0.577 0.577 0.577 
Median 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Mean 0.654 0.640 0.640 0.659 0.648 0.633 0.644 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.933 0.857 0.892 0.933 0.933 0.807 0.933 
Lo
w
 
Minimum 0.050 0.045 0.036 0.036 0.043 0.041 0.055 
1st Quartile 0.408 0.408 0.408 0.408 0.399 0.371 0.371 
Median 0.408 0.408 0.408 0.408 0.408 0.408 0.408 
Mean 0.496 0.501 0.499 0.495 0.496 0.493 0.488 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
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Triplicates 
  70 80 90 100 110 120 130 
R
N
A
 
H
ig
h
 
Minimum 0.112 0.114 0.098 0.105 0.115 0.085 0.105 
1st Quartile 0.481 0.500 0.468 0.456 0.467 0.409 0.373 
Median 0.577 0.577 0.577 0.577 0.541 0.540 0.481 
Mean 0.553 0.556 0.544 0.549 0.541 0.524 0.515 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.816 0.816 0.816 0.816 0.816 0.816 0.894 
M
ed
iu
m
 
Minimum 0.035 0.035 0.036 0.038 0.038 0.032 0.027 
1st Quartile 0.284 0.284 0.273 0.284 0.273 0.273 0.288 
Median 0.333 0.333 0.333 0.333 0.333 0.311 0.311 
Mean 0.442 0.441 0.442 0.441 0.441 0.439 0.446 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Lo
w
 
Minimum -0.003 -0.003 -0.003 -0.003 -0.003 -0.004 -0.003 
1st Quartile -0.003 -0.002 -0.002 -0.002 -0.003 -0.004 -0.003 
Median -0.001 -0.001 -0.001 -0.001 -0.001 -0.002 -0.001 
Mean 0.002 0.000 0.000 0.000 0.000 -0.002 0.000 
3rd Quartile 0.012 0.001 0.001 0.001 0.006 -0.001 0.002 
Maximum 0.012 0.007 0.007 0.006 0.006 -0.001 0.006 
D
N
A
 
H
ig
h
 
Minimum 0.124 0.119 0.125 0.127 0.134 0.134 0.136 
1st Quartile 0.577 0.577 0.577 0.577 0.577 0.577 0.577 
Median 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Mean 0.663 0.651 0.655 0.673 0.655 0.645 0.661 
3rd Quartile 0.707 0.707 0.707 0.735 0.707 0.707 0.707 
Maximum 0.892 0.892 0.892 0.913 0.866 0.852 0.866 
Lo
w
 
Minimum 0.056 0.057 0.050 0.050 0.050 0.052 0.062 
1st Quartile 0.408 0.408 0.408 0.408 0.408 0.408 0.408 
Median 0.408 0.408 0.408 0.408 0.408 0.408 0.408 
Mean 0.503 0.502 0.502 0.505 0.503 0.505 0.499 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
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Quadruplicates 
  70 80 90 100 110 120 130 
R
N
A
 
H
ig
h
 
Minimum 0.132 0.135 0.115 0.128 0.142 0.105 0.133 
1st Quartile 0.481 0.500 0.481 0.481 0.522 0.489 0.430 
Median 0.577 0.596 0.577 0.583 0.577 0.577 0.521 
Mean 0.571 0.579 0.569 0.569 0.564 0.552 0.543 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.816 0.816 0.816 0.816 0.816 0.816 0.894 
M
ed
iu
m
 
Minimum 0.033 0.034 0.034 0.035 0.036 0.036 0.023 
1st Quartile 0.408 0.408 0.408 0.408 0.408 0.408 0.408 
Median 0.408 0.408 0.408 0.408 0.408 0.408 0.408 
Mean 0.494 0.494 0.492 0.492 0.494 0.489 0.497 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Lo
w
 
Minimum -0.003 -0.003 -0.003 -0.003 -0.002 -0.011 -0.002 
1st Quartile -0.003 -0.002 -0.002 -0.002 -0.002 -0.005 -0.002 
Median -0.001 -0.001 -0.001 -0.001 -0.001 -0.002 -0.001 
Mean -0.001 -0.001 -0.001 -0.001 -0.001 -0.004 0.000 
3rd Quartile 0.001 0.000 0.000 0.000 0.000 -0.001 0.002 
Maximum 0.001 0.001 0.001 0.000 0.000 -0.001 0.002 
D
N
A
 
H
ig
h
 
Minimum 0.152 0.151 0.154 0.155 0.171 0.175 0.184 
1st Quartile 0.577 0.577 0.577 0.577 0.577 0.577 0.577 
Median 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Mean 0.669 0.661 0.664 0.686 0.668 0.652 0.672 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.913 0.913 0.913 0.913 0.881 0.870 0.870 
Lo
w
 
Minimum 0.063 0.063 0.061 0.063 0.062 0.058 0.078 
1st Quartile 0.408 0.408 0.408 0.408 0.408 0.408 0.408 
Median 0.408 0.408 0.408 0.408 0.408 0.408 0.408 
Mean 0.504 0.504 0.503 0.510 0.508 0.510 0.508 
3rd Quartile 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
Maximum 0.707 0.707 0.707 0.707 0.707 0.707 0.707 
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Supplementary table 3.3. MuMCC distribution of different percentage frequency cut-off 
parameters. The distribution of median micro-averaged MCC (MuMCC) scores generated 
from testing different read length parameters for each swarm type replicate combinations 
following alignment of reads using GEM3 and chosen qScore and read length parameters. 
The MuMCC scores representing the suggested percentage frequency cut-offs are highlighted 
in green. 
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Supplementary table 5.1. Amount of FMDV produced in the cell cultures replication kinetics 
during each cell passage. The estimated PFU/ml generated for each virus sample following 
cell passage. 
  
  Passage 
    One Two Three Four 
Fi
el
d
  
3159 2.95x107 2.40x107 2.40x107 1.90x107 
3157 1.90x107 2.95x107   
3817 2.95x107 2.40x107 2.40x107 1.90x107 
C
h
al
le
n
ge
d
 4942 3.10x106 5.66x106 6.00x106 1.33x107 
4926 6.36x106 6.22x106 2.26x107 3.33x107 
4914 1.43x106 7.60x106 3.60x107 1.20x107 
C
o
n
tr
o
l 
4942C 3.20x107 1.73x107 3.36x107 2.30x107 
4926C 1.16x107 2.33x107 4.50x107 3.50x107 
4914C 8.00x107 2.33x107 2.53x107 2.36x107 
  
 215 
 
Supplementary table 5.2. HTS read and alignment analysis for each passage and technical 
replicate for each of the sequenced Starting viruses. Critical difference score is obtained from 
each technical replicate and is used to determine the frequency cut-off.  
 
  
Sample Replicate 
Total 
reads 
Reads 
mapped 
Mean 
coverage 
Critical 
difference 
Frequency 
cut-off 
St
ar
ti
n
g 
vi
ru
s Start1 
1 5.52x105 97.83% 2.06x104 
0.07% 0.20% 
2 6.35x105 97.07% 2.35x104 
Start2 
1 2.42x105 98.79% 8.44x103 
0.23% 0.50% 
2 2.78x105 98.57% 9.53x103 
Start3 
1 3.42x105 99.10% 1.29x104 
0.37% 0.50% 
2 3.61x105 98.86% 1.36x104  
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Sample Passage Replicate 
Total 
reads 
Reads 
mapped 
Mean 
coverage 
Critical 
difference 
Frequency 
cut-off 
C
o
n
tr
o
l g
ro
u
p
 
4942C 
1 
1 3.01x105 99.35% 1.17x104 
0.50% 0.50% 
2 2.43x105 99.34% 9.41x103 
2 
1 2.80x105 99.02% 1.08x104 
0.50% 0.50% 
2 1.75x105 99.49% 6.74x103 
3 
1 5.24x105 98.45% 1.98x104 
0.06% 0.20% 
2 4.72x105 98.46% 1.77x104 
4 
1 3.89x105 98.49% 1.44x104 
0.07% 0.20% 
2 2.74x105 98.48% 1.00x104 
4926C 
1 
1 5.91x105 96.38% 2.19x104 
0.06% 0.20% 
2 5.71x105 95.91% 2.09x104 
2 
1 4.39x105 97.71% 1.64x104 
0.06% 0.20% 
2 4.52x105 98.46% 1.68x104 
3 
1 3.70x105 98.31% 1.39x104 
0.06% 0.20% 
2 3.69x105 97.88% 1.38x104 
4 
1 5.60x105 98.92% 2.12x104 
0.06% 0.20% 
2 5.57x105 98.60% 2.08x104 
4914C 
1 
1 3.24x105 97.67% 1.10x104 
0.32% 0.50% 
2 1.16x105 98.63% 3.92x103 
2 
1 2.46x105 98.63% 8.46x103 
0.27% 0.50% 
2 2.47x105 98.06% 8.46x103 
3 
1 3.25x105 97.61% 1.09x104 
0.38% 0.50% 
2 2.93x105 98.36% 1.01x104 
4 
1 2.28x105 99.21% 8.20x103 
0.48% 0.50% 
2 2.01x105 98.72% 6.92x103 
Supplementary table 5.3. HTS read and alignment analysis for each passage and technical 
replicate for each of the sequenced Control samples. Critical difference score is obtained 
from each technical replicate and is used to determine the frequency cut-off.  
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Sample Passage Replicate 
Total 
reads 
Reads 
mapped 
Mean 
coverage 
Critical 
difference 
Frequency 
cut-off 
Fi
el
d
 g
ro
u
p
 
3159 
1 
1 4.58x105 98.98% 1.75x104 
0.22% 0.50% 
2 4.12x105 98.74% 1.56x104 
2 
1 4.60x105 98.87% 1.74x104 
0.23% 0.50% 
2 2.27x105 97.86% 8.15x103 
3 
1 2.86x105 99.17% 1.08x104 
0.59% 0.50% 
2 8.34x104 99.05% 2.98x103 
4 
1 3.28x105 98.88% 1.25x104 
0.31% 0.50% 
2 4.54x105 98.87% 1.71x104 
3157 
1 
1 3.67x105 93.38% 1.31x104 
0.09% 0.20% 
2 1.20x105 75.20% 3.28x103 
2 
1 3.36x105 95.10% 1.21x104 
0.06% 0.20% 
2 3.34x105 96.22% 1.21x104 
3817 
1 
1 1.98x105 98.77% 6.99x103 
0.24% 0.50% 
2 2.13x105 98.87% 7.48x103 
2 
1 2.25x105 99.22% 7.96x103 
N/A 0.80% 
2 2.31x103 3.45% 2.64x100 
3 
1 1.92x105 99.10% 6.87x103 
0.32% 0.50% 
2 2.04x105 99.29% 7.32x103 
4 
1 2.74x105 99.52% 9.83x103 
0.21% 0.50% 
2 3.21x105 99.47% 1.15x104 
Supplementary table 5.4. HTS read and alignment analysis for each passage and technical 
replicate for each of the sequenced Field samples. Critical difference score is obtained 
from each technical replicate and is used to determine the frequency cut-off.  
Due to the low number of reads generated for the Field 3817 Passage two, replicate two 
sample, it was removed from further downstream analysis.  
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Sample Passage Replicate 
Total 
reads 
Reads 
mapped 
Mean 
coverage 
Critical 
difference 
Frequency 
cut-off 
C
h
al
le
n
ge
 g
ro
u
p
 
4942 
1 
1 4.24x105 98.44% 1.58x104 
0.22% 0.50% 
2 3.75x105 98.37% 1.39x104 
2 
1 4.74x105 98.94% 1.80x104 
0.35% 0.50% 
2 3.85x105 98.71% 1.41x104 
3 
1 3.39x105 98.73% 1.28x104 
0.57% 0.50% 
2 5.52x105 98.84% 2.08x104 
4 
1 3.94x105 98.63% 1.50x104 
0.35% 0.50% 
2 4.11x105 98.87% 1.57x104 
4926 
1 
1 5.12x105 96.56% 1.88x104 
0.05% 0.20% 
2 3.57x105 96.20% 1.31x104 
2 
1 5.35x105 96.42% 1.98x104 
0.08% 0.20% 
2 4.83x105 95.36% 1.76x104 
3 
1 4.45x105 98.42% 1.67x104 
0.04% 0.20% 
2 1.13x106 97.49% 4.22x104 
4 
1 3.29x105 94.36% 1.17x104 
0.06% 0.20% 
2 4.80x105 96.61% 1.77x104 
4914 
1 
1 3.39x105 99.22% 1.21x104 
0.34% 0.50% 
2 2.40x105 99.23% 8.47x103 
2 
1 3.49x105 99.38% 1.25x104 
0.33% 0.50% 
2 3.56x105 99.34% 1.27x104 
3 
1 2.87x105 99.00% 1.01x104 
0.41% 0.50% 
2 2.49x105 99.38% 8.88x103 
4 
1 6.19x105 99.16% 2.26x104 
0.29% 0.50% 
2 5.51x105 99.06% 2.02x104 
Supplementary table 5.4. HTS read and alignment analysis for each passage and technical 
replicate for each of the sequenced Challenged samples. Critical difference score is 
obtained from each technical replicate and is used to determine the frequency cut-off.  
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Supplementary figures  
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 4.1. RT-qPCR primer comparison between A/IRN/22/2015 and 
O/UKG/25/2001. Alignment to confirm sequence identity of each primer component of the 
RT-qPCR (241) using BioEdit (257). The sequence of FMDV A IRN/08/2015 was obtained from 
The Pirbright Institute.   
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Supplementary figure 5.1. ‘Kill’ plots generated showing the time CPE for each passage 
series for all three Control samples at a dilution of 1/10. Passage one is shown in green, 
passage two in purple, passage three in blue and passage four in red. The average times 
of the non-serum controls for all four passage series is shown in black.  
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Supplementary figure 5.2. ‘Kill’ plots generated showing the time CPE for each passage 
series for all three Field samples at a dilution of 1/10. Passage one is shown in green, 
passage two in purple, passage three in blue and passage four in red. The average times 
of the non-serum controls for all four passage series is shown in black.  
 222 
 
  
Supplementary figure 5.3. ‘Kill’ plots generated showing the time CPE for each passage 
series for all three Challenge Serum samples at a dilution of 1/50. Passage one is shown 
in green, passage two in purple, passage three in blue and passage four in red. The 
average times of the non-serum controls for all four passage series is shown in black.  
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Supplementary figure 5.4. The average read coverage depth per sequenced genome 
position between technical replicates for each of the Starting Virus sample sets.  
Starting one is shown purple, Starting two is shown in green and Starting three is shown 
in blue.  
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Supplementary figure 5.5. The average read coverage depth per sequenced genome 
position between technical replicates for each passage series for Control sample sets. 
Passage one is shown in green, passage two in purple, passage three in blue and passage 
four in red.  
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Supplementary figure 5.6. The average read coverage depth per sequenced genome 
position between technical replicates for each passage series for Field group sample sets. 
Passage one is shown in green, passage two in purple, passage three in blue and passage 
four in red. For Field 3817 Passage two, only a single replicate is shown due to the second 
technical replicate failing to sequence.  
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Supplementary figure 5.7. The average read coverage depth per sequenced genome 
position between technical replicates for each passage series for Challenged sample sets. 
Passage one is shown in green, passage two in purple, passage three in blue and passage 
four in red. 
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Supplementary figure 5.8. (A) Accumulative Shannon’s entropy scores across the 
amplicon region for each of the Starting viruses sequenced. (B) Percentage of the 
Shannon’s entropy scores for each Starting virus across the sequenced amplicon region. 
Entropy scores for Start one are shown purple, Start two shown in green and Start three 
shown in blue.  
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Supplementary figure 5.9. Accumulative entropy plots of each of the three Control 
samples across the sequenced amplicon region. Passage one is shown in green, passage 
two in purple, passage three in blue and passage four in red. Respective starting viruses 
are shown in grey.  
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Supplementary figure 5.10. Percentage of overall entropy across the sequenced amplicon 
region for all passages of the Control sample sets. Passage one is shown in green, passage 
two in purple, passage three in blue and passage four in red. Respective starting viruses 
are shown in grey.  
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Supplementary figure 5.11. Accumulative entropy plots of each of the three Field samples 
across the sequenced amplicon region. Passage one is shown in green, passage two in 
purple, passage three in blue and passage four in red. Respective starting viruses are 
shown in grey.  
 231 
 
  
Supplementary figure 5.12. Percentage of overall entropy across the sequenced amplicon 
region for all passages of the Field sample sets. Passage one is shown in green, passage 
two in purple, passage three in blue and passage four in red. Respective starting viruses 
are shown in grey.  
  
 232 
 
  
Supplementary figure 5.13. Accumulative entropy plots of each of the three Challenged 
samples across the sequenced amplicon region. Passage one is shown in green, passage 
two in purple, passage three in blue and passage four in red. Respective starting viruses 
are shown in grey.  
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  Supplementary figure 5.14. Percentage of overall entropy across the sequenced amplicon 
region for all passages of the Challenged sample sets. Passage one is shown in green, 
passage two in purple, passage three in blue and passage four in red. Respective starting 
viruses are shown in grey.  
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Supplementary sequence  
Supplementary sequence 3.1. Artificial swarm consensus sequence. The consensus sequence 
of the DNA and RNA swarms created. This sequence was generated via de novo assembly 
using IDBA UD (255). Primer sequences were trimmed prior to HTS read alignment. BLASTn 
analysis revealed that FMDV-O1K polyprotein (Accession: X00871) was the closest match with 
a 99.40% identify.    
>pT7S3_artifical swarm 
ATGAATACAACTGACTGTTTTATCGCTTTGGTACAGGCTATCAGAGAGATTAAAGCACTTTTTCTATCACGCAC
CACAGGGAAAATGGAACTGACACTGTACAACGGTGAGAAGAAGACCTTTTACTCCAGGCCCAACAACCACGA
CAACTGCTGGTTGAACGCCATCCTCCAGTTGTTCAGGTACGTTGAAGAACCATTCTTCGACTGGGTCTACAGTT
CGCCTGAGAACCTCACGCTTGAAGCCATCAAGCAGTTGGAGGATCTCACAGGACTTGAACTGCATGAGGGTG
GACCACCTGCTCTCGTGATCTGGAACATCAAGCACTTGCTCCACACCGGCATCGGCACCGCCTCGCGACCCAG
CGAGGTGTGCATGGTGGATGGTACGGACATGTGCTTGGCTGATTTCCATGCTGGCATTTTCCTTAAGGGGCAA
GAACACGCTGTGTTTGCGTGTGTCACCTCCAACGGGTGGTACGCGATTGACGATGAGGACTTCTACCCCTGGA
CGCCGGACCCGTCCGACGTTCTGGTGTTTGTCCCGTACGATCAAGAACCACTCAACGGGGAATGGAAAGCCAA
GGTTCAACGCAAGCTCAAAGGGGCTGGACAATCCAGTCCAGCGACCGGCTCGCAGAACCAATCTGGCAATAC
TGGCAGCATAATAAACAACTATTACATGCAGCAGTATCAAAACTCCATGGACACACAGCTTGGTGACAACGCA
ATCAGTGGAGGCTCTAACGAGGGCTCCACCGACACAACCTCCACCCACACAACCAACACCCAGAACAATGACT
GGTTCTCCAAACTTGCCAGCTCTGCTTTCAGCGGTCTTTTCGGCGCTCTTCTCGCCGACAAGAAGACAGAGGAG
ACCACTCTCCTCGAAGACCGCATCCTCACCACCCGTAACGGCCACACCACGTCGACAACCCAGTCAAGCGTTG
GAGTCACATACGGGTACGCAACAGCTGAAGATTTTGTGAGCGGACCGAACACTTCCGGTCTCGAAACCAGAG
TTGTGCAGGCAGAACGGTTTTTCAAAACCCACCTCTTCGACTGGGTCACCAGTGACTCATTCGGACGTTGCCAC
CTCCTGGAACTCCCGACCGACCACAAAGGTGTCTACGGCAGCCTGACTGACTCGTATGCATATATGAGAAACG
GCTGGGATGTCGAGGTCACCGCGGTTGGCAACCAGTTCAACGGAGGGTGCCTGCTGGTCGCAATGGTACCAG
AGCTTTGTTCTATCCAAAAGAGGGAACTGTACCAGCTCACACTTTTCCCTCACCAGTTCATCAACCCACGCACG
AACATGACTGCGCACATCACAGTGCCCTTTGTTGGCGTCAACCGCTACGACCAGTACAAGGTTCACAAGCCTT
GGACCCTTGTGGTTATGGTTGTAGCCCCTCTGACCGTCAACGCGGAAGGTGCCCCTCAGATCAAGGTGTATGC
CAACATTGCCCCAACCAACGTGCACGTCGCGGGTGAGTTTCCTTCCAAGGAGGGAATATTCCCCGTGGCCTGT
AGCGACGGCTATGGTGGCCTGGTGACCACGGACCCGAAGACGGCTGACCCCGTTTATGGGAAAGTGTTCAAC
CCCCCCCGCAACCAGTTGCCGGGGCGTTTTACCAACCTCCTTGATGTGGCTGAGGCATGCCCGACGTTTCTGCA
CTTCGTGGGTGACGTACCGTACGTGACCACGAAAATGGACTCGGACAGGGTGCTTGCTCAGTTTGACATGTCT
TTGGCAGCAAAACACATGTCAAACACCTTCCTCGCAGGTCTTGCGCAGTACTACACACAGTACAGTGGCACCA
TCAACCTGCACTTCATGTTCACAGGACCCACTGACGCGAAGGCGCGTTACATGATTGCCTACGCCCCACCAGG
CATGGAGCCGCCCAAGACACCTGAGGCGGCCGCGCACTGCATTCATGCTGAATGGGACACTGGGTTAAACTC
AAAGTTTACTTTTTCCATCCCCTACCTCTCGGCCGCCGATTACGCGTACACCGCGTCTGACGTGGCCGAGACCA
CAAATGTGCAGGGATGGGTCTGCTTGTTTCAAATTACACATGGCAAGGCCGACGGCGACGCTCTGGTCGTACT
GGCTAGTGCTGGTAAAGACTTTGAGCTAAGGCTGCCGGTGGACGCCCGTGCGGAAACCACTTCTGCGGGCGA
GTCAGCGGATCCTGTCACCACCACCGTTGAAAACTACGGTGGCGAAACACAGATCCAGAGGCGCCAACACAC
GGACGTCTCGTTCATCATGGACAGATTTGTGAAGGTGAAACCGCAAAACCAAATTAACATTTTGGACCTCATG
CAGATTCCATCACACACTTTGGTGGGAGCACTCCTACGCGCGTCCACTTACTACTTCTCTGACTTGGAGATAGC
AGTAAAACACGAGGGAGACCTCACCTGGGTTCCAAATGGAGCGCCCGAAAAGGCGTTGGACAACACCACCAA
CCCAACTGCTTACCACAAGGCACCACTCACCCGGCTTGCCCTGCCCTACACTGCGCCCCACCGCGTGTTGGCAA
CCGTGTACAACGGTGAGTGCAGGTACAACAAAAATGCTGTGCCCAACTTGAGAGGTGACCGTCATGCGTTGG
CTCAAAAGGTGGCACGGACGCTGCCTACCTCCTTCAACTACGGTGCCATCAAAGCGACCCGGGTCACCGAGTT
GCTTTACCGGATGAAGAGGGCCGAAACATACTGTCCAAGGCCCTTGCTGGCAATCCACCCAACTGAAGCCAGA
CACAAACAGAAAATTGTGGCACCGGTGAAACAGACTTTG 
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